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Summary 
The major histocompatibility complex (MHC) plays crucial roles in many biological processes, most 
especially disease resistance. Classical MHC molecules are extremely polymorphic and encode cell 
surface glycoproteins that present antigenic peptides to T lymphocytes of the immune system. 
Several other molecules are involved in loading and optimising the peptides for the two major groups 
of classical MHC molecules, including the transporter associated with antigen processing (TAP) for 
MHCI molecules, and the dedicated chaperone DM for the MHCII molecules. In mammals, these 
critical antigen loading molecules have limited polymorphism, providing peptides for a multigene 
family of well-expressed classical MHC molecules.  
Outside of mammals, the chicken is the only system in which peptide loading and presentation has 
been studied in molecular detail. Compared to mammals, the chicken MHC is small, simple and 
arranged differently. Chickens have two classical MHCI genes but strongly express only one at the 
RNA and protein levels which presents the majority of peptides. This phenomenon is apparently due 
to co-evolution with the polymorphic TAP genes, among other peptide loading associated genes. The 
exact polymorphic TAP residues involved in peptide loading of chicken MHCI remain unclear. For the 
class II system, there are two MHCII B genes and two DMB genes, but only BLB2 and DMB2 are 
expressed at high levels in haemopoietic cells. One hypothesis is that each MHCII B gene co-evolves 
with one of the two DMB genes, resulting in differential expression, but the interactions and 
importance of each DM gene are unknown.  
In this thesis, the genome editing approach of clustered regularly interspaced short palindromic 
repeats (CRISPR)-Cas9 was used to begin to understand the peptide loading systems in the chicken. 
For the first time, the CRISPR-Cas9 system was optimised and implemented in avian cell lines, 
beginning with the creation of MHCI and TAP gene knock-out (KO) chicken cell lines. TAP-dependent 
peptide transport was assessed in each line allowing for the first steps to determine the critical 
peptide binding residues in chicken TAP transport.  
To understand the role of DM in chickens, KO cell lines for BLB and DM genes were created and 
analysed at the RNA and protein levels, additionally the peptide repertoire was determined by 
immunopeptidomics. Striking and unexpected changes in MHCII expression were seen by deleting 
different components of MHCII presentation.  
Initial findings suggest the chicken MHCII system utilises two DM chaperones for effective MHCII 
expression, stability and peptide presentation. The work in this thesis provides some of the first 
detailed insights into the peptide loading systems for MHC molecules in an organism outside of 
mammals and provides the basis for genome editing in primordial germ cells (PGCs), eventually 
allowing analysis of MHC presentation in vivo for improved understanding of pathogen resistance 
and vaccine responses. 
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1. General introduction 
1.1 Major histocompatibility complex molecules 
In mammals the major histocompatibility complex (MHC) molecules have been shown to 
play a crucial role in histocompatibility (graft rejection), immune responses and disease 
resistance and susceptibility. Most of our knowledge of the MHC comes from studies in 
humans and mice (Ploegh 1981, Kaufman et al 1984, Germain 1994, Jones 1997, Vyas et al 
2008, Neefjes 2011). The MHC region is known to have the most associations to disease 
resistance and susceptibility. In humans, the strong associations are generally with 
autoimmune diseases and are weak or non-existent with infectious pathogens, with a few 
exceptions such as HIV progression (Carrington et al 1999, 2003). 
 The MHC molecules are comprised of two classes, class I (MHCI) and class II (MHCII); both 
classes are further broken down into classical and non-classical MHC molecules. Classical 
MHCI and II are incredibly polymorphic and encode cell surface glycoproteins that enable 
the immune system to recognize foreign antigens. Through the antigen processing pathway, 
MHCI molecules present mainly cytosolic antigens to CD8 positive T-cells, whereas MHCII 
molecules present mainly endosomal peptides to CD4 positive T-cells (Neefjes et al. 2011). 
The small protein fragments (peptides) are presented by MHC molecules and the 
presentation of these peptides to T lymphocytes of the immune system initiates effector and 
regulatory cell activation. MHCI and MHCII molecules have differences in their structure and 
expression that enables them to achieve different functions of antigen presentation. The 
overall structure of MHCI and MHCII molecules is similar, with both classes having two 
membrane-distal domains that form a peptide binding groove and two immunoglobulin-like 
membrane-proximal domains (Kaufman et al 1984, Bjorkman et al 1987, Brown et al 1993, 
Jardetzky et al 1994, Stern et al 1994). MHCI molecules are present on all nucleated cells and 
17 
 
consist of a large α chain (heavy chain), which contains the peptide binding groove, and a 
small non-covalently-associated chain named β2-microglobulin (β2m); MHCI molecules 
present peptides to cytotoxic T cells (CTLs) expressing the co-receptor CD8. MHCII molecules 
are comprised of two non-covalently associated α and β chains, with each chain contributing 
a membrane-proximal immunoglobulin-like domain and a membrane-distal domain. The 
membrane distal-domain of the α and β chains comprise the peptide groove, and both 
chains have a transmembrane domain anchoring the MHC to the cell surface. MHC II 
expression is generally restricted to antigen presenting cells (APCs) such as macrophages, 
and present peptides to T cells expressing the CD4 co-receptor. 
 
1.1.1 MHC class I structure 
The MHCI heavy chain is separated into three domains, with the immunoglobulin-like α3 
domain forming the only anchorage point through the transmembrane domain. The α1 and 
α2 domains together form the platform for peptide binding, which is comprised of an eight 
stranded β-sheet with two long α-helices (one from α1 and the other from α2) overlaying 
the β-sheet and forming the edges of the peptide binding groove (Bjorkman et al 1987) (fig 
1.1.1). The key binding pockets in MHCI are defined as interacting with the side chains from 
peptide position P2 (or sometimes P5/6) and P8/9, with strong binding generally occurring at 
either end of the binding groove causing the bound peptide to bulge in the middle, resulting 
in peptide side chains pointing out of the groove (Falk et al 1991, Hunt et al 1992). Unlike 
MHCII, MHCI has conserved residues at either end of the binding groove, leading to a closed 
binding groove which restricts the length of peptides bound; these peptides are generally 
between 8-10 amino acids in length (Matsumura et al 1992, Bouvier and Wiley 1994). 
Polymorphisms of MHCI are mostly localised to that of the peptide binding groove and it is 
18 
 
generally accepted that the residues associated with peptide binding are under selection 
primarily for pathogen recognition, in what has been termed a ‘molecular arms race’ 
(Hughes and Nei 1988). 
 
 
 
 
 
 
 
 
Figure1.1.1 Cartoon representation of human HLA-A crystal structure. 
a) MHCI molecules consist of a large α chain (heavy chain), which contains the peptide binding groove, and a 
small non-covalently-associated chain named β2-microglobulin (β2m). b) The α1 and α2 domains together 
form the platform for peptide binding, which is comprised of an eight stranded β-sheet with two long α-
helices (one from α1 and the other from α2) overlaying the β-sheet and forming the edges of the peptide 
binding groove (Bjorkman et al 1987). 
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1.1.2 MHC class II structure 
MHCII molecule expression is generally restricted to APCs including B cells, 
monocytes/macrophages, dendritic cells and thymic epithelial cells (TECs). MHCII expression 
can be induced in other cell types by stimulation, including by interferon gamma (IFN-y), in 
endothelial cells and fibroblasts (Geppert and Lipsky 1985, Umetsu et al 1986), keratinocytes 
(Czernielewski and Bagot 1986, Baker et al 1988), mesenchymal stromal cells (Chan et al 
2006, Romieu-Mourez et al 2007) and intestinal epithelial cells (IECs) (Hershberg et al 1997, 
Thelemann et al 2014). As previously mentioned, MHCII consists of two non-covalently 
associated chains (α and β), both of which have a cytoplasmic, transmembrane and 
immunoglobulin-like domain, and together comprise the peptide binding groove (Springer et 
al 1977, Kaufman et al 1984) (figure 1.1.2). The α chain has one disulphide bond in the α2 
domain whilst the β chain has two disulphide bonds, one in the β1 domain and one in the β2 
domain (Kaufman et al 1984). The peptide binding groove consists eight anti-parallel β 
strands covered by two α helices (Brown et al 1988, 1993). Peptides are bound in the 
peptide binding groove by a hydrogen bonds between residues in the peptide backbone and 
the binding groove in a sequence independent manner. Conversely, sequence specific 
interactions are formed between the side chains of peptide residues and residues in the 
binding groove that form ‘pockets’ (Stern et al 1994).  Unlike MHCI, MHCII has an open-
ended binding groove and can bind peptides of varying lengths, with optimal peptides being 
of 12-20 amino acids in length (Jardetsky et al 1996, Godkin et al 2001). The most significant 
pockets for binding are P1, P4, P6 and P9 and bind ‘anchor residues’ from the peptide; P3, P7 
potentially have smaller binding pockets (Suri et al 2006). Stability of MHCII is dependent on 
the peptide that is bound, with different peptide sequences and lengths effecting stability 
and flexibility of MHCII (Nelson et al 1996, O’Brien et al 2008, Ferrante 2013). As with MHCI, 
20 
 
polymorphisms of MHCII are mostly localised to the peptide binding groove and are under 
strong selection for diversity, presumably for response to pathogens (Hughes and Nei 1989). 
 
 
1.2 MHC class I antigen processing and presentation 
Antigen processing and presentation have been primarily and extensively studied in human 
and murine systems, giving a detailed understanding of MHC antigen processing and 
presentation. MHCI molecules classically present peptides that are cytosolic in origin that 
have been generated by the proteasome and are pumped into the lumen of the endoplasmic 
reticulum (ER) by the transporter-associated with antigen processing (TAP) heterodimer (fig 
1.2.1). The TAP1 and TAP2 genes encode the TAP transporter which translocate peptides 
from the cytosol into the ER, ready for binding to class I molecules (Deverson et al 1990, 
Trowsdale et al 1990, Spies et al 1990). The TAP heterodimer is a four-domain structure with 
two hydrophobic transmembrane domains (TMDs) and two hydrophilic nucleotide-binding 
domains (NBDs). The TMDs provide a passage of peptides to be transported and the 
Figure1.1.2 Cartoon representation of DR1 crystal structure. 
a) MHCII molecules are comprised of two non-covalently associated α and β chains. The α chain consists of 
two domains, α1 and α2 domain whilst the β chain consists of β1 and β2 domains. b) the peptide binding 
groove consists eight anti-parallel β strands covered by two α helices formed by the associated α1 and β1 
domains (adapted from Pos 2012)  
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substrate-binding site. The two NBDs are located in the cytoplasm and are involved in ATP 
binding and hydrolysis. In humans, the TAP genes are located in the class II region, separated 
from the highly polymorphic class I genes, and are monomorphic, having evolved to 
transport peptides which will bind to all class I alleles.  In the ER, peptides are trimmed 
further by endoplasmic reticulum aminopeptidase 1 (ERAP1) 1 and ERAP2 after being bound 
by MHCI.  
The MHCI heavy chain folding is assisted by the ER resident chaperones calnexin, calreticulin 
and the protein disulphide isomerase (PDI), ERp57, which assists disulphide bond formation 
in the MHCI heavy chain and then associates with the β2m subunit before binding peptide 
(Sadasivan et al 1996, Leach et al 2002, Zhang et al 2006). MHCI forms a large complex with 
the TAP transporter bridged by the chaperone tapasin, calreticulin and ERp57 in what is 
known as the peptide loading complex (PLC) (Blees et al 2017). The order in which the PLC is 
formed is still not fully understood, though it is thought it is thought to start with ERp57 then 
forming a disulphide bond with tapasin.  
Tapasin interacts with a loop below the α2 helix and a β-strand in the α3 domain of the 
MHCI; then tapasin binds the TAP transporter through positive residues located in the 
transmembrane domain, confining the MHCI to the source of peptides as well as acting to 
stabilise the empty MHCI (Sadasivan et al 1996, Ortmann et al 1997, Petersen et al 2005). 
ERp57 associates with calreticulin and has been shown to be essential for effective PLC 
activity (Ortmann et al 1997 and Petersen et al 2005). Stable bound peptide-MHCI 
complexes then dissociate from the PLC and are subject to a second round of peptide editing 
by a second peptide editor, TAPBPR. TAPBPR binds the MHCI at similar contact sites to 
tapasin and catalyses the exchange of low affinity peptide for those with a higher affinity 
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(Boyle et al 2013). Stable peptide-MHCI complexes loaded with peptides of high affinity are 
then transported to the cell surface for presentation to CD8+ T cells.  
 
 
 
1.3 MHC class II antigen processing and presentation 
Initially MHCII α and β chains fold in the ER in association with a third chain, known as the 
invariant chain (Ii) or CD74 (Cresswell 1996), which is a non-polymorphic transmembrane 
domain protein that is expressed in conjunction with MHCII (Long 1985). Ii is well conserved 
from sharks to humans (Cristiello et al 2012), has a critical role in MHCII trafficking and is 
Figure1.2.1 Schematic of MHCI antigen processing and presentation  
Intracellular antigens are processed into peptides by the immunoproteasome, which is comprised of 
multiple subunits, such as LMP2. Peptides are then transported into the lumen of endoplasmic reticulum 
(ER) via transporter associated with antigen presentation (TAP) proteins, where they are loaded into the 
binding groove of the MHC class I complex. MHC class I-peptide complexes migrate to the cell surface for 
presentation to CD8+ T cells (Groettrup et al 2010). 
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required for MHCII transport through the endocytic pathway, with li absence resulting in 
MHCII localisation in the ER (Lamb et al 1991, Viville et al 1993). In addition Ii is vital for 
immune development, as mice lacking li have impaired thymic CD4+ T cell maturation and 
MHCII presentation (Viville et al 1993, Elliot et al 1994). Biochemical and structural studies 
have suggested that the Ii forms a trimer and associates with three MHCII heterodimers to 
form a nonameric complex or that li trimers associate with MHCII heterodimer to form a 
pentameric structure (Koch et al 2011, Marks et al 1990, Roche et al 1991, Park et al 1995). 
MHCII and li associate through the transmembrane and ectodomains (King and Dixon 2010); 
residues 90-104 of li bind to MHCII occupying the peptide binding groove. This binding stops 
MHCII binding peptides in the ER and early endosomes, as well as stabilising the class II 
molecule (Roche and Cresswell 1991, Sette et al 1992). 
 MHCII molecules are then transported through the endocytic pathway to the late 
endosomal compartment, MHC class II compartment (MIIC) (Peters et al 1991), which is 
governed by signalling from the li cytoplasmic domain (Lamb et al 1991, Benaroch et al 
1995). In the MIIC, Ii is cleaved by cathepsin and other proteases (Costantino et al 2008, 
Hűttl et al 2016) leaving a short peptide (li 91-104) named the class II-associated invariant 
chain peptide (CLIP) occupying the MHCII binding groove (Riberdy et al 1992) (fig 1.3.1). 
CLIP is then exchanged for higher affinity peptides, that are derived from proteolytically 
degraded proteins present in late endocytic compartments. This peptide exchange is 
catalysed by the non-classical class II molecule HLA-DM in humans (H-2Mb in mice) and is 
termed a ‘peptide editor’, with different MHCII alleles being more or less dependent on DM 
activity for peptide loading (Pious et al 1994, Stebbins et al 1995, Patil et al 2001). Once a 
peptide is stably bound, the MHCII-peptide complex is transported to the cell surface for 
presentation to CD4+ T cells. 
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In mammals, there is another non-classical class II molecule (HLA-DO in humans and H2-O in 
mice), which binds to DM inhibiting its activity in a competitive manner providing further 
control of the peptide repertoire (Glazier et al 2002, Mellins and Stern 2014). DO acts in 
direct competition with MHCII by binding DM at the same contact sites as MHCII binds (Guce 
et al 2013) and is found in the late endosome, with its transport from the ER being 
dependent on DM association (Mellins and Stern 2014). DO expression is more cell type 
restricted than that of DM, being expressed in B cells, thymic epithelial cells and some 
subsets of dendritic cells (Hornell 2006, Xiu 2011). One role proposed for DO is to reduce the 
presentation of self antigens, striking a balance between response to pathogens and 
preventing autoimmunity (Mellins and Stern 2014). 
 
 
 
 
Figure1.3.1 schematic of MHCII antigen processing and presentation 
Antigens from endosomal compartments are processed by endolysosomal enzymes into peptides. These 
peptides are then bound to the MHC class II complex after the class II-associated invariant chain peptide 
(CLIP) is dissociated. HLA-DM and HLA-DO regulate the antigen-loading process. The MHC class II presents 
antigens to CD4+ T cells (Roche and Furuata 2015) 
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1.4 Structure and function of DM 
HLA-DM is comprised of an α/β heterodimer and has a similar overall structural fold to 
MHCII but with noticeable differences (Kelly 1991, Moysak et al 1998, Pos et al 2012). Firstly, 
unlike MHCII, DM has limited polymorphism. Secondly, structures show that segments of the 
α-helices in DM are packed more closely together and result in a closed binding groove 
which prevents peptide binding, with the residues of the binding groove in MHCII not 
conserved in DM. Additionally, residues that keep the α helices of the α1 and β1 domains of 
DM close together are conserved in many species (Fremont et al 1998, Mosyak et al 1998, 
Pos et al 2012), which suggests that the region is not under selection for diversity. 
Structurally, HLA-DM has three disulphide bonds at conserved positions and two additional 
disulphides compared to HLA-DR. It has been suggested that these additional disulphides 
may increase the stability of DM when compared to MHCII (Fremont et al 1998). A crystal 
structure of HLA-DM in complex with the HLA-DR1 show that HLA-DM mainly contacts the 
α1 domain of MHCII close to P1 and the membrane-proximal β2 domain, supporting 
previous mutational analysis (Doebele et al 2000, Painter et al 2011, Anders et al 2011). The 
mechanism of DM action is now known in molecular detail, starting with the dissociation of 
the N-terminus of the bound peptide from the P1 pocket, which is either caused by or causes 
the DRA W43 to flip away from the P1 pocket and become available for interaction with DM. 
The empty DR is then stabilised by DM whilst the DRα residues F51 and βF89 guard the P1 
pocket; peptides then attempt to bind the partially available groove (Pos et al 2012). 
Peptides that fail to outcompete the DR residues in the P1 and P2 pockets are not bound, 
but when the N-terminus of a peptide is bound the conformational changes in DR are 
reversed and DM is dissociated (Pos et al 2012) (fig 1.4.1). The key residues for DR-DM 
interaction are heavily conserved across species, including the chicken.  
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Figure1.4.1 Model proposing the key steps in HLA-DM – HLA-DR action  
 1) CLIP is bound in DR peptide binding groove whilst DR αW43 (red) stabilises the P1 pocket. 2) The N-
terminus of the peptide dissociates from DR binding groove and the DR αW43 rotates away from the P1 
pocket and becomes available for interaction with DM. DR residues (arrows) move into the peptide groove 
during the transition to a DM-bound state. 3) DM stabilizes the empty DR, whilst the DR αF51 and βF89 
protect the hydrophobic P1 pocket. 4) Binding of peptides to partially accessible peptide groove of DR result 
in peptides that do not successfully outcompete DR residues (yellow) for P2 site and P1 pocket are not stably 
bound or outcompete the DR residues. 5) Peptides that outcompete the DR residues (yellow) result in 
binding of the peptide N-terminus and reverse the conformational changes of DR and the dissociation of DM 
(Pos et al 2012). 
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1.5 Organisation of the mammalian MHC 
Classical and non-classical class I and II genes are encoded in the multi-locus region of the 
genome known as the MHC; this includes the TAPs and tapasin for the class I system and DM 
and DO for the class II system (The MHC sequencing consortium 1999, Kelley et al 2005). The 
MHC was originally discovered as the locus responsible for tissue allograft rejection in the 
mouse and was later described in humans (Gorer 1936, Dausset 1958). 
The MHC region of most mammals is large, covering hundreds of kilobases, and contains the 
multigene families of class I and class II. The MHC also includes many other genes with a 
variety of functions which are mainly immune associated, as well as numerous pseudogenes 
and repetitive regions (Kelley et al 2005). The human MHC is 3.8 megabases with over 220 
genes. The locus is divided into three regions, such as the class I region, that contains the 
classical class I genes HLA-A, B and C and some but not all non-classical class I genes (Kelley 
2005, Trowsdale et al 2011). 
The class II region in humans contains the classical class II genes that encode HLA-DP, DQ 
and DR, as well as the non-classical class II genes that encode HLA-DM and DO; in each case 
(except DO), the α and β chains are encoded adjacently (Ting and Trowsdale 2002). For DP 
and DQ one copy of each gene is well-expressed and functional; DRB is an exception where 
more than one copy per haplotype can be functional. In mice, one classical class II molecule 
is encoded by H-2A and another by H-2E, but in many mouse strains the H-2E molecule is 
lacking due to disruptions in the H-2Eα or H-2Eβ genes. Interestingly, the mouse contains 
two H2-Mb genes, Mb1 and Mb2, both of which are expressed. Sequence analysis reveals H-
2E is most closely related to HLA-DR, whilst H-2A is most similar to HLA-DQ and there is no 
functional murine homologue of HLA-DP. The organisation of the class II region is similar 
throughout mammals, although there are many species-specific differences to (van der Poel 
et al 1990, Yuhki et al 2003). The class II region also contains genes involved in class I antigen 
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processing such as TAP1 and TAP2, whilst tapasin is located in the extended class II region 
(Beck and Trowsdale 1999, Kelley et al 2005). The class II region has strong associations with 
autoimmunity (Beck and Trowsdale 1999, Marsh et al 2000, Kelley et al 2005) (fig 1.5.1). 
The class III region includes complement component genes, cytokines and many other 
immune and non-immune associated genes (Kelley et al 2005); interestingly the class III 
region separates the class I and class II regions. 
 
 
1.6 Transcriptional regulation of MHCII expression 
MHCII molecules are constitutively expressed on APCs with all three MHCII molecules being 
expressed at the same time, although some subsets of B cells only express DQ. The promoter 
elements for MHCII are very conserved, with all classical and non-classical promoters 
(including li) containing the S, X1/X2 and Y boxes, some of which are bound by proteins 
factors such as cAMP-responsive-element binding protein (CREB), regulatory factor X (RFX) 
Figure1.5.1 Schematic of the MHC organisation in humans  
representation of the class I, class III and class II regions of the human MHC. Classical MHCI genes are shown 
to be in the class I region and classical and non-classical MHCII genes are seen in the class II region. Genes 
associated with MHCI peptide loading are found in the class II region (TAP and tapasin). The class I and class 
II regions are separated by the class III region. Genes are represented as grey boxes (Trowsdale 2011). 
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and nuclear factor Y (NFY), whilst the binding protein of the S box (sometimes called W box) 
has yet to be defined (Choi et al 2011). Collectively this protein complex recruits the class II 
transactivator (CIITA) protein, which binds to conserved elements of the proteins that bind 
the proximal-promoter regions of the class II genes (Choi et al 2011) (fig 1.6.1). Activation of 
the CIITA is driven by phosphorylation and ubiquitylation, and multiple transcriptional start 
sites (Sisk et al 2003 Greer et al 2004, Bhat et al 2010). Expression of CIITA in humans is 
regulated by four distinct promoters (each having a different product), with different 
isoforms being expressed in different cell types (Smith et al 2011, Choi et al 2011). Studies 
have also shown that changes in chromatin organisation can affect transcriptional activation 
or repression in specific cell types, providing a mechanism for differential expression of class 
II molecules, despite sharing the same transcriptional elements (Choi et al 2011). This 
additional level of regulation could explain previous findings that show that HLA-DR is 
generally more highly expressed than HLA-DP and HLA-DQ molecules. The relative levels of 
different MHCII molecules expressed will change the contribution that each isotype makes 
to the total peptide repertoire presented by the cell, and is of interest as previous findings 
have shown that particular HLA-DP, DQ and DR alleles are strongly associated with 
autoimmune diseases. 
 
Figure1.6.1 Regulation of MHCII by proximal promoter 
The highly conserved W, X and Y box is bound by RFX, CREB, and NFY. This unique structure is recognized by 
CIITA. The CIITA recruits many additional transcriptional co-activators and their associated complexes that 
modulate CIITA activation (Choi et al 2011). 
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1.7 The chicken MHC 
The chicken MHC is contained in the B locus, which was first identified as a serological blood 
group that encodes the highly polymorphic and immunogenic BG genes (Briles et al 1952). 
The B locus has strong associations with graft rejection, graft-vs-host reactions and mixed 
lymphocyte reactions (Pazderka et al 1975, Vainio et al 1988), leading to reasoning that the 
B locus must contain the chicken MHC, which was conclusively shown by full sequencing 
(Kaufman et al 1999).  
 The chicken MHC is found on chromosome 16 and separated into two regions by 
recombination. The BF/BL region contains class I and class II genes as well as the BG1 gene; 
importantly no recombination has been seen within this region by experimental mating, and 
only one natural recombinant has been seen (Scandinavian B19 haplotype). The TRIM/BG 
region is filled with tripartite motif (TRIM) genes and then immediately followed by the BG 
region, which is shown to undergo huge expansion and contraction between chicken 
haplotypes. A further locus, the Rfp-Y region was also identified on chromosome 16 and 
contains a non-classical class I gene (YF), non-classical class IIB (YLB) genes and lectin like 
genes, though it is genetically unlinked to the B locus, being separated by a repetitive GC 
region (Briles et al 1993, Miller et al 1994, 1996, Rogers et al 2003, Salomonsen 2014). 
Sequencing of the BF/BL region was initially shown in the B12 haplotype and revealed 
striking differences to that of the typical mammalian MHC. The chicken BF/BL region is small 
(92 kb) and simple, encoding just 19 genes (Kaufman et al 1999), organised as predicted 
previously (Pink et al 1977, Gulliemot et al 1988) and was shown to be consistent in 15 
different haplotypes (Jacob et al 2000, Shaw et al 2007, Hosomichi 2008). 
The chicken MHC region is even more compact (44 kb) containing only 11 genes, with many 
of the mammalian MHC genes being present including MHCI, MHCII B, TAP, tapasin and DM 
genes. It is important to note that there are only two classical class I genes (BF1 and BF2) and 
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two classical class II B genes (BLB1 and BLB2).  Interestingly, not all typical mammalian MHC 
genes are found in or near to the chicken MHC, including the classical class II α, inducible 
proteasome (low molecular mass polypeptide, LMP) and DO genes, and has been described 
as a minimal essential MHC (Kaufman et al 1999). 
The organisational structure of the chicken MHC is vastly different from that of typical 
mammals. As mentioned previously, for the typical mammalian MHC, the class I and II 
regions are separated by the class III region. In the chicken, the class II and I regions are 
located next to each other with the class III region on the outside (fig 1.7.1). Importantly, it is 
noted that the TAP genes are flanked by the classical class I genes and that tapasin is flanked 
by the class II B genes (fig 1.7.1). It is also observed that the genes involved in peptide 
loading for class I and II (TAP, tapasin and DM) are all polymorphic whereas in typical 
mammalian systems they are functionally monomorphic or have limited polymorphism 
(Jacob et al 2000, van Hateren et al 2013, Walker et al 2011). 
 
 
 
 
Figure1.7.1 Organisation and co-evolution in the chicken MHC 
The chicken MHC is small and simple containing most genes necessary for antigen presentation. This 
includes the classical class I and class II B genes, the non-classical class I and class II genes TAP1, TAP2, 
tapasin, DMA, DMB1 and DMB2. The TAP genes are seen to be flanked by the classical class I genes, with co-
evolution being indicated (curved red arrow). The possible co-evolution of class II genes is shown by the 
presence of curved blue arrows. The differences in expression of all genes (in haematopoietic cells) are 
shown by varying thickness of straight arrows.  
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1.7.1 The chicken MHC encodes a dominantly expressed classical class I molecule  
Cloning and sequencing of cDNA showed the presence of two classical class I genes 
expressed in most common MHC haplotypes (Kaufman et al 1999). Surprisingly, the number 
of cDNA clones showed that one MHCI gene (BF2) was found in much greater abundance 
than the other (BF1), with up to 10-fold more expression being found in many haplotypes 
(Kaufman et al 1999, Wallny et al 2006), leading BF2 to be referred to as the major and BF1 
the minor class I gene. To understand this difference of expression the whole of both BF 
genes was sequenced, which showed all BF2 genes and promoter elements were intact. BF1 
showed a variety of differences between haplotypes, including deletions and divergence in 
the promoter elements as well as disruptions to the BF1 gene itself (Kaufman et al 1999, 
Livant et al 2004, Shaw et al 2007). This difference in BF abundance was also seen at the 
protein level by two-dimensional electrophoresis in peripheral blood lymphocytes and at the 
peptide level, where isolation of bound peptides showed all peptide motifs were consistent 
with the binding motif of the BF2 molecule (Wallny et al 2006). 
Dominant class I expression is due to co-evolution with class I antigen processing genes. The 
polymorphic class I genes are in strong linkage disequilibrium with the polymorphic peptide 
loading genes (tapasin and TAP), resulting in co-evolution. This co-evolution of the class I 
system results in specific alleles of the TAP genes that specify peptide translocation of 
peptides with a motif that correlates with that of one particular MHCI, specifically the 
dominantly expressed BF2 but not BF1 (Walker et al 2011) (fig 1.7.1). This results in the BF2 
molecule receiving many suitable peptides and in contrast, BF1 receives much less and is 
expected to have become less important in antigen presentation (Walker et al 2011). 
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1.7.2 MHC-association with pathogen response 
As previously mentioned, in humans the MHC region is known to have the most associations 
to disease resistance and susceptibility, with strong associations being generally with 
autoimmune diseases. In the chicken, there are strong associations with infectious 
pathogens that were found by poultry researchers over half a century ago. These 
associations were initially located to the B locus, which was later shown to contain the MHC. 
Unlike in humans, there is a wealth of data detailing MHC disease associations to a variety of 
infectious pathogens, including viruses, bacteria and parasites (Briles et al 1977, Bacon 1981, 
Plachy et al 1994, Lamont 1998, Hudson et al 2002, Lui et al 2002, Schou et al 2007, Miller 
and Taylor 2016). The hypothesis of a minimal essential MHC provides a potential 
explanation for these incredibly strong pathogen associations seen in the chicken. In 
humans, the TAP genes are monomorphic and able to pump a very broad repertoire of 
peptides to the multigene family of MHCI molecules, which allows the presentation of a 
wide variety of peptides by HLA-A, B and C molecules. This allows humans to confer more or 
less protection to a diverse variety of pathogens, which reads out as weak genetic 
association to most infectious disease. In the chicken, peptide presentation is restricted by 
the polymorphic TAPs to one particular class I (BF2), which reads out as a strong genetic 
association, giving rise to the concept that ‘chickens live or die by their MHC’ (Walker et al 
2011). Many studies have shown that the presence of a particular MHC haplotype confers 
life or death resistance or susceptibility to a particular pathogen, including commercially 
important pathogens such as Marek’s disease virus (MDV) and Rous sarcoma virus (RSV) as 
well as pathogens central to zoonosis, for example avian influenza virus (AIV) (Briles et al 
1977, Plachy et al 1994, Boonyanuwat et al 2006). Moreover, it could be reasoned that one 
of the six expressed human class I molecules (in a heterozygote) is more likely to bind a self-
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peptide and could explain the strong associations with autoimmunity found with the human 
MHC.  
 
1.7.3 Generalists and specialists 
One major question arising from the discovery of one dominantly expressed MHCI molecule 
is how the chicken survives with only one MHCI molecule in a homozygote, or two in a 
heterozygote? Unlike in humans, it was demonstrated that the MHCI molecules of some 
chicken MHC haplotypes are able to bind a very broad spectrum of peptides (termed 
promiscuous) compared to what is seen for typical mammalian MHC molecules (Chappell et 
al 2015, Kaufman 2018). Interestingly, the TAP complex found in these haplotypes were also 
found to be very promiscuous, pumping a huge variety of peptides (Tregaskes et al 2016). It 
was proposed that these promiscuous MHC haplotypes present such a breadth of peptides 
that they can functionally act similarly to that of a multigene family found in typical 
mammals (Kaufman et al 2018). Between the haplotypes analysed, the breadth of peptide 
presentation by the chicken MHCI was found to be a spectrum, with some MHCI molecules 
being promiscuous and other presenting a narrow repertoire that is limited by more 
restrictive TAPs, termed fastidious MHCI molecules (Walker et al 2011, Chappell et al 2015, 
Tregaskes et al 2016, Kaufman 2018). The more fastidious MHC molecules are thought to 
have arisen during particularly virulent pathogen outbreaks, resulting in a purifying selection 
for a particular peptide presented in high abundance by a fastidious MHCI. This notion has 
been supported by findings that show fastidious MHCI molecules are much more abundant 
on the cell surface than that of promiscuous MHCI molecules (Chappell et al 2015). The 
spectrum of MHCI peptide presentation breadth and cell surface expression has led to the 
hypothesis that chicken MHCI molecules can be split into generalist and specialist MHCI 
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molecules, with generalists providing a broad range of protection to many pathogens, whilst 
specialists provide protection to particularly virulent pathogens (Kaufman 2018). 
 
1.7.4 The chicken MHC class II processing and presentation system 
The first MHC gene isolated outside of mammals was a chicken MHCII gene, using a human 
HLA-DQB cDNA probe which isolated chicken gDNA clones and were then mapped to the 
chicken BF/BL region (Bourlet et al 1988). Initially, five class II β genes were identified by 
cosmid isolation for chickens of the B12 haplotype and numbered I-V. Further studies 
revealed that one cosmid cluster mapped BLB-I and II to the BF/BL region, whilst the 
remaining three BLBs on other cosmids were located to the unlinked Rfp-Y region. Genes 
derived from the BF/BL region appeared to be classical MHCII B genes, based on their high 
levels of polymorphism and sequence diversity and were eventually renamed BLB1 and 
BLB2, whilst the other three BLB genes had little polymorphism and sequence diversity and 
therefore appeared to be non-classical MHCII genes and were renamed Y-LB genes (Zoorob 
et al 1990, Miller et al 1994, Kaufman et al 1999). It was demonstrated in the B12 haplotype 
that the two BLB genes in the BF/BL region flanked the tapasin gene and are in opposite 
transcriptional orientation (Kaufman et al 1999). 
Similarly to what is seen for MHCI, the chicken has two classical MHC II B chains (BLB1 and 
BLB2) with only one BLB (BLB2) being strongly expressed at the RNA level in haematopoietic 
cells (Jacob et al 2000). Analysis of the class II α chain (BLA) cDNA revealed it to be non-
polymorphic and much like DRA of humans (Salomonsen et al 2003).  In contrast to humans, 
the class II α chain (BLA) is located outside of the MHC, being mapped 5 cM away from the 
BF/BL region (Jacob et al 2000). Similar to humans, the chicken has genes encoding the 
peptide editor and chaperone DM. Humans encode one α chain and one β chain for DM 
(HLA-DMA and DMB), but interestingly the chicken has two DMB chains (DMB1 and DMB2) 
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giving the possibility of two DM peptide editors to be expressed and notably, only one of the 
DMB genes is strongly expressed in haematopoietic cells (DMB2) (Kaufman et al 1999, 
Parker and Kaufman 2017). Moreover, the non-classical MHCII genes are highly polymorphic 
unlike typical mammals, reflecting what is seen in the MHCI system. The combination of 
dominantly expressed BLB2 and DMB2 genes as well as polymorphic DM genes suggested 
that there may be co-evolution between MHCII genes and its chaperones, as is seen for the 
MHCI system (Parker and Kaufman 2017) (fig 1.7.1). 
 
1.8 Genome editing 
Programmable nucleases that make permanent effects to the genome are a desirable 
technique and have been developed in multiple forms. Programmable nucleases are designed 
to make site-specific DNA double-stranded breaks (DSBs); these DSBs are then repaired in one 
of two ways (fig 1.8.1). The first is the error-prone DNA repair pathway non-homologous end 
joining (NHEJ) which often results in an insertion or deletion (indel) event that potentially 
disrupts the target genes function, making a knockout (KO). The second, homology-directed 
repair (HDR) relies on supplying a 'DNA repair template' that has homology to the surrounding 
genomic region of the DSB break allowing a specific sequence to be 'knocked in' (KI) to that 
region (Kim et al 2014).  
Zinc-finger nucleases (ZFN) were the first technology for successful precise genome editing. 
ZFNs have been successfully used to modify genes of various organisms, ranging from viruses 
and bacteria to mammals such as mice and pigs as well as cultured avian cell lines (Segal and 
Meckler 2013, Perez-Pinera et al 2013, Urnov et al 2010). ZFNs are comprised of two 
domains: a DNA-binding zinc-finger protein (ZFP) domain and a DNA nuclease domain that is 
derived from the FokI restriction enzyme (Kim et al 1996). The DNA-binding domain of FokI is 
replaced with ZFPs to create a ZFN, two ZFN monomers are needed to create an active 
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nuclease as the dimerization of the FokI nuclease domains allows DNA cleavage. Each ZFN 
monomer must bind to adjacent half recognition sites that are separated by the 5-7 bp linker 
from the FokI domain. The FokI interacting interfaces were modified to require heterodimers 
to form, as wild-type FokI domains can only form homodimers allowing monomeric binding 
of DNA to result in cleavage and off-target effects. 
ZFN sequence specificity is determined by ZFPs, which consist of tandem arrays of C2H2 zinc-
fingers; the most common DNA-binding motif in higher eukaryotes. Each zinc-finger 
recognizes 3-bp of DNA sequence, and 3–6 zinc-fingers are used to generate a single ZFN 
subunit that binds to DNA sequences of 9–18 bp. Importantly, the DNA-binding specificities 
of zinc-fingers can be altered by mutagenesis, which is a key feature of constructing a 
programmable nuclease. 
The next major breakthrough in genome editing came through the development of 
transcription activator-like effector nucleases (TALENs). Like ZFNs TALENs have been used to 
edit a whole multitude of organisms including viruses, plants, insects, frogs, fish and 
mammals, as well as in cultured mammalian cells (Nemudryi et al 2014). The structure of 
TALENs is similar to that of ZFNs, containing a FokI nuclease domain at the C-terminus.  
The differences are found at the DNA binding domains, where they use transcription activator-
like effectors (TALEs), which are derived from the plant pathogen Xanthomonas spp. TALEs are 
comprised of tandem arrays of 33–35 amino acid repeats, each of which recognizes a single 
base-pair. The nucleotide specificity of each repeat domain is determined by two amino acids 
located at positions 12 and 13, these two amino acids are termed repeat variable diresidues 
(RVDs). Four different RVD combinations are used to recognise guanine, adenine, cytosine and 
thymine, the most commonly used are; Asn-Asn, Asn-Ile, His-Asp and Asn-Gly, respectively. As 
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with ZFN two monomers are needed for dimerization of the FokI nuclease domains to create 
a functional DNA nuclease and allow DNA cleavage. 
TALENs were followed by RNA-guided engineered nuclease (RGEN) technology, which was 
derived from the adaptive immune system found in some prokaryotic organisms. The 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) locus was discovered in 
1987 as an unusual repeating cluster that, at the time, had little homology to known 
sequences. The CRISPR region was found to create small RNAs (Tang et al 2002). From here it 
was discovered that in bacteria and archaea, an RNA-guided DNA cleavage system provides 
adaptive immunity against invading phages or plasmids (Makarova et al. 2006). These organ-
isms regularly capture small DNA fragments from the foreign DNA of an invading phage or 
plasmid and then insert a sequence termed as a protospacer into their own genome to form 
a CRISPR. 
In type II CRISPR systems, these CRISPR regions are transcribed as a pre-CRISPR RNA (pre-
crRNA) and are processed to give rise to target-specific crRNA fragments. In addition, an 
invariant target-independent trans-activating crRNA (tracrRNA) is also transcribed from the 
same locus, which adds to the processing of pre-crRNA (Deltcheva et al. 2011). Both the crRNA 
and tracrRNA are then complexed with CRISPR-associated protein 9 (Cas9), forming an active 
DNA endonuclease. The resulting targeted DNA nuclease cleaves a 23-bp target DNA 
sequence, which is comprised of the 20-bp guide sequence in the crRNA (the protospacer) and 
the NGG sequence known as protospacer adjacent motif (PAM), which is recognized by the 
Cas9 itself facilitating DNA cleavage (Hsu et al. 2013, Mali et al. 2013, Mojica et al. 2009). Cas9 
proteins derived from species other than Streptococcus pyogenes recognise different PAM 
sequences (Cong et al. 2013, Shah et al 2013, Hou et al 2013). 
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The two RNA components (crRNA and tracrRNA) can be fused to form a chimeric single-chain 
guide RNA (sgRNA), giving a simplified component for RGEN mediated genome editing (Jinek 
et al 2012). The most successful CRISPR-Cas9 guided genome editing method uses a plasmid 
containing the sgRNA with cloning sites to simply insert a 20-bp guide site of choice to specify 
the editing location (Ran et al 2013) (fig 1.8.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.8.1 Schematic of targeted genome cleavage and editing by CRISPR-Cas9 
The Cas9 nuclease from S. pyogenes (in yellow) is targeted to desired genomic DNA by a chimeric sgRNA 
consisting of a 20-nt guide sequence (blue) and an RNA scaffold (red). The guide sequence pairs with the 
DNA target directly upstream of a required 5′-NGG adjacent motif. Cas9 mediates a DSB ~3 bps upstream of 
the PAM site (red triangle). This cleavage is then repaired in either two ways; the error prone NHEJ pathway, 
often resulting in indel mutations (green bar) or by HDR that results in a precise gene editing event (Ran et al 
2011). 
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1.9 Project aims 
  
The main aim of the project is to gain a deeper understanding of the antigen processing 
systems in the chicken. This includes antigen processing and selection from both the class I 
and class II antigen presentation pathway. 
 
1. Assess the importance of particular chicken TAP1 and TAP2 polymorphisms in the 
activity and specificity of peptide transport and class I loading, with the goal of 
understanding which residues are important for function. 
2. Assess the importance of DMA, DMB1 and DMB2 for expression and peptide 
loading of the classical class II molecules including BLB1 and BLB2, with the goal of 
understanding whether there is co-evolution between DM and class II isotypes.  
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2. Materials and Methods 
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2. Material and Methods 
2.1 Chickens 
 White leghorn chicken derived lines 61 MHC haplotype (B2), C-B4 (B4), C-B12 (B12), 15I 
(B15), P2a (B19) and 0 (B21) (Shaw et al. 2007) were bred and maintained under defined 
pathogen-free environment at the Institute for Animal Health (Compton, UK). The inbred 
MHC-homozygous lines 61, 15I, and 0 were developed by the Regional Poultry Research 
Laboratory (East Lansing, MI). Lines C-B4 and C-B12 are sub-lines derived from the 
Reaseheath line C developed at the Northern Poultry Breeding Station (Reaseheath, UK). The 
P2a line was acquired from the Institute for Animal Science and Health (Lelystad, The 
Netherlands) and originated from the line P2a from Cornell University (Ithaca, NY). The 
histories of some of these lines are reviewed in Schat et al. 1980, Simonsen et al. 1982, Hála 
et al. 1987, and Briles et al. 1982. 
 
2.2 Development of REV cell lines and culture conditions 
 Chicken cell lines were transformed with replication-defective avian reticuloendotheliosis 
virus strain T (REV-T). The cell line TG12A5 was generated by in vitro REV-T transformation of 
concanavalin A-activated splenocytes from B12 birds and the TG15 cell line was made from 
REV-T transformed bursa (E. K. Meziane, personal communication. 2014). These cell lines 
were generated at the Basel Institute for Immunology by Thomas Göbel (Marmor et al. 1993 
and Walker et al. 2011). REV cell lines were cultured in suspension in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 0.3 g/l L-glutamine and 10 % fetal bovine 
serum (FBS) (Gibco) at 37 °C, 5 % CO2. 
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2.3 Agarose gel electrophoresis 
Agarose gels were prepared as 1 % UltraPure™ Agarose (Invitrogen) in 1x Tris acetate EDTA 
(TAE) buffer (40 mM Tris-acetate pH 8.0, 1 mM EDTA) containing GelRed dye (Biotium) at 
1/40,000 and visualised using a FluorChem fluorescent imager (AlphaInnotech). 
 
2.4 Genomic DNA extraction and molecular cloning 
Genomic DNA from REV-T cell lines was extracted using GenElute™ Genomic DNA Miniprep 
Kit (Sigma-Aldrich). Genomic regions of interest were amplified by PCR using the "high 
fidelity" buffer in the VELOCITY™ DNA Polymerase kit (Bioline) or “high fidelity” in the 
Phusion® DNA polymerase kit (New England Biolabs). The following PCR mixture was 
prepared 
Component   Amount (l) 
gDNA                                    1 
100mM dNTP's                      0.5 
5x high fidelity buffer                        5 
Forward primer (10 M)                 1 
Reverse primer (10 M)                   1 
DNA polymerase            0.5 
Nuclease free H2O                        15.5 
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The samples were placed in a thermocycler under the following conditions: 5 min at 98 °C, 
followed by 30 cycles of 60 s at 98 °C, 60 s at 60-70 °C and 240 s at 72 °C followed by 10 min 
at 72 °C.  
The PCR product was run on a 1 % agarose gel, the correct sized band was excised from the 
gel and purified using a MinElute Gel Extraction Kit (Qiagen). Purified amplicons were ligated 
into the pJET1.2/blunt vector (Fermentas) which contains a lethal restriction enzyme gene 
that is disrupted by ligation of a DNA insert into the cloning site. Ligated plasmids were 
transformed into DH5α chemically competent E.coli, prepared by Alicia Martín-López  
(protocol was adapted from Molecular Cloning, 3rd edition, Sambrook J and Russell D, 2001). 
Colonies were picked in 2 ml cultures of LB containing 100 g/ml ampicillin and grown 
overnight at 37°C and shaking at 250 rpm. Plasmid DNA was purified from bacterial cultures 
using the QIAprep Spin Miniprep Kit (Qiagen) (based on the method of Vogelstein and 
Gillespie. 1979). Purified plasmid DNA was screened by PCR and electrophoresis on a 1 % 
agarose gel to identify plasmids containing an insert of the expected size. Plasmids with an 
insert of the expected size were confirmed by dideoxy/chain termination sequencing (Sanger 
et al. 1977). This was performed on an Applied Biosystems 3730xl DNA Analyser by the 
University of Cambridge Biochemistry Department Sequencing Facility, using a T7 
sequencing primer (5' - TAA TAC GAC TCA CTA TAG GG - 3'). 
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Primer Sequence Gene 
UC54 GTGCCCGCAGCGTTCTTC BLB 
UC55 TCCTCTGCACCGTGAAGG 
DMA indel FP TCTGTGCCTGCAGAGCCAT DMA 
DMA indel RP TGGCGATTCTGGTGAGCAA 
C321 TCCCCATGCCCCCAACGCAG DMB1 
C322 CCACTTGCATGCAGCGGTGC 
DMB2 indel FP 
(f) 
TGCCTTCATGGTGCATGTG DMB2 
DMB2 indel RP 
(r) 
TCTGTGCCCAGAACTGTGC 
b2m indel FP 
 
CAAGGTGCAGGTGTACTCC 
 
B2m 
b2m indel RP 
 
ACTTGTAGACCTGCGGCTC 
 T1_intFor 
 
CACCACAGATGCAGAAGGC 
 
TAP1 
T1_intRev 
 
ATAGGAGATGTTGGCGTGGAG 
 T2_intFor 
 
GCTGCTGTCGGCCTCATG 
 
TAP2 
T2_intRev 
 
GGTAGCGGTGCTCGTAGTCC 
  
 
2.5 RNA extraction 
Cell lines were harvested and 3x106 cells were used for RNA extraction. RNA extraction was 
performed using the NucleoSpin® RNA II RNA extraction kit (Machery-Nagel), following the 
manufacturer’s protocol. The area where the RNA extraction was performed, and the 
pipettes used were first treated with the RNase removing agent RNAseZAP® (Sigma). 
2.6 Reverse transcription of RNA to cDNA 
RNA was reverse-transcribed to cDNA using an oligo-dT primer and the Maxima H Minus 
First Strand cDNA Synthesis Kit (ThermoFisher) as per manufacturer’s instructions. One 
microgram of RNA was incubated with dNTPs, oligo-dT, RNase inhibitors and the reverse 
transcriptase enzyme mix for 45 min at 55°C. Reactions were inactivated at 85°C for 45 min 
and stored at -20°C. 
 
 
Table 2.1 Primers used to assess genome editing. 
 This table details the primers that were used to amplify the regions surrounding the guide sites for 
CRISPR-Cas9 editing. 
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2.7 Reverse transcription quantative polymerase chain reaction (RT-qPCR) 
RT-qPCR primers were designed to amplify products between 100–150 base pairs (bp) with 
an optimal annealing temperature of ~60°C. Primers were checked for specificity against the 
NCBI database using the BLAST algorithm (Altschul et al. 1990). Targets were amplified from 
2, 10 and 100 ng  of cell line derived cDNA in 10 μl reactions of Power Up™ SYBR® Green 
Master Mix (Thermo Fisher) as per the manufacturer’s instructions.  Primer pairs were 
optimised with primers having an amplification efficiency of >80% were considered for 
further use. All amplifications were performed on a 7500 Real-Time PCR System (applied 
Biosystems). Primer pairs were subject to melt curve analysis using the 7500 software 
(applied biosystems). At 95°C the melt curve was checked for the presence of multiple 
products. Primer pairs producing one single peak were used for further experimentation. 
Target genes were amplified under the following conditions: 15 min at 95 °C, followed by 40 
cycles of 60 s at 95 °C, 60 s at 60°C and 30 s at 72 °C. Fluorescence data was collected after 
each cycle and analysed using the 7500 software (applied biosystems), with subsequent 
analysis preformed in Microsoft Excel.  
The amplification baseline threshold was automatically determined by the 7500 Real-Time 
PCR System as the point where amplification curves are at the start of the log phase. The 
cycle at which the amplification curves crossed the baseline threshold were recorded, 
generating the Ct value. Each sample was normalised to the slope and intercept of the 
standard curve generated by the 3 x dilution series for every experimental plate. Samples 
were run in triplicate before results were analysed by the delta delta ct method. The 
averages of the triplicates for each sample were then represented as fold-increases and fold-
decreases in expression between each sample. Error bars represent the standard error of 
the mean. 
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Primer Gene Sequence 
UC111 FP DMA ATGCCTGAAGCCAAGGGC 
UC112 RP DMA TAGGAGAAGCGCATGAAGCC 
      
UC116 FP DMB2 ATGTTGGTGCTATTGGGGCTG 
UC118 RP DMB2 AGTCGCAGGCGTTGAAGAG 
      
UC230 FP BLB2 TCTTCGTGTTCCTGCGCGGT 
UC232 RP BLB2 ATCGTGGCGACATCTCCAACG 
      
UC29 FP BLA CTCAGACCGTATGGAGGCTG 
UC30 RP BLA CAGATGAGGACGTTGGGTTC 
      
qPCR DMB1 FP1.2 DMB1 ATGGCCTTCAACAAGAA 
qPCR DMB1 RP1.2    DMB1 AAACATGGCAGATGAGGT 
      
qPCR BLB1 FP1 BLB1 ATGCTGAATTAGCTGCTG 
qPCR BLB1 RP1 BLB1 GTCTGAGCGACTTCTTGG 
      
HPRT FP     HPRT GATGAACAAGGTTACGACCTGGA 
HPRT RP    HPRT TATAGCCACCCTTGAGTACACAGAG 
      
GAPDH FP    GAPDH GTGGTGCTAAGCGTGTTATCATC 
GAPDH RP    GAPDH GGCAGCACCTCTGCCATC 
      
18S FP      18S CGAAAGCATTTGCCAAGAAT 
18S RP        18S GGCATCGTTTATGGTCGG 
 
 
2.8 Clustered random interspaced palindromic repeats (CRISPR)-cas9 mediated genome 
editing 
Selected REV-T cell lines were edited using the CRISPR-cas9 genome editing technique (Rang 
et al. 2013). CRISPR-cas9 sgRNA plasmids (table 2.1) were assembled to include targeted 
guide sites (Rang et al. 2013). 
 
Table 2.2 RT-qPCR primers. 
 This table details the primers that were used for all RT-qPCR experimentation. 
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Plasmid name Selection marker Addgene reference 
PX330 None 42230 
PX458 GFP 48138 
PX459 Puromycin 48139 
 
2.6 Guide site design using the “optimised CRISPR design” online tool 
Initially guide sites were designed to target DMA, DMB1, DMB2 and BLB2 genes using the 
optimised CRISPR online design tool (http://crispr.mit.edu/). For each gene, early exons 
were selected to increase the chance of gene KO by indel generation. The genomic DNA 
sequence for each chosen exon was analysed for viable guide sites using the “optimised 
CRISPR design” tool. Potential guides sites are assigned a quality score. The quality score 
Table 2.3 CRISPR-Cas9 sgRNA plasmids.  
This table details the sgRNA plasmids used currently. 
Figure 2.1. Sequence map of the CRISPR-Cas9 sgRNA plasmid 
(https://www.addgene.org/48138/). 
This figure shows the structural organisation of a sgRNA plasmid. Including features such as the 
human U6 promoter, eGFP and triple flagged regions. 
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ranges from 0 (many off target effects) to 100 (no off-target effects). Guide sites with the 
highest quality score were selected for cloning into chosen sgRNA plasmids. 
 
Plasmid name Sequence 5' to 3'  Location 
DMA sgRNA1 gtttggcccggtggcgattc Exon 2 
DMA sgRNA2 catcagtgaggacacatcgt Exon 2 
DMB1 sgRNA1 ctgtaggtccagtccccgtt Exon 3 
DMB1 sgRNA2 ccaacggggactggacctac Exon 3 
DMB2 sgRNA1 gtgcggggacgatgcggacc Exon 2 
DMB2 sgRNA2 ccagatgatggtcacctcgg Exon 2 
BLB2 sgRNA1 ctggtggcactgctggcgct Exon 1 
BLB2 sgRNA2 cccggcggcgggggccgtgc Exon 1 
 
 
 
 
2.9 Guide site design using the “sgRNA designer” online tool 
Subsequently, guide sites were designed using the sgRNA designer online design tool. Guides 
were made to target DMA, DMB1, DMB2, BLB1, BLB2 and β2m genes. Again, early exons 
were selected to increase the chance of successful gene KO. The genomic DNA sequence for 
each chosen exon was analysed for potential guide sites by the “sgRNA designer online tool" 
(http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design).  
Available guide sites were given an 'on-target efficacy' score. The 'on-target efficacy' score 
ranges from 0 (low efficacy) to 1 (high efficacy). Guide sites with the highest 'on-target 
efficacy' score and fewest off target effects were selected for cloning into sgRNA plasmids. 
 
Table 2.4 Guide sites selected for DMA, DMB1, DMB2 and BLB2. This figure details the guide sites 
selected for genome editing. The guides were selected from the optimised CRISPR design tool 
analysis. 
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Oligo Name Sequence 5' to 3'  Location Broad institute score (0-1) 
BI B2m sgRNA1 tcttggtgcccgcagaggcg Exon 2 0.757 
BI B2m sgRNA1 tcttggtgcccgcagaggcg Exon 2 0.757 
BI B2m sgRNA2 gccgacttcacgcccagcag Exon 2 0.638 
B2m sgRNA2 gccgacttcacgcccagcag Exon 2 0.638 
BI B2m sgRNA3 tccatcacgctgatgaagga Exon 2 0.629 
BI B2m sgRNA3 tccatcacgctgatgaagga Exon 2 0.629 
BI B2m sgRNA4 gaacgtcctcaactgcttcg Exon 2 0.549 
BI B2m sgRNA4 gaacgtcctcaactgcttcg Exon 2 0.549 
BI DMA sgRNA1 gagcagctcacggcacagcg Exon 2 0.834 
BI DMA sgRNA2 tcgatgtccccaactcgcag Exon 2 0.661 
BI DMB1 sgRNA1 gcagcagcccccaatcgcaa Exon 2 0.940 
BI DMB1 sgRNA2 gcttctacccttgcgattgg Exon 2 0.594 
BI DMB2 sgRNA1 gcagccaatggctctctgcg Exon 1 0.770 
BI DMB2 sgRNA2 gcggggcttcgacctcaccg Exon 1 0.633 
BI BLB1 sgRNA1 cagcgacgtggggaaatacg Exon 2 0.677 
BI BLB1 sgRNA2 tacgtggctgatacaccgct Exon 2 0.596 
BI BLB2 sgRNA1 ttgcagatacctcacccgct Exon 2 0.756 
BI BLB2 sgRNA2 tttgtggccgattcaccgct Exon 2 0.730 
 
 
 
 
 
 
 
 
 
Table 2.5 Guide sites selected using the sgRNA designer tool. This figure details the 'new' guide 
sites selected for genome editing for the following genes; β2m, DMA, DMB1, DMB2, BLB1 and BLB2. 
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2.10 Assembly of CRISPR -cas9 sgRNA expression construct 
The selected sgRNA plasmid was digested with the restriction enzyme Bbs I  at 37 oC for 120 
min. The linearised plasmid DNA was run on a 1 % agarose gel; the correct sized band was 
excised from the gel and purified using MinElute Gel Extraction Kit (Qiagen). Selected guide 
site oligonucleotide sequences were synthesised (Sigma-Aldrich) for assembly into the 
sgRNA plasmid. The following mixture was prepared to phosphorylate the guide site insert 
and to anneal the guide site insert together ready for ligation into the sgRNA plasmid. The 
prepared mixture was placed into a thermocycler under the following conditions: 37 °C for 
30 min; 95 °C for 5 min; ramp down to 25 °C at 5 °C per min. 
 
Component   Amount (l) 
sgRNA top (100 μM)  1 
sgRNA bottom (100 μM) 1 
T4 Polynucleotide Kinase 1 
Milli-Q H2O   7 
Total    10 
 
The guide sites were phosphorylated and annealed together during the treatment, ready for 
ligation. The guide site inserts were diluted in milli-Q H2O at a ratio of 1:200. The annealed 
guide sites were ligated into the linearised sgRNA plasmid by preparation of the following 
mixture. 
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Component   Amount (l) 
sgRNA plasmid (5 fM)               1 
Guide site insert (50 M) 1 
10x T4 DNA ligase buffer 1 
T4 DNA ligase               0.5 
Milli-Q H2O   6.5 
Total    10 
The ligation mixture was left at room temperature for 60 min. Ligated plasmids were 
transformed into DH5α chemically competent E.coli. Plasmids were incubated with aliquots 
of bacterial cells on ice for 30 min, incubated 45 s at 42°C, chilled on ice then incubated at 37 
°C, shaking at 250 rpm in 500 l Luria-Bertani (LB) medium (1% w/v Bacto tryptone, 0.5% 
w/v Bacto yeast extract, 0.5% w/v NaCl). Aliquots (100 μl) of cultures were spread onto LB-
agar plates containing 100 g/ml ampicillin and colonies were allowed to grow overnight at 
37°C. Colonies were picked in 2 ml cultures of LB containing 100 g/ml ampicillin and grown 
overnight at 37°C and shaking at 250 rpm. Plasmid DNA was purified from bacterial cultures 
using the QIAprep Spin Miniprep Kit (Qiagen) (based on the method of Vogelstein and 
Gillespie. 1979). Plasmid DNA was screened for insertion of the guide site by sequencing. The 
primers designed to sequence the guide site of the sgRNA plasmids used are found in table 
2.3. Dideoxy/chain termination sequencing (Sanger et al. 1977) was performed on an 
Applied Biosystems 3730xl DNA Analyser by the University of Cambridge Biochemistry 
Department Sequencing Facility. 
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Primer name Sequence 
PX459 FP GACTATCATATGCTTACCGT 
PX458 FP GGCTGTTAGAGAGATAATTGG 
PX330 FP CACATGTGAGGGCCTATTTC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 (Ran et al. 2013) Schematic for scarless cloning of the guide sequence into a sgRNA 
expression construct.  
The guide oligos for the top strand (blue) have overhangs for ligation into the pair of BbsI sites in 
pSpCas9(BB) plasmid. The top and bottom strand orientations match those of the genomic target 
with the top oligo being the 20-bp sequence preceding 5′-NGG in genomic DNA. Digestion of 
pSpCas9(BB) with BbsI allows the replacement of the Type II restriction sites (blue outline) with 
direct insertion of annealed oligos. A G-C base pair (grey rectangle) is added at the 5′ end of the 
guide sequence for U6 transcription, this does not adversely affect targeting efficiency. 
Table 2.6 Primers designed for Dideoxy/chain termination sequencing of sgRNA plasmid guide 
sites. 
 This table shows the primers used to verify the ligation of the chosen guide site sequence into the 
sgRNA plasmid. 
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2.11 Transfection of sgRNA expression constructs 
Purified assembled sgRNA construct was used at 5 g for 3.5 x 106 REV-cells diluted in 100 μl 
Amaxa™ Solution T (Lonza Bio). Cells were transfected by electroporation using the 
Nucleofector™ II device (Lonza Bio) set to program X-001. Transfected cells were transferred 
to 6-well plates and maintained in 5 ml RPMI 1640 supplemented with 0.3 g/l L-glutamine 
and 10 % FBS (Gibco) at 37 °C, 5 % CO2. Thirty hours post-transfection, depending on the 
sgRNA plasmid transfected, cells were either sorted for positive GFP expression using an S3 
cell sorter (Bio-Rad) or the selection marker puromycin (Sigma-Aldrich) was added at 1 
g/ml. Cells were left to grow to confluence at 37 °C, 5 % CO2. 
 
2.12 Flow cytometry 
Approximately 3 x 106 REV-cells were washed twice in PBS (spins at 400 g for 3 min at 4°C) 
and re-suspended in pre-chilled FACS buffer [PBS plus 0.5% bovine serum albumin (BSA) and 
0.05% sodium azide (Sigma-Aldrich)]. For intracellular staining, cells were first fixed in 200 μl 
of 2 % paraformaldehyde (PFA) for 10 min at room temperature. Then permeabilised in 200 
μl of permeabilization buffer [PBS plus 0.5% bovine serum albumin (BSA), 0.5 % Polysorbate-
20, NP-40 (Sigma-Aldrich) and 0.05% sodium azide (Sigma-Aldrich)] for 15 min at room 
temperature and were washed twice. 
Aliquots (200 μl) of cells were added to a round-bottomed 96-well plate (Greiner) and 
incubated at room temperature for 1 hour with 200 μl primary antibody dilution. After, cells 
were spun down at 400 g for 3 min at 4°C, the supernatant was removed and cells were 
washed by re-suspension in 200 μl FACS buffer, spinning and washing was repeated three 
times. Cells were then incubated for 45 min with the secondary antibody goat anti-mouse 
IgG-PE (Dako) at 1/200 in FACS buffer, and then washed a further three times. Fluorescence 
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was then detected using a FACScan II Analyser (Becton-Dickinson) and CellQuest software 
(BD). Data was post analysed by FloJo software (www.flowjo.com). 
 
2.13 Membrane enriched lysates 
Cell lysates were prepared according to a method described in Walker et al. 2011. Cultured 
REV-cells were spun down (at 400 g for 3 min at 4 °C), washed twice in PBS and re-
suspended in 1 ml PBS. Twenty microlitres of cells were mixed with 20 μl Trypan Blue 
solution (Sigma-Aldrich) for live/dead discrimination, the live cell count was estimated using 
an improved Neubauer haemocytometer (Thermo Scientific). Cells were re-suspended in 1 
ml cold ‘freeze/thaw buffer’ [1 mM MgCl2 in PBS solution with 0.1 mM 4-(2-amino ethyl) 
benzenesulfonyl fluoride (AEBSF; Pefabloc; Roche)], frozen on dry ice and thawed at room 
temperature twice and centrifuged at 17,900 g, 4 °C for 1 hour. Pellets were solubilised on 
ice for 30 min in digitonin lysis buffer [150 mM NaCl, 1 mM MgCl2, 10 mM TrisCl, pH 8, with 
1% digitonin (Calbiochem) and 0.1 mM AEBSF] to give 2 x 108 cells equivalent per ml and 
centrifuged as described above for 10 min. Supernatants were used immediately or stored at 
-80 °C. 
 
2.14 SDS-PAGE and Western blotting 
Western blotting was performed according to an optimised method detailed in Walker et al. 
2011. Ten microlitre aliquots of membrane-enriched REV-cell lysates, prepared as above, 
were heated at 95 °C for 5 min in 15 μl 1 x Laemmli sample buffer (2.5 % SDS, 50 mM TrisCl, 
pH 8, 20 % glycerol, 0.1 % bromophenol blue, with or without 5 % β-mercaptoethanol as a 
reducing agent). Proteins were electrophoresed on 4 % stacking/12 % separating 
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polyacrylamide/bis-acrylamide (37.5:1) gels. Standards were XP Western Blot Standards 
(Invitrogen) and BlueEye Prestained Protein Standards (Jena Bioscience). Gels were soaked 
for 2 min with rotation in ‘transfer buffer’ (25 mM Tris, 192 mM glycine, 20 % methanol, 
0.0375 % SDS). Gels were transferred in the same buffer to Hybond-C Extra supported 
nitrocellulose membranes (GE Healthcare) for 40 min using the Trans-Blot SD semidry 
transfer apparatus (BioRad). Membranes were blocked overnight with ‘block buffer’ [TBS-T 
(150 mM NaCl, 50 mM TrisCl pH 8, 0.05 % Tween-20) plus 3% milk powder]. Membranes 
were then incubated with primary mAb diluted in block buffer for 1–2 hours at room 
temperature or overnight at 4 °C. Membranes were washed three times for 1 min and one 
time for 15 min with TBS-T and incubated with secondary antibody (goat anti-mouse IgG-
HRP, Sigma-Aldrich) at 1/2500 in block buffer for 30 min at room temperature before 
washing as previously described. Membranes were incubated with chemiluminescent 
detection reagent (ECL reagents, GE Healthcare) and exposed to XAR-5 film (Konica Minolta) 
or the membrane was directly measure using the G:BOX Chemi XX6 (syngene). 
 
2.15 Antibodies 
Monoclonal antibodies (mAbs) to chicken class I heavy chain (F21-2), β2m (F21-21) and MHC 
class II β chain (2G11) were raised against chicken erythrocytes and lymphocytes (Crone et 
al. 1985). mAbs were raised to the cytoplasmic tail of DMA (DMA-8 and DMA-31), DMB1 
(DMB12-3) and DMB2 (DMB2-19). Synthetic peptides were generated by Lawrence Hunt, and 
hybridoma supernatants were generated and provided by Karsten Skjødt and colleagues. 
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2.16 Radiolabelled Transport Assay  
For the transport assays the cells were harvested, washed twice in PBS, resuspended in ICT 
buffer (78 mM KCl, 4 mM MgCl2, 8.37 mM CaCl2, 10 mM EGTA, 1 mM DTT, 1 mg/mL BSA, 50 
mM Hepes, pH 7) and then were divided into aliquots of 5 × 106 cells. Each sample was 
treated with 2 μg (1,500 hemolytic units) streptolysin O (Sigma) at 37 °C for 45 min to 
permeabilize the cells. Cells were washed twice in ice-cold ICT buffer, before being 
resuspended in 750 μL ICT buffer. 1 μL of radiolabelled transport peptide (with or without 
competitor peptide) and ATP to 2 mM final concentration was added, before samples were 
incubated at 41 °C for 5 min. The cells were then lysed by the addition of 400 μL of lysis 
buffer (1% Triton X-100, 150 mM NaCl, 50 mM TrisCl, pH 8) with 1 mM AEBSF and 1 mM 
iodoacetamide and incubated on ice for 10 min. The subcellular debris was removed by 
centrifugation at 17000g for 10 min at 4 °C. The supernatant was added to silica spin 
columns containing 50 μL of 50% Con A–Sepharose (Sigma) in lysis buffer. The Con A–
Sepharose was washed three times with 1 mL wash buffer (TBS, 0.1% Triton X-100) by 
centrifugation for 10 min at 17000g. Columns were then place in γ-counter tubes (Perkin-
Elmer 1270-401) and counted in a γ-counter. Each Sample was performed in in triplicate and 
results were analysed in Microsoft Excel. 
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3. Establishing CRISPR Cas-9 mediated genome editing in avian cells 
3.1 Introduction 
The modification of the genome at a precise locus, referred to as targeted genome editing, is 
a broadly applicable technology capable of furthering research in many fields. The ability to 
specifically alter aspects of a genomic region can be used to answer many biological questions, 
for example the disruption of targeted genes in a view to determining function. Techniques 
such as small interfering RNAs (siRNAs) and microRNAs (miRNAs) have been employed to 
silence protein coding of specific genes, although gene 'knockdown' (KD) by these means are 
often incomplete and nonspecific, as well as being transient in their effect (Krueger et al. 2007, 
Jackson et al. 2003). The field was drastically changed with the development of the CRISPR-
Cas9 system for precision gene editing, using a method derived from the adaptive immunity 
system found in some prokaryotic organisms (Ishino et al 1987). 
 The CRISPR systems fall into two classes, class I and class II, but it is the class II system that 
has primarily been ulitlised as a genome editing tool. The composition of the class II system 
sees the CRISPR regions transcribed as a pre-CRISPR RNA (pre-crRNA) and are processed to 
give rise to target-specific crRNA fragments. In addition, an invariable target-independent 
trans-activating crRNA (tracrRNA) is also transcribed from the same locus, which adds to the 
processing of pre-crRNA (Deltcheva et al. 2011). Both the crRNA and tracrRNA are then 
complexed with CRISPR-associated protein 9 (Cas9), forming an active DNA endonuclease. The 
resulting targeted DNA nuclease cleaves at a 23-bp target DNA sequence, which is comprised 
of the 20-bp guide sequence in the crRNA (the protospacer) and the NGG sequence known as 
protospacer adjacent motif (PAM) The PAM is recognized by the Cas9 itself facilitating DNA 
cleavage (Hsu et al. 2013, Mali et al. 2013, Mojica et al. 2009). This system was quickly adapted 
into a versatile tool following the publication of a method illustrating simple and efficient 
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assemble of specific single guide RNAs (sgRNAs) which are comprised of the crRNA and 
tracrRNA fused together. A simple cloning system was introduced enabling the 20 nucleotide 
protospacer or guide site to be changed to a target of choice, allowing genome editing to 
become easily accessible (Zhang et al 2015). 
The original aim was to understand the immunological role of the two MHC classical class II 
molecules, BLB1 and BLB2, as well as the three non-classical class II molecules; DMA, DMB1 
and DMB2. In mammals, the class II peptide editor DM is comprised of one α and one β chain 
pairing. In the chicken it was predicted that DMα is encoded for by DMA and DMβ by DMB2 
but there is the potential of a second DM editor comprised of DMα and DMβ1 from DMB1. 
We began editing these genes as a starting point for disentangling the mechanism of class II 
presentation. This chapter details the initial teething problems when establishing the CRISPR-
Cas9 procedure in chicken cell lines and ultimately the development of a robust protocol for 
genome editing in chicken lymphocytes. 
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3.2 Attempts to edit DMA and DMB1 in the TG12 cell line 
TG12 REV-cells are fast growing cells that were derived from CB B12 chickens (that have been 
fully sequenced for the BF/BL region) and were initially selected for targeted genome editing 
using the CRISPR-Cas9 system. In view to understanding the role of DM in peptide loading and 
presentation, the genes DMA and DMB1 were targeted for a DSB in exon 2 to disrupt the gene 
by indel generation from NHEJ. Guide sites complementary to viable cut sites were identified 
from the genomic DNA sequence using the online design tool "optimised CRISPR design" 
(http://crispr.mit.edu/); guides with the fewest off-target effects were chosen and assembled 
in the PX459 plasmid. 
Two sgRNAs were created to target DMA, DMA sgRNA1 and DMA sgRNA2 and two sgRNAs 
were created to target DMB1, DMB1 sgRNA1 and DMB1 sgRNA2. Four TG12 cell aliquots were 
separately transfected with the four guides, two to DMA (DMA sgRNA1 and DMA sgRNA2) and 
two guides to DMB1 (DMB1 sgRNA1 and DMB1 sgRNA2). The cells transfected with guides to 
DMA were then analysed by flow cytometry of permeabilised cells. Both cell pools showed no 
reduction in DMA expression with the DMA expression of transfected pools matching mock 
transfected samples (fig 3.2.1). 
 
 
 
 
 
 
 
Figure 3.2.1 TG12 REV cell pool transfected with a DMA targeting sgRNA show no reduction is DMA 
expression.  
TG12 cells were separately transfected with a sgRNA:cas9 plasmid targeted to a genomic DNA sequence of DMA. 
Cell pools were analysed via flow cytometry using the antibody DMA-31, which was raised to the membrane-
proximal peptide of the cytoplasmic tail. TG12 cells transfected with PX459 DMA sgRNA1 (a) and PX459 DMA 
sgRNA2 (b) were stained after permeabilisation for DMA (green) and compared to untransfected stained cells 
(orange). Untransfected and unstained cells (red) and untransfected cells stained with only the secondary antibody 
(blue) were included. 
 
 
a) b) 
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To confirm this result, detergent lysates were made from membranes prepared from the 
pools of cells transfected with TG12 DMA sgRNA 1 and 2, and untransfected TG12 cells.  The 
lysates were assessed for amount of protein by western blotting. The TG12 DMA sgRNA 1 
and 2 showed no reduction in protein expression compared to the negative control (fig 
3.2.2). These results indicate that the sgRNAs had not disrupted the DMA gene to a 
discernible level in the transfected pools. Transfected cell pools were cloned, and the single 
cells were expanded, enabling the assessment of DMA expression in individual clones. 
 
 
 
 
 
 
 
 
 
La
d
d
e
r
D
M
A
 s
gR
N
A
1
D
M
A
 s
gR
N
A
2
TG
12
 w
ild
 t
p
ye
40 kDa
30 kDa
DMA
Figure 3.2.2 TG12 REV cell pools transfected with a DMA targeting sgRNA show no 
reduction is DMA protein expression. 
TG12 cells were transfected with two sgRNA:cas9 plasmids (DMA sgRNA1 and sgRNA2) targeted to a 
genomic DNA sequence of DMA. Cell pools were lysed using digitonin after a membrane enriching 
protocol. The lysates were analysed via western blotting using the antibody DMA-31. 
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In addition to analysing the DMA transfected pools, the transfected pools targeting DMB1 
(TG12 DMB1 sgRNA1 and 2) were cloned as single cells by limiting dilution. These clones 
were screened by western blotting for DMB1 protein expression. No screened clones 
displayed significant reduction in DMB1 protein levels (fig3.2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.1 Screening of DMA clonal lines 
The clones from TG12 cells that had been transfected with DMA sgRNA1 or sgRNA2 were 
screened by western blot. One of the screened clones showed almost a complete reduction 
in DMA expression, DMA sgRNA1 clone 13 (DMA.1 cl-13) (fig3.2.4). 
 
 
Figure 3.2.3 Single clones of TG12 cells transfected with DMB1 targeting sgRNA1 and 
sgRNA2 show no strong reduction in DMB1 protein expression. 
TG12 cell pools separately transfected with DMB1 sgRNA1 and sgRNA2 were cloned via limiting 
dilution and clones were expanded. Clones were lysed using digitonin after a membrane enriching 
protocol. The clone lysates were probed for DMB1 protein expression via western blotting using the 
antibody DMB12-3. 
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In mammalian systems, DMA comprises the α chain of the peptide editor DM, which 
mediates the dissociation of CLIP; a loss of DMA would disrupt DM function and the 
exchange of CLIP in class II molecules. Class II molecules bound with only CLIP would be 
expected to have a less stable confirmation, resulting in sensitivity to SDS.  
Non-boiled class II from normal cells run at a mobility of 50 kDa by SDS gel electrophoresis, 
whereas non-boiled class II from DMA KOs do not as the SDS in Laemmli sample buffer can 
destabilise class II molecules that are stabilised by CLIP (Pious et al. 1994). Therefore, clone-
13 class II protein levels were compared to TG12 untransfected cells and two negative clones 
(clones with an undiminished level of DMA protein) with and without boiling in SDS. 
Figure 3.2.4 TG12 DMA sgRNA1 clone-13 shows a dramatic reduction in DMA protein 
expression.  
TG12 cell pools separately transfected with DMA sgRNA1 and sgRNA2 were single cell cloned via 
limiting dilution and clones were expanded. Clones were lysed using digitonin after a membrane 
enriching protocol. The clone lysates were probed for DMA protein expression via western blotting 
using the antibody DMA-31. Clones were subsequently stained for β -actin levels as a loading control. 
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Non-boiled untransfected TG12 and negative clone lysates showed a similar level of MHCII 
protein at a mobility of ~50 kDa while clone-13 showed a significant reduction (fig3.2.5). For 
most samples, the boiled and reduced negative clone samples showed a ~28 kDa band 
indicating the presence of free class II β chain. However, clone-13 shows significantly 
reduced free class II β chain in boiled samples, so it is not stability but the amount of MHCII β 
chain that is reduced in clone 13. One possibility to explain this finding is that this particular 
MHCII allele is able to dissociate CLIP without DM but DM is still integral in stabilising the 
MHCII. In this case with DMA absent the MHCII could degrade more quickly resulting in less 
MHCII overall. Another possibility was that CRISPR caused a large deletion in clone 13, 
removing not only DMA but other nearby genes including class II β chain genes. 
 
 
 
 
 
 
 
 
 
 
 
Figure3.2.5 TG12 DMA sgRNA1 clone-13 shows a significant reduction in BLB2 protein expression. 
 TG12 DMA sgRNA1 clone-13 lysate was probed for BLB2 protein expression using the antibody 2G11. The 
protein expression of clone-13 was compared to two negative  clones, 4 and 6 as well as untransfected TG12 
cell lysate. Samples were either 'non-boiled ' and ' non-reduced' (NB, NR) or 'boiled' and  'reduced' (B, R). 
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When a CRISPR-Cas9 KO is generated by NHEJ, the size of the insertion or deletion can vary 
dramatically. Current literature suggests that indels are usually small, between 1-10bp, 
although indels over 1 kb have been reported. To assess whether a large deletion had taken 
place during CRISPR-Cas9 editing, untransfected TG12, two negative clones and clone-13 
lysates were probed for tapasin expression by western blotting. All samples showed the same 
level of tapasin expression (fig3.2.6), demonstrating that any successful indel generation had 
not disrupted the tapasin gene which is located next to BLB2, suggesting that a large scale 
deletion has not occurred. 
 
 
 
 
 
 
 
 
 
 
 
 
To further examine the reduced protein expression of class II in TG12 DMA.1 cl-13 found by 
western blotting, the levels of class II on the cell surface were assessed by flow cytometry. 
Figure 3.2.6 TG12 DMA sgRNA1 clone-13 shows no significant reduction in tapasin protein 
expression. 
TG12 DMA sgRNA1 clone-13 lysate was probed for tapasin protein expression using the antibody TPN. 
The protein expression of clone-13 was compared to two negative clones, 4 and 6 as well as 
untransfected TG12 cell lysate. Samples were either 'non-boiled ' and ' non-reduced' (NB, NR) or 'boiled' 
and  'reduced' (B, R). 
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Clone-13 showed a clear reduction of class II cell surface expression compared to 
untransfected TG12 cells (fig 3.2.7). In contrast, no change can be observed in class I 
expression, with levels of β2m being the same in clone-13 and untransfected TG12 cells (fig 
3.2.7). 
 
 
 
 
 
 
 
 
 
In order to confirm that clone-13 was a CRISPR-Cas9 derived KO, genomic DNA was 
extracted from clone-13 and untransfected TG12 cells, the DMA region was amplified by PCR 
and the amplicons were sequenced. In the first instance the DMA PCR product was 
sequenced directly. If an indel event had occurred, the indel should be seen in the chosen 20 
bp targeted guide site as the cas9 enzyme cuts at the 18th bp of the guide site.  
Direct sequencing of the amplicon from DMA.1 cl-13 cells shows a messy trace sequence 
possibly with a modified guide site (fig 3.2.8). The sequence shows the addition of an extra 
thymine in the guide site at the 3’ end (position 2-5) of the antisense guide site, making the 
chosen guide site 21 bp long on one chromosome; the chromatograph shows conflicting 
Figure 3.2.7 TG12 DMA sgRNA1 clone-13 shows a reduction in cell surface class II but not 
class I expression. 
TG12 DMA clone-13 cells were analysed for extracellular B2m and MHCII protein expression using 
the antibodies F2-21 and 2G11 respectively. a) DMA clone-13 (green) class II protein expression 
were compared to untransfected TG12 cells (orange). b) DMA clone-13 (green) β2m cell surface 
levels were compared to untransfected TG12 cells (orange). In both histograms untransfected and 
unstained cells (red) and untransfected cells stained with only the secondary antibody (blue) were 
included. 
a) b) 
68 
 
sequence, which would be expected if editing had occurred (fig 3.2.8). This insertion is not 
present in untransfected TG12 cells, which has a much clearer trace sequence (fig 3.2.8). 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm that an indel had been generated in DMA.1 cl-13, the DMA amplicon that was 
sequenced previously was cloned into the pJET cloning vector. A total of 20 colonies where 
picked, cultured and the DNA extracted, the size of the insert was then checked by PCR before 
sending 10 clones for sequencing. The guide site remained intact for all 10 clones selected for 
sequencing, a representative selection of these clones are shown below (fig 3.2.9). These 
results shows that an indel had not been generated in DMA.1 cl-13 and that CRISPR mediated 
genome editing had not occurred. This result does not agree with figure 3.2.7, the previous 
result could have stemmed from a mixed sequence being present in DMA.1 cl-13. 
Figure 3.2.8 TG12 DMA sgRNA1 clone-13 shows a potential indel in the sgRNA target site 
in the DMA gDNA sequence.  
Genomic DNA was extracted from TG12 DMA clone-13 and untransfected TG12 cells, DMA was 
amplified and directly sequenced via Sanger sequencing using the primers C532 and C534. a) gDNA 
sequence of DMA clone-13 showed the addition an of a thymine in position 2-5 in the targeted 
guide site. b) gDNA sequence of untransfected TG12 cells showed no indel generation in the 
targeted guide site. 
a) 
b) 
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As no indel event in the cloned amplicons from clone-13 cells could be detected, DMB1 and 
DMB2 protein expression was assessed, to check for down regulation of other class II 
associated proteins. A clear reduction of DMB1 and DMB2 protein expression in clone-13 cells 
was seen by flow cytometry (fig 3.2.10). No reduction could be seen in the class I related 
protein β2m, suggesting a defect in the class II pathway of clone-13 rather than successful 
genome editing. A possible explanation for this global down regulation of class II proteins 
could be changes in the class II, major histocompatibility complex, transactivator (CIITA) gene. 
The CIITA gene encodes a protein that regulates class II gene expression; therefore a random 
mutation in this region would result in reduced expression of class II related genes in DMA.1 
cl-13. The possibility of a naturally occurring mutation in clones derived from single cells 
bacterial cl-11 
bacterial cl-12 
bacterial cl-29 
Figure 3.2.9 TG12 DMA sgRNA1 clone-13 shows no indel generation in DMA gene. 
DMA amplicons from TG12 DMA.1 clone-13 was cloned in to the pJET 1.2 vector. Bacterial clones 
were screened via PCR and then sequenced via Sanger sequencing. No indels were found in the 
targeted guide site for DMA clone-13 pJET clone-11 ,  DMA clone-13 pJET clone-12 and DMA clone-
13 pJET clone-29. The guide site is highlighted in purple. 
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illustrates the importance of having a homogeneous cell population when beginning genome 
editing. This would reduce the risk of identifying cells with varying protein expression that 
could be mistaken for genome edited cells.  
 
 
 
 
 
 
 
 
 
 
 
 
3.2.3 Co-transfection of DM targeting sgRNAs with a GFP reporter plasmid 
In the previous experiments, transfected cell pools were under no selection meaning that the 
proportion of transfected cells in the pool was undetermined. To ensure that cell pools only 
contained transfected cells, two previously designed sgRNAs each targeted to the DMA, 
DMB1, DMB2 and BLB2 genes were co-transfected with a green fluorescent protein (GFP) 
reporter plasmid. The GFP reporter plasmid allowed GFP positive cells to be isolated by cell 
sorting. The transfected pools contained ~30 % GFP positive transfected cells with sgRNAs 
Figure 3.1.10 TG12 DMA clone-13 cells were stained intracellularly for DMA, DMB1 and DMB2 
protein expression, using the antibodies DMA-8, DMB11-19 and DMB2-19. 
DMA clone-13 DMA (a), DMB1 (b), DMB2 (c) protein expression (green) was compared to untransfected 
TG12 cells (orange). d) β2m protein levels in DMA clone-13 (green) were compared to untransfected TG12 
cells (orange). In all histograms untransfected and unstained cells (red) and untransfected cells stained with 
only the secondary antibody (blue) were included. 
 
a) b) 
c) d) 
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before sorting. These GFP positive pools were assessed for expression of the respective 
protein. No reduction in the desired proteins was discernible in any of the transfected cell 
pools (fig3.2.11). In fact, the targeted protein showed a distinct increase in expression, 
illustrating that a mock transfected control would be essential for all subsequent experiments. 
 
 
 
 
 
 
 
 
 
3.3 Creation of CRISPR-Cas9 mediated β2m KO in the IS19 cell line 
The previously described attempts to create a CRISPR-Cas9 mediated KO line had failed. The 
literature regarding CRISPR-Cas9 genome editing details many considerations that may 
affect the efficiency of genome editing and indel generation. These considerations include 
the stage of cell cycle, the origin of the cell line, the cell type, the genomic region targeted, 
the guide site chosen, the nucleotides immediately flanking the guide and PAM site as well 
the GC content of the chosen region. The previous experiments targeted multiple different 
genes making it seem unlikely that it was the genomic region selected that was responsible 
for the previous failed attempts.  
a) b) c) 
Figure 3.2.11 TG12 REV cells separately transfected with a DMA, DMB1 and DMB2 targeting 
sgRNA show no reduction is DM expression. 
TG12 cells were co-transfected with a GFP expression plasmid and GFP positive cell pool were collected via 
cell sorting. TG12 cells transfected with either a) DMA.1, b) DMB1.1 and c) DMB2.1 sgRNA shown in green 
were compared to untransfected TG12 cells (orange) in all histograms. The levels of the targeted protein, 
DMA (a), DMB1 (b) and DMB2 (c) were stained with the respective antibodies DMA-31, DMB11-19 and DMB2-
19. Untransfected unstained cells (red), untransfected cells stained with only the secondary antibody (blue) 
and untransfected cells stained for β2m (brown) were included in all histograms. 
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Three changes were made in the revised strategy to optimise the CRISPR-Cas9 mediated 
editing based on the following reflections. One consideration was the transfection efficiency 
of the sgRNA, as previous experiments had either no selection for transfected cells or relied 
on the co-transfection of a GFP reporter, which is an indirect method for selecting 
transfected cell populations. To ensure that cells transfected with the sgRNA were isolated, a 
new sgRNA plasmid was used that contained a GFP reporter marker (PX458). Secondly, it is 
possible that all the guide sites selected happened to be low efficiency in their ability to 
mediate cutting, although many different guide sites had been tested. A third revision was to 
design the targeted guide site using a different protocol, the "sgRNA designer" online tool 
(http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design) that calculates the 
on-target efficacy of potential guide sites.  
Thirdly, the chosen target for KO was changed to β2m, as β2m cell surface levels can be 
conveniently assessed by flow cytometry as opposed to the DM proteins, which are 
intracellular. Using the new plasmid and designs detailed above, four β2m targeting sgRNAs 
were assembled and IS19 cells were transfected with two of these sgRNAs (one and four). A 
clear difference was the low transfection efficiency of the GFP containing sgRNAs, with only 
~10 % of the cell population being GFP positive (data not shown). Previously ~30 % of the 
cells were GFP positive when transfected with a GFP reporter plasmid. This discrepancy in 
transfection efficiency between the GFP tagged sgRNA and co-transfection with a GFP 
reporter shows that the sorted GFP positive population of cells co-transfected with the GFP 
expressing plasmid were not highly enriched with the sgRNA. This could explain why CRISPR-
cas9 mediated KOs could not be seen in figure 3.2.10, as the sorted population may not have 
contained many cells transfected with the targeting sgRNA. 
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The IS19 cells transfected with the sgRNAs, β2m sgRNA1 and sgRNA4, were sorted for 
positive GFP expression. The IS19 β2m sgRNA1 (fig 3.3.1) and β2m sgRNA4 (fig 3.3.2) cell 
pools showed a subset of cells that had a reduction in β2m cell surface expression compared 
to mock transfected cells. In addition, there was a similar reduction in class I cell surface 
expression, as would be expected in the absence of β2m (fig 3.3.1 and 3.3.2). The cell lines 
IS19 β2m sgRNA1 and sgRNA4 were both stained for surface expression of class II as a 
control; unexpectedly a small reduction in class II levels can be seen in both cell lines. 
     
 
 
 
   
 
 
 
Figure 3.3.1 IS19 REV-cell pool transfected with the β2m targeting sgRNA PX458 sgRNA1 show a clear 
reduction in β2m expression. 
 IS19 PX458 β2m sgRNA1 cells (green) β2m (a), MHC class I (b) and MHC class II (x) protein levels were compared 
to mock transfected stained cells (orange).  The antibodies F21-21, F21-2 and 2G11 were used respectively. Mock 
transfected and unstained cells (red) and mock transfected cells stained with only the secondary antibody (blue) 
were included in all histograms. 
Figure 3.2.2 IS19 REV-cell pool transfected with the β2m targeting sgRNA PX458 sgRNA4 show a clear 
reduction in β2m expression. 
 IS19 PX458 β2m sgRNA4 cells (green) β2m (a), MHC class I (b) and MHC class II (c) protein levels were compared to 
mock transfected stained cells (orange).  The antibodies F21-21, F21-2 and 2G11 were used respectively. Mock 
transfected and unstained cells (red) and mock transfected cells stained with only the secondary antibody (blue) 
were included in all histograms. 
 
a) b) c) 
a) b) c) 
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Next clonal lines of the B2m KOs were made by limiting dilution and assessed for β2m levels 
(fig 3.3.3). All clonal lines (B2m.1 cl-4, B2m.1 cl-7, B2m.4 cl-2 and B2m.4 cl-4) were shown to 
have no β2m expression when compared to wild type staining and β2m staining in all KO lines 
overlaid with the secondary antibody control. 
 
 
 
 
β2m KO clonal lines were then screened by PCR, cloning and sequencing of the β2m locus 
revealed that successful editing had taken place. Figure 3.3.4 shows the B2m KO clonal line, 
with the PAM site at position 100-102, the edits consist of a two base pair deletion on one 
allele and a one base pair insertion on the second allele (fig 3.3.4a). 
The effect of the editing on the coding sequence when compared to the wild type sequence 
show disruptions to the gene begin at amino acid position 36 for the two different edits. 
Although the indels generated a frameshift the amino acid coding sequence, no premature 
stop codon was generated (fig 3.3.4b). 
a) b)
c) d)
Figure 3.3.3. Flow cytometry cell surface staining of β2m in IS19 β2m KO clonal lines. 
 IS19 wild type and B2m KO clonal lines B2m,1 cl-4 (a), B2m.1 cl-7 (b), B2m.4 cl-2 (c) and B2m.4 cl-4 (d) were 
analysed via flow cytometry using the antibody F21-21 to B2m. B2m KO clonal lines were either derived from IS19 
cells transfected with PX458 B2m sgRNA1 (a & b) or PX458 b2m sgRNA4 (c & d). B2m KO clonal lines were stained 
for b2m (orange) and secondary antibody only (blue) and compared to wild type cell expression (red). IS19 PX458 
β2m sgRNA4 cells (green) β2m (A), MHC class I (B) and MHC class II (C) protein levels were compared to mock 
transfected stained cells (orange).  
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                              110       120       130       140       150     
                      ....|....|....|....|....|....|....|....|....|....| 
IS-19 B2m WT          CCGCC~TCTGCGGGCACCAAGAACGTCCTCAACTGCTTCGCGGCCGGCTT  
IS-19 B2m.1 Cl-4 (1)  CCGCC~T~~GCGGGCACCAAGAACGTCCTCAACTGCTTCGCGGCCGGCTT  
IS-19 B2m.1 cl-4 (2)  CCGCCCTCTGCGGGCACCAAGAACGTCCTCAACTGCTTCGCGGCCGGCTT  
 
                               10        20        30        40        50          
                      ....|....|....|....|....|....|....|....|....|....| 
IS-19 B2m WT          MGKAAAVVLVTLVALLGLAQADLTPKVQVYSRFPASAGTKNVLNCFAAGF  
IS-19 B2m.1 cl-4 (1)  MGKAAAVVLVTLVALLGLAQADLTPKVQVYSRFPACGHQERPQLLRGRLP  
IS-19 B2m.1 cl-4 (2)  MGKAAAVVLVTLVALLGLAQADLTPKVQVYSRFPALCGHQERPQLLRGRL  
 
                               60        70        80        90       100         
                      ....|....|....|....|....|....|....|....|....|....| 
IS-19 B2m WT          HPPKISITLMKDGVPMEGAQYSDMSFNDDWTFQRLVHADFTPSSGSTYAC  
IS-19 B2m.1 cl-4 (1)  PTQDLHHADEGRRAHGGCAVLRHVLQRRLDVPAPGARRLHAQQRFHLRVQ  
IS-19 B2m.1 cl-4 (2)  PPTQDLHHADEGRRAHGGCAVLRHVLQRRLDVPAPGARRLHAQQRFHLRV  
 
                              110       120  
                      ....|....|....|....| 
IS-19 B2m WT          KVEHETLKEPQVYKWDPEF   
IS-19 B2m.1 cl-4 (1)  GGARDPEGAAGLQVGSRVL   
IS-19 B2m.1 cl-4 (2)  QGGARDPEGAAGLQVGSRVL  
 
 
Figure 3.3.5 shows the B2m KO clonal line b2m.1 cl-7 has one successful editing events which 
can be seen immediately downstream of the PAM site at position 100-102. The edit consists 
of a two base pair deletion (fig 3.3.5a). 
The effect of the editing on the coding sequence when compared to the wild type sequence 
show disruptions to the gene begin at amino acid position 36. Although the indels generated 
a frameshift, the amino acid coding sequence has no premature stop codon (fig 3.3.5b). 
 
 
 
Figure 3.3.4 DNA and amino acid sequence alignment of clonal line B2m.1 cl-4 
shows editing events and the generation of a premature stop codon. 
 
a) The editing events revealed by sequencing exon 2 of B2m were mapped onto the whole of the B2m DNA sequence and 
compared to the wild type, editing events can be seen in both alleles immediately before the PAM site at position 100-102. b)  The 
effect of these editing events on the whole amino acid sequence were then shown for each of the two edited alleles. Changes in 
the coding sequence begin at position 36. The three sequences are labelled on the left-hand margin; wild type sequence (IS19 
b2m WT), the first edited allele of clonal line b2m.1 cl-4 (IS19 b2m.1 cl-4 (1)) and the second allele (IS19 b2m.1 cl-4 (2)). 
b) 
a) 
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                          110       120       130       140       150     
                  ....|....|....|....|....|....|....|....|....|....| 
IS-19 B2m WT      CCGCCTCTGCGGGCACCAAGAACGTCCTCAACTGCTTCGCGGCCGGCTTC  
IS-19 B2m.1 cl-7  CCGCCT~~GCGGGCACCAAGAACGTCCTCAACTGCTTCGCGGCCGGCTTC  
 
                         10        20        30        40        50          
                   ....|....|....|....|....|....|....|....|....|....| 
IS-19 B2m WT       MGKAAAVVLVTLVALLGLAQADLTPKVQVYSRFPASAGTKNVLNCFAAGF  
IS-19 B2m.1 cl-7   MGKAAAVVLVTLVALLGLAQADLTPKVQVYSRFPACGHQERPQLLRGRLP  
 
                            60        70        80        90       100         
                   ....|....|....|....|....|....|....|....|....|....| 
IS-19 B2m WT       HPPKISITLMKDGVPMEGAQYSDMSFNDDWTFQRLVHADFTPSSGSTYAC  
IS-19 B2m.1 cl-7   PTQDLHHADEGRRAHGGCAVLRHVLQRRLDVPAPGARRLHAQQRFHLRVQ  
 
                           110       
                   ....|....|....|.... 
IS-19 B2m WT       KVEHETLKEPQVYKWDPEF  
IS-19 B2m.1 cl-7   GGARDPEGAAGLQVGSRVL  
 
3.4 Discussion 
The starting point of the project was to establish CRISPR-Cas9 KO lines in chicken cell lines, 
which had yet to be demonstrated in the literature. The cell line selected was the TG12A5-
REV cell line and the target genes were DMA, DMB1 and DMB2. The attempts detailed in 
section 3 failed to create a KO cell pool for the three genes. Consulting the literature and 
reviewing the previous failed attempts, I identified what seemed to be the most likely 
causes. 
 The first cause was the variability in on-target efficacy of prospective guide sites. Current 
reports have stated that some guide sites work and that some do not; the mechanism 
Figure 3.3.5 DNA and amino acid Sequence alignment of clonal line B2m.1 cl-7 
shows editing events and the generation of a premature stop codon. 
 
a) The editing events revealed by sequencing exon 2 of B2m were mapped onto the whole of the B2m 
DNA sequence and compared to the wild type, the editing events can be seen in both alleles 
immediately before the PAM site at position 100-102. b)  The effect of the editing events on the whole 
amino acid sequence were suggested to be the same for both alleles. Changes in the coding sequence 
begin at position 36. The two sequences are labelled on the left-hand margin; wild type sequence (IS19 
b2m WT) and edited alleles of clonal line b2m.1 cl-7 (IS19 b2m.1 cl-7). 
b) 
a) 
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behind target guide site efficacy is still unclear (Zhang et al. 2013). The guide sites that do 
work vary in their efficiency to generate an indel derived KO. A recent report assessed the 
variation in sequence including 5' of the guide site, 3' of the PAM site and the guide site itself 
to derive an on-target efficacy score for potential guide sites. The report details how the on-
target efficacy score is experimentally defined based on a logistic regression classifier trained 
on 1841 sgRNAs targeting multiple genes (Doench et al. 2014). An online guide site design 
tool ("sgRNA designer") was created from these findings, which allows the analysis of 
potential guide sites for on-target efficacy. 
I then analysed my guide sites, previously designed in the "Optimised CRISPR design tool", to 
DMA, DMB1, DMB2 and BLB2 using the "sgRNA designer". Surprisingly, I found that all of the 
previously designed guides received a low on-target efficacy score. Therefore, I decided to 
design new guide sites to genes of interest using the "sgRNA designer" and to select guides 
with the highest on-target efficacy scores (detailed in materials and methods). 
The second cause of my initial failures was the delivery and isolation of sgRNAs in target 
cells. Previously, cells were transfected without selection or were co-transfected with a GFP 
expressing plasmid to allow GFP positive cells to be sorted. It was clear that it would be 
advantageous if not essential to isolate the sgRNA transfected population and I was 
concerned that the transfection of the GFP reporter plasmid did not represent the 
transfection of the sgRNA. To address this issue a different sgRNA plasmid (PX458) was 
sourced, that contained a GFP selection marker. Using this new plasmid I could be sure that 
cell sorting GFP positive cells reflected cells transfected with the sgRNA. 
I decided to use a different target gene (β2m), one for which I could easily assess the cell 
surface levels, to facilitate the optimisation of the CRISPR-Cas9 system. Taking into 
consideration both points detailed above, I decided to design guide sites using the sgRNA 
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designer and selected guide sites with a high on-target efficacy score. These sites were cloned 
into the PX458 sgRNA plasmid. Of the four sgRNAs designed to target β2m, two were 
transfected into IS19 REV-cells and the cell pools were sorted for positive GFP expression. The 
two sorted cell lines, named IS19 b2m sgRNA1 and 2, were found to have reductions in β2m 
cell surface expression. This result strongly suggests that the guide site on-target efficacy 
and/or the isolation of the transfected population was responsible for the previous failed 
attempts to generate a CRISPR-Cas9 mediated KO, although further work would be required 
to confirm this. 
 B2m KO clonal lines were then derived from the polyclonal edited populations IS19 B2m.1 
and IS9 b2m.4 These lines were initially screened by flow cytometry. Figure 3.2.3 shows four 
clones B2m.1 cl-4, B2m.1 cl-7, B2m.4 cl-2 and B2m.4 cl-4, all of which have B2m levels 
overlaying with the secondary antibody control suggesting that no B2m is present. To confirm 
this result B2m KO clonal lines were further screened by PCR of the B2m locus, cloning and 
sequencing. Figure 3.2.4 shows sequencing results of the clonal lines B2m.1 cl-4 and B2m.1 cl-
7, which showed that indels had been generated in the expected region (between position 16 
and 18 of the PAM site). B2m.1 cl-4 was shown to have two different indels on the two 
different alleles, a two base pair deletion and a one base pair insertion. B2m.1 cl-7 was shown 
to only have one edit of a two base pair deletion. To check that both alleles of B2m were not 
edited 10 bacterial clones were screened from two independent PCRs, as well as direct 
sequencing of the PCR projects. All of which showed one clear trace sequence with a two base 
pair deletion which suggests that editing has occurred on both chromosomes. With the 
CRISPR-Cas9 system optimised in chicken lymphocytes we were then ready to begin making 
class II KOs to begin our study of class II antigen presentation in the chicken.  
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4. IS19 Class II single KO generation and screening 
4.1 Introduction 
The main goal of this project was to begin to understand how the chicken MHC class II 
antigen presentation functions, and to see how similar or different this system is when 
compared to mouse and human class II presentation for which there is an abundance of 
data. The chicken MHC loci has a number of differences to the human MHC when we look at 
MHC class II classical and non-classical genes. Notably: the chicken only has two classical 
class II B genes (BLB1 and BLB2), whereas humans have three (DP, DQ and DR), the chicken 
has three non-classical DM class II genes DMA, DMB1 and DMB2, whereas humans have 
DMA and DMB, and lastly no chicken non-classical class II genes for DO have been found, 
whereas DO is present in humans (comprised of two genes DOA and DOB). The differences 
in genes found in the MHC (not to mention the differences in organisation) suggest that the 
way class II presentation may be achieved is different between chickens and classic model 
organisms. For example, the fact that two DM beta chains are found in the chicken suggests 
that chickens have two different DM chaperones, and as we know that DM is responsible for 
the ensuring the class II molecule is loaded with high affinity peptide, this suggest that 
chicken class II molecules could be subject to two different types of peptide editing and 
therefore have more possibilities for the peptide repertoire presented. 
To even begin to understand how these two different DMs effect the peptide repertoire 
displayed on chicken MHC class II molecules and more broadly to understand the 
mechanisms involved in antigen presentation, we need a strategy of how to look at the 
effect of each component of the chicken class II presentation system. To start to answer this 
question, we took the approach of using CRISPR-Cas9 to KO each of the key components in 
the class II presentation. For this study we initially started by making KOs of the following 
81 
 
genes: BLB1, BLB2, DMA, DMB1 and DMB2. Detailed in the first data chapter were the initial 
teething problems we had in establishing CRISPR-Cas9 mediated editing and how we 
optimised this technique for reliable and accurate editing; with the technique working 
consistently in our hands we were able to start the class II KOs in earnest. We decided to 
start our study in the REV transformed cell line IS19, which is homozygous for the B19 
haplotype. 
This chapter will give full details of how the class II KO clonal lines were generated, how the 
cell lines were characterised; the identification of the indel at the DNA level, how this effects 
the translation and ultimately the effect it has on protein expression for the target gene. In 
addition, we touch upon initial results at the protein level that warrant more thorough 
investigation and describe optimisation and preparation for analysis at the RNA level by RT-
qPCR, both of which are detailed in chapter 5. 
 
4.2 Generation of MHCII specific sgRNAs 
Initially two guide sites each were designed ( detailed in material and methods) to the 
following genes: BLB1, BLB2, DMA, DMB1 and DMB2. The nomenclature for naming each 
guide was as follows BLB1 sgRNA1 = BLB1.1, BLB1 sgRNA2 = BLB1.2 and so on. This naming 
convention is used for all sgRNA guides designed. All guides designed were tested for their 
ability to make successful edits in vitro and the guides which yielded successful editing 
results were chosen for future work. Unfortunately, the two guides designed to target DMB1 
(guides DMB1.1 and DMB1.2) showed no editing events. A further two guides were designed 
for DMB1 (DMB1.3 and DMB1.4); initial screening showed successful editing with DMB1.4. 
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The guide sgRNAs which showed successful editing events for each class II gene are shown in 
figure 4.2.1, these guides were selected for future experiments. 
 
               BLB1 sgRNA2     BLB2 sgRNA2                   DMA sgRNA2 
            
 
              DMB1 sgRNA4                     DMB2 sgRNA1 
         
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.1 cloning of MHC class II specific guide sites into PX458 and PX459V2. 
Guide sites cloned into PX458 were sequenced and aligned against PX458 to show that the 
sequence is that of the of the vector. Sequences were then checked for the presence of the 
expected guide site. Only guides that produced successful edits after screening are shown 
above. a)  BLB1 sgRNA2 b) BLB2 sgRNA2 c) DMA sgRNA2 d) DMB1 sgRNA4 and e) DMB2 
sgRNA1. The blue arrow shows the sequence of the cloned guide site.  
a b c 
d e 
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4.3 Identification of indels and frameshifts in class II single KO clonal lines 
IS19 cells that were transfected with guides that showed some successful editing events in 
the bulk population were then sorted for a single cell per well of a 96 well plate; two plates 
were sorted per bulk population of each gene KO (BLB1, BLB2, DMA, DMB1 and DMB2). 
Initially, 10 clonal lines for each gene KO line were screened by PCR, molecular cloning and 
sequencing. Two to five edited clones were found for each cell line. The sequencing results 
for each clonal line were aligned to the appropriate gene, the successful editing events are 
shown below. 
Starting with the selected BLB1 KO clonal line BLB1.2 cl-1, two successful editing events can 
be seen adjacent to the PAM site at position 238-240, the edits consist of a one base pair 
insertion on one allele and a two base pair insertion on the second allele (figure 4.3.1a). It is 
important that editing events are not a multiple of three bases pairs deleted or insert, this is 
to ensure that the target gene is out of frame and that the edit disrupts the gene. 
Next, we looked at the effect of the edit on the coding sequence when compared to the 
original sequence. Disruptions to the gene begin at amino acid positions 78 and 79 for the 
two different edits, these changes in codon frame result in an early stop codon at positions 
81 and 98 terminating the protein (figure 4.3.1b).  
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                                210       220       230       240       250     
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB1 WT          CAGCGACGTGGGGAAATACGTGGCTGATACACC-GCTGGGTGAGCCGCAA  
IS-19 BLB1.2 cl-1 (1)  CAGCGACGTGGGGAAATACGTGGCTGATACACCCGCTGGGTGAGCCGCAA  
IS-19 BLB1.2 cl-1 (2)  CAGCGACGTGGGGAAATACGTGGCTGATACC--CGCTGGGTGAGCCGCAA  
 
                          60        70        80        90       100         
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB1 WT          RFLDREIYNRQQYAHFDSDVGKYVADTPLGEPQAEYWNSNAEFMENRMNE  
IS-19 BLB1.2 cl-1 (1)  RFLDREIYNRQQYAHFDSDVGKYVADTPAG*AAS*ILEQQRRVYGEPNE*  
IS-19 BLB1.2 cl-1 (2)  RFLDREIYNRQQYAHFDSDVGKYVADTRWVSRKLNTGTATPSLWRTE*MK  
 
                         110       120       130       140       150     
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB1 WT          VDTFCRHNYGVGESFTVQRSVEPKVRVSALQSGSLPETDRLACYVTGFYP  
IS-19 BLB1.2 cl-1 (1)  SGHVLPAQLRGWGVLHGAEERGAQGEGLGAAVGLPARNRPSGVLRDGLLP  
IS-19 BLB1.2 cl-1 (2)  WTRSAGTTTGLGSPSRCRGAWSPR*GSRRCSRAPCPKPTVWRAT*RASTR  
 
                         160       170       180       190       200     
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB1 WT          PEIEVKWFLNGREETERVVSTDVMQNGDWTYQVLVVLETVPRRGDSYVCR  
IS-19 BLB1.2 cl-1 (1)  AGDRGEVVPERAGGDGARGVHGRDAERGLDVPGAGGAGDRPAARGQLRVP  
IS-19 BLB1.2 cl-1 (2)  RRSR*SGS*TGGRRRSAWCPRT*CRTGTGRTRCWWCWRPSRGAGTATCAG  
 
                         210       220       230       240       250     
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB1 WT          VEHASLRQPISQAWEPPADAGRSKLLTGVGGFVLGLVFLALGLFVFLRGQ  
IS-19 BLB1.2 cl-1 (1)  GGARQPAAAHQPGVGAAGGRGQEQAADGRGGLRAGARLPGAGALRVPARS  
IS-19 BLB1.2 cl-1 (2)  WSTPACGSPSARRGSRRRTRAGASC*RAWGASCWGSSSWRWGSSCSCAVR  
 
                         260  
                       ....|....|.... 
IS-19 BLB1 WT          KGRPVAAAPGMLN   
IS-19 BLB1.2 cl-1 (1)  ERAPRRRRSRDAEL  
IS-19 BLB1.2 cl-1 (2)  KGAPSPPLQGC*I   
 
 
 
Figure 4.3.1 DNA and amino acid Sequence alignment of clonal line BLB1.2 cl-1 
show editing events and the generation of a premature stop codon. 
 
a) The editing events revealed by sequencing exon 2 of BLB1 were mapped onto the whole of BLB1 
cDNA sequence and compared to the wild type, editing events can be seen in both alleles immediately 
before the PAM site (red line) at position 238-240. b)  The effect of these editing events on the whole 
amino acid sequence were then shown for each of the two edited alleles. Changes in the coding 
sequence begin at position 88 and 89, premature stop codons can be seen down stream of these 
positions. 
The three sequences are labelled on the left-hand margin; wild type sequence (IS19 BLB1 WT), the first 
edited allele of clonal line BLB1.2 cl-1 (IS19 BLB1.2 cl-1 (1)) and the second allele (IS19 BLB1.2 cl-1 (2)). 
a) 
b) 
85 
 
Due to the high DNA sequence similarities between BLB1 and BLB2 the primers to amplify 
BLB1 amplify both BLB1 and BLB2. This enabled us to check that we did not have off-target 
editing events in BLB2. From cloned PCR product a total of 20 clones were screened, two 
different editing events were found in BLB1 as shown above and eight clones of BLB2 
showed no editing event had occurred (not shown) suggesting that our targeting was 
specific. 
 
The selected clonal line for BLB2 KO, BLB2.1 cl-1 also showed two distinct successful editing 
events again in the expected position, slightly downstream of the PAM site at position 238-
240. The edits consist of a one base pair insertion on one allele and a two base pair deletion 
on the second allele (figure 4.3.2a), both of which result in a frameshift. The effect of the 
mutation on the coding sequence showed disruptions beginning at amino acid positions 78 
and 79 for the two different edits, this change in translation frame results in early stop 
codons at positions 80 and 81 terminating the protein (figure 4.3.2b). 
A total of 20 bacterial clones were screened 11 of which showed wild type BLB1 sequence 
(not shown) giving confidence that off-target editing had not taken place in BLB1. 
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                                210       220       230       240       250     
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB2 WT          CAGCGACGTGGGGAAATTTGTGGCCGATTCAC-CGCTGGGTGAGCCGCAA  
IS-19 BLB2.2 cl-1 (1)  CAGCGACGTGGGGAAATTTGTGGCCGATTC---CGCTGGGTGAGCCGCAA  
IS-19 BLB2.2 cl-1 (2)  CAGCGACGTGGGGAAATTTGTGGCCGATTCACCCGCTGGGTGAGCCGCAA  
 
                              60        70        80        90       100         
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB2 WT          RYLQRYIYNRQQYAHFDSDVGKFVADSPLGEPQAEYWNSNAELLENRMNE  
IS-19 BLB2.2 cl-1 (1)  RYLQRYIYNRQQYAHFDSDVGKFVADSAG*AAS*ILEQQRRASGEPNE*S  
IS-19 BLB2.2 cl-1 (2)  RYLQRYIYNRQQYAHFDSDVGKFVADSPAG*AAS*ILEQQRRASGEPNE*  
 
                               110       120       130       140       150     
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB2 WT          VDRFCRHNYGGVESFTVQRSVEPKVRVSALQSGSLPETDRLACYVTGFYP  
IS-19 BLB2.2 cl-1 (1)  GQVLPAQLRGCGVLHGAEERGAQGEGLGAAVGLPARNRPSGVLRDGLLPA  
IS-19 BLB2.2 cl-1 (2)  SGQVLPAQLRGCGVLHGAEERGAQGEGLGAAVGLPARNRPSGVLRDGLLP  
 
                               160       170       180       190       200     
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB2 WT          PEIEVKWFLNGREETERVVSTDVMQNGDWTYQVLVVLETVPRRGDSYVCR  
IS-19 BLB2.2 cl-1 (1)  GDRGEVVPERAGGDGARGVHGRDAERGLDVPGAGGAGDRPAARGQLRVPG  
IS-19 BLB2.2 cl-1 (2)  AGDRGEVVPERAGGDGARGVHGRDAERGLDVPGAGGAGDRPAARGQLRVP  
 
                               210       220       230       240       250     
                       ....|....|....|....|....|....|....|....|....|....| 
IS-19 BLB2 WT          VEHASLRQPISQAWEPPADAGRSKLLTGVGGFVLGLVFLALGLFVFLRGQ  
IS-19 BLB2.2 cl-1 (1)  GARQPAAAHQPGVGAAGGRGQEQAADGRGGLRAGARLPGAGALRVPARSE  
IS-19 BLB2.2 cl-1 (2)  GGARQPAAAHQPGVGAAGGRGQEQAADGRGGLRAGARLPGAGALRVPARS  
 
                               260  
                       ....|....|.... 
IS-19 BLB2 WT          KGRPVAAAPGMLN   
IS-19 BLB2.2 cl-1 (1)  RAPRRRRSRDAEL   
IS-19 BLB2.2 cl-1 (2)  ERAPRRRRSRDAEL  
 
The clonal line selected for DMA KO, DMA.2 cl-1, showed only one editing event in all 
bacterial clones screened. The edit is a one base pair deletion immediately downstream of 
the PAM site located at position 193-195 (figure 4.3.3a). The effect of the mutation on the 
coding sequence shows disruption beginning at amino acid position 63, this change in 
Figure 4.3.2 DNA and amino acid sequence alignment of clonal line BLB2.2 cl-1 
show editing events and the generation of a premature stop codon. 
 
a) The editing events revealed by sequencing exon 2 of BLB2 were mapped onto the whole of BLB1 DNA 
sequence and compared to the wild type, editing events can be seen in both alleles immediately before 
the PAM site (red line) at position 238-240. b)  The effect of these editing events on the whole amino 
acid sequence were then shown for each of the two edited alleles. Changes in the coding sequence 
begin at position 78 and 79, premature stop codons can be seen down stream of these positions. 
The three sequences are labelled on the left-hand margin; wild type sequence (IS19 BLB2 WT), the first 
edited allele of clonal line BLB2.2 cl-1 (IS19 BLB2.2 cl-1 (1)) and the second allele (IS19 BLB2.2 cl-1 (2)). 
a) 
b) 
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translation frame results in an early stop codon at position 134 terminating the protein 
(figure 4.3.3b). 
A total of 14 bacterial clones were screened from two separate PCRs. The uncloned PCR 
product was also sequenced and showed one clear trace with the one base pair deletion at 
position 190. 
 
                          160       170       180       190       200     
                  ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMA WT      GACTCAGAGCAGCTCTTCTCATTCGATGTCCCCAACTCGCAGTGGCTGCC  
IS-19 DMA.2 cl-1  GACTCAGAGCAGCTCTTCTCATTCGATGTCCCCAACTCG-AGTGGCTGCC  
 
                           60        70        80        90       100         
                  ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMA WT      DSEQLFSFDVPNSQWLPQLPDGPSWPADIEQPHELLHDAALCRELLDLLT  
IS-19 DMA.2 cl-1  DSEQLFSFDVPNSSGCRSSPMAPRGPQTSSSPTSCCTTPRCAVSCSICSP  
 
                          110       120       130       140       150     
                  ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMA WT      RIATGPNPMPEAKGIPVADVFLQQPLQLGYPNTLICMVGNIFPPAITISW  
IS-19 DMA.2 cl-1  ESPPGQTQCLKPRASRWPTSSCSSLCSSATPTL*SVWWATSSPQPSLSAG  
 
                          160       170       180       190       200     
                  ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMA WT      QRDGIPVTDGVTHLTYTPTEDLGFMRFSYLAVTPHSGDIYACIVTRERDN  
IS-19 DMA.2 cl-1  SGMASPSPMASPTSPTPPPRTWASCASPTWR*HRTLVTSMPALSPARGTT  
 
                          210       220       230       240       250     
                  ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMA WT      ISVVAYWVPQDPIPSDVLATAVCGAVTALGILLALLGLGLLLSARRRSMW  
IS-19 DMA.2 cl-1  SLWWLTGCHRTPSLRTCWPRRCAAQ*RRWASCWHCWVWGCCCPPAGAVCG  
 
                          260  
                  ....|....|... 
IS-19 DMA WT      GQWRQQGHPPRTH  
IS-19 DMA.2 cl-1  DNGDSRDTRPVLT  
 
The clonal line selected for DMB1 KO, DMB1.4 cl-10, showed only one editing event in all 
bacterial clones screened. The edit is a two base pair deletion immediately downstream of 
Figure 4.3.3 DNA and amino acid sequence alignment of clonal line DMA.2 cl-1 
show editing events and the generation of a premature stop codon. 
 
a) The editing events revealed by sequencing exon 2 of DMA were mapped onto the whole of DMA 
cDNA sequence and compared to the wild type, the editing event appears to be the same on both 
alleles immediately before the PAM site (red line) at position 193-195. B)  The effect of this editing 
event on the whole amino acid sequence is shown. The change in the coding sequence begins at 
position 63, a premature stop codon can be seen down stream of this position. 
The two sequences are labelled on the left-hand margin; wild type sequence (IS19 DMA WT), the edited 
alleles are labelled (IS19 DMA.2 cl-1). 
a) 
b) 
88 
 
the PAM site located at position 239-241 (figure 4.3.4a). The effect of the mutation on the 
coding sequence shows disruption beginning at amino acid position 82, this change in 
translation frame results in an early stop codon at position 84 terminating the protein (figure 
4.3.4b). 
A total of 16 bacterial clones were screened from two separate PCRs. The uncloned PCR 
product was also sequenced and showed one clear trace with a two base pair deletion at 
position 243-244. 
 
                            210       220       230       240       250     
                    ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB1 WT       CGATTGGGGGCTGCTGCACACCGTTGCCACTTTGCTCGCCGCCATCCTAA  
IS-19 DMB1.4 cl-10  CGATTGGGGGCTGCTGCACACCGTTGCCACTTTGCTCGCCGC--TCCTAA  
 
                             60        70        80        90       100         
                    ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB1 WT       KNPLLCYDPDVHRFYPCDWGLLHTVATLLAAILNDDTTWVQRAEARRQAC  
IS-19 DMB1.4 cl-10  KNPLLCYDPDVHRFYPCDWGLLHTVATLLAAPK**YHMGAACRGTQAGVH  
 
                            110       120       130       140       150     
                    ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB1 WT       TELAAQFWTHTALRRTPPQVRIVPIPISNDPDTVHLICHVWGFYPPAVTI  
IS-19 DMB1.4 cl-10  *AGCTVLDTHSTAQDTTPGPHRPHPHLQRPRHRPPHLPCLGLLPTRSDHP  
 
                            160       170       180       190       200     
                    ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB1 WT       QWLHNGLVVASGDTKLLPNGDWTYRTQVALRASTAAGSTYTCSVWHSSLE  
IS-19 DMB1.4 cl-10  VAAQRPRGGLR*HQTAAQRGLDLQDTGGPEGQHCSREHLHMLSVALQPGA  
 
                            210       220       230       240       250     
                    ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB1 WT       QPLQEDWSPNLSPAMMVKVAVAAMALTLGLVALSAGVFSFCQRPRVWGVP  
IS-19 DMB1.4 cl-10  AAAGGLESQFVPGDDGEGGSGGHGADVGVGGTQRRGFQLLSAATGVGCTS  
 
                           
                    ....|.... 
IS-19 DMB1 WT       PHSSSSSPS  
IS-19 DMB1.4 cl-10  SFIIFFPVL  
 
 
 
 
 
 
Figure 4.3.4 DNA and amino acid sequence alignment of clonal line DMB1.4 cl-10  
show editing events and the generation of a premature stop codon. 
 
a) The editing events revealed by sequencing exon 2 of DMB1 were mapped onto the whole of DMA 
cDNA sequence and compared to the wild type, the editing event appears to be the same on both 
alleles immediately before the PAM site (red line) at position 239-241. b)  The effect of this editing 
event on the whole amino acid sequence is shown. The change in the coding sequence begins at 
position 82, a premature stop codon can be seen down stream of this position. 
The two sequences are labelled on the left-hand margin; wild type sequence (IS19 DMB1 WT), the 
edited alleles are labelled (IS19 DMB1.4 cl-10). 
a)
b) 
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The final class II clonal line, selected for DMB2 KO (DMB2.1 cl-11), showed only one editing 
event in all bacterial clones screened. The edit is a one base pair insertion immediately 
downstream of the PAM site located at position 102-104 (figure 4.3.5a). The effect of the 
mutation on the coding sequence shows disruption beginning at amino acid position 34, this 
change in translation frame results in an early stop codon at position 79 terminating the 
protein (figure 4.3.5b). 
A total of 15 bacterial clones were screened from two separate PCRs. The uncloned PCR 
product was also sequenced and showed one clear trace with a one base pair insertion at 
position 98. 
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                             60        70        80        90       100         
                    ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB2 WT       CATGGTGCATGTGGCCAACTCCTGCTCACTGGCAGCCAATGGCTCTC-TG  
IS-19 DMB2.1 cl-11  CATGGTGCATGTGGCCAACTCCTGCTCACTGGCAGCCAATGGCTCTCTTG  
 
                              10        20        30        40        50          
                     ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB2 WT        MLVLLGLLLGARGAGAFMVHVANSCSLAANGSLRGFDLTVAFNKNPLVCY  
IS-19 DMB2.1 cl-11   MLVLLGLLLGARGAGAFMVHVANSCSLAANGSLAGLRPHRGLQQEPSGVL  
 
                              60        70        80        90       100         
                     ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB2 WT        DPDGHLFNACDWGLLHGVAGQIAIALNNDSTWVQRAEARRRACSKLAAQF  
IS-19 DMB2.1 cl-11   RPRWPPLQRLRLGAAARRGWTDCHCPQQ*QHLGAACRGTETGVQQTGCTV  
 
                             110       120       130       140       150     
                     ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB2 WT        WAQTALRRTQPQVRIVPAQTGNPSVPIRLTCHVWGFYPPEVTIIWLHNGD  
IS-19 DMB2.1 cl-11   LGTDGAAQDSAPGPHRPRTDREPQRAHPPHLPRVGLLPPRGDHHLAAQWG  
 
                             160       170       180       190       200     
                     ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB2 WT        IVGPGDHSPMFAIPNGNWTYQTQVALSVAPEVGDTYTCSVQHASLEEPLL  
IS-19 DMB2.1 cl-11   HRGTWRPLTHVCHPQWELDLPDTGGPLGGPRGGGHLHVLGAAC*LGGAPP  
 
                             210       220       230       240       250     
                     ....|....|....|....|....|....|....|....|....|....| 
IS-19 DMB2 WT        EDWRPGLTLEVTLMVAVATVVMVLGLSLLFIGVYCWRAQPPAPGYAPLPG  
IS-19 DMB2.1 cl-11   GGLASWADAGGDADGGCGHCSDGVGAQLALHWCLLLAGPTPCPRLRPASR  
 
                            
                     ....|.... 
IS-19 DMB2 WT        HNYPSGSI   
IS-19 DMB2.1 cl-11   SQLPFRQHL  
 
 
 
 
 
 
From the five selected clones of MHC class II gene KO lines it is noted that three of the five 
clonal lines appear to have the same indel event on both alleles, which initially seemed like a 
strange occurrence if the indel generated is thought to be largely random. Upon deeper 
reading of the exploding literature of CRISPR-Cas9 it seems that this may not be an 
uncommon phenomenon. When an allele is cut and edited and then an indel is generated, a 
subsequent cut to the second allele may be repaired by homology directed repair using the 
Figure 4.3.5 DNA and amino acid sequence alignment of clonal line DMB2.1 cl-11 
show editing events and the generation of a premature stop codon. 
 
a) The editing events revealed by sequencing exon 1 of DMB2 were mapped onto the whole of DMA 
cDNA sequence and compared to the wild type, the editing event appears to be the same on both 
alleles immediately before the PAM site (red line) at position 102-104. b)  The effect of this editing 
event on the whole amino acid sequence is shown. The change in the coding sequence begins at 
position 34, a premature stop codon can be seen down stream of this position. 
The two sequences are labelled on the left-hand margin; wild type sequence (IS19 DMB2 WT), the 
edited alleles are labelled (IS19 DMB2.1 cl-11). 
a) 
b) 
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first edited allele as the ‘repair template’. This would result in the same indel being present 
on both alleles. The likelihood of this occurring depends on the cellular preference for either 
NHEJ or HDR as the repair method; this preference can be completely dependent on the cell 
type used and the stage of cell cycle when the edit occurs. The literature has many detailed 
examples of genes similar to the target gene being unexpectedly used as a repair template 
for the targeted gene, resulting in the presence of chimeric proteins, an issue that was 
encountered when making double KO mutations of the class II genes. 
The next step was to show that our edited cell lines had no protein expression of our target 
genes, proving that our frameshift mutation had resulted in disruption of the gene and that 
our cell lines were viable for further characterisation and study. 
 
4.4 Confirmation that indel generation in class II single KO lines results in no protein 
expression. 
Membrane enriched lysates were prepared at a concentration of 2x108 cells per mL for wild 
type IS19 cells and all five class II KO clonal lines to study protein expression by Western 
blotting. Initially, the cell lines BLB1.2 cl-1 and BLB2.2 cl-1 were examined by denaturing SDS-
PAGE with samples being boiled before loading. Samples were stained with the primary 
antibody BLBcyt10, targeted to the conserved cytoplasmic tail of both BLB proteins enabling 
us to detect both BLB chains. 
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Figure 4.4.1 shows the wild type IS19 has two bands present, with the top band being BLB1 
at 35 kDa and the bottom BLB2 at 31 kDa. BLB1.2 cl-1 shows a complete loss of the upper 
band (BLB1) and BLB2.2 cl-1 shows a complete loss of the lower band (BLB2), as is expected 
from the change in translation detailed in the sequencing results (figures 4.4.1 and 4.4.2). 
Unexpectedly, BLB2.2 cl-1 appeared to show reduced protein expression of BLB1 in addition 
to the complete loss of BLB2 despite our sequencing results showing that the BLB1 locus 
remained unedited; this result will be addressed further later in this chapter. 
 
 
 
 
 
 
                        
Figure 4.4.1 BLB1 and BLB2 KO clonal lines lack protein expression of the targeted BLB. 
IS19 WT cells and clonal derived cell lines BLB1.2 cl-1 and BLB2.2 cl-1 were lysed using digitonin after a 
membrane enriching protocol. The clone lysates were probed for BLB protein expression by western blotting 
using the antibody BLBcyt10. Membranes were subsequently stained for β -actin levels as a loading control. 
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The cell line DMA.2 cl-1 was examined by denaturing SDS-PAGE with samples being boiled 
before loading and samples were stained with the primary antibody DMA-8; targeted to the 
cytoplasmic tail. Figure 4.4.2 shows wild type IS19 DMA present at a mobility of 31 kDa. IS19 
DMA.2 cl-1 shows a complete loss of DMA, as expected from the change in translation 
detailed in the sequencing results (figure 4.3.3). In addition, BLB1, BLB2 and DMB2 KO lines 
were also stained for the presence of DMA. It was seen that BLB1 and BLB2 seemed to show 
comparable levels of DMA when compared with the actin staining, but it was noted that the 
DMB2 KO line had a considerable reduction in DMA expression. This was not unexpected 
and has been seen in human and mouse class II literature but warranted closer investigation 
(see chapter 5). 
 
 
 
Figure 4.4.2 DMA KO clonal line has no protein expression of the targeted DMA. 
IS19 WT cells and the clonal derived cell line DMA.2 cl-1 were lysed using digitonin after a membrane 
enriching protocol. The lysates were probed for DMA protein expression by western blotting using the 
antibody DMA-8. Clones were subsequently stained for β -actin levels as a loading control. 
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The cell line DMB2.1 cl-11 was examined by denaturing SDS-PAGE with samples being boiled 
before loading and samples were stained with the primary antibody DMB2-11, targeted to 
the cytoplasmic tail. Figure 4.4.3 shows the wild type IS19 has DMB2 present at an 
approximate mobility of 38 kDa. IS19 DMB2.1 cl-11 shows a complete loss of DMB2, as 
expected from the change in translation detailed in the sequencing results (figure 4.3.5). 
 
As before, BLB1, BLB2 and DMB2 KO lines were stained for the presence of DMB2. It was 
seen that BLB1 KO showed comparable levels of DMB2 when compared with the actin 
staining.  The BLB2 KO line appeared to show a reduction in DMB2 expression and the 
presence of a smaller band at ~20 kDa, which was unexpected and is investigated further in 
chapter 5.  It was also seen that the DMA KO line showed the complete loss of DMB2 
Figure 4.4.3 DMB2 KO clonal line has no protein expression of the targeted DMB2. 
IS19 WT cells and the clonal derived cell line DMB2.1 cl-11 were lysed using digitonin after a membrane 
enriching protocol. The lysates were probed for DMB2 protein expression by western blotting using the 
antibody DMB2-11. Clones were subsequently stained for β -actin levels as a loading control. 
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expression. Human and mouse class II literature has shown that the loss of DMA can result in 
the reduction of DMB, but it was unexpected to see a complete loss of DMB2 protein. 
Next, we determined if the chicken class II protein in IS19 is resistant to SDS and can remain 
as a heterodimeric complex when examined by reducing PAGE and the samples are not 
boiled before loading onto the gel. 
 
 
 
 
 
IS19 WT was seen to have the phenomena of SDS-resistance as described in other species, 
illustrated by the class II protein remaining in complex and running at ~50 kDa. Once the WT 
sample is boiled the complex disappears and instead is seen as the two single class II β-
chains (fig 4.4.4). For the BLB1 and BLB2 KO lines we observe the same pattern as the wild 
type. The DMA KO line shows no sensitivity to SDS but appears to show reduced protein 
expression of BLB1 and BLB2. The DMB1 KO line shows heterodimeric MHCII complex and is 
concluded to be SDS-insensitive, but again shows reduced BLB1 and BLB2 protein 
Figure 4.4.4 Assessment of SDS-sensitivity in all class II KO clonal lines. 
IS19 WT cells and the clonal derived cell lines BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and 
DMB2.1 cl-11 were lysed using digitonin after a membrane enriching protocol. The lysates were probed for 
BLB protein expression by western blotting using the antibody BLBcyt10. Before loading lysates were either 
not boiled (NB) or boiled (B).  
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expression, in particular BLB1. The DMB2 KO line also shows heterodimeric MHCII complex 
and is concluded to be SDS-insensitive. 
Interestingly, in these preliminary results we saw not only the loss of the gene targeted for 
KO but what appeared to be reductions in protein expression of other class II associated 
proteins. These results will be explored in greater detail in chapter 5. 
 
4.5 Identification and optimisation of housekeeping gene standards for RT-qPCR 
In the class II single KO lines generated, we began to look at the effect of protein expression 
of the components of class II antigen presentation, but also to characterise these lines at the 
peptide (chapter 6) and RNA level (chapter 5). Before we could begin to look at effects on 
the RNA level, suitable housekeeping genes had to be tested and optimised as well as 
primers for each of the class II genes of interest. 
 
Three housekeeping genes were tested as standards for RT-qPCR. Hypoxanthine 
phosphoribosyltransferase (HPRT), a transferase which mainly functions to recover purines 
from DNA that has been degraded to introduce them back into the purine synthetic 
pathways. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a dehydrogenase enzyme 
from glycolysis. 18S, a component of the small eukaryotic ribosomal subunit (40S). The 
primers tested were from a publication optimising qRT-primers in chicken tissue (Olias et al 
2014). 
Primers were tested for HPRT with successful results. Average Cts ranged from ~31 to ~27 
(figure 4.5.1a) and producing a standard curve that has an R2 value of 0.993 indicating a high 
efficiency of amplification by the primers (figure 4.5.1b). Importantly, the primers also 
showed a ‘clean’ melt curve with only one clear peak for all replicates of all cDNA 
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concentrations (figure 4.5.1c). 
 
 
 
 
 
 
 
Next GAPDH was tested, giving average Ct values from ~24 to ~17 (figure 4.5.2a) and 
producing a standard curve that has an R2 value of 0.998 indicating a high efficiency of 
amplification by the primers (figure 4.5.2b). The melt curve showed one clear peak for all 
replicates of all cDNA concentrations (figure 4.5.2c), showing specific primers that amplified 
one product. 
 
Figure 4.5.1 optimisation of housekeeping HPRT showing the average Ct, standard curve 
and melt curve. 
RNA was extracted from IS19 WT cells, followed by cDNA synthesis. 2, 10 or 100 ng of cDNA was 
then used for qRT-PCR analysis to amplify the housekeeping gene HPRT, 3 technical replicates were 
used for each concentration. a) the average Ct was plotted as a bar graph for each concentration. b) 
the standard curve was plotted from 3 replicates of each concentration generating an R2 value of 
0.993 (replicates are shown as red boxes). c) the melt curve of each replicate at each cDNA 
concentration. 
R2= 0.993 
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The last set of primers tested were for 18S. Average Ct values were seen from ~21 to ~17 
(figure 4.5.3a) and produced a standard curve with an R2 value of 0.919 indicating a high 
efficiency of amplification by the primers (figure 4.5.3b). The melt curve showed one clear 
peak for all replicates of all cDNA concentrations (figure 4.5.2c), showing specific primers 
that amplified one product. 
 
Figure 4.5.2 optimisation of housekeeping GAPDH showing the average Ct, standard 
curve and melt curve. 
RNA was extracted from IS19 WT cells, followed by cDNA synthesis. 2, 10 or 100 ng of cDNA was 
then used for qRT-PCR analysis to amplify the housekeeping gene GAPDH, 3 technical replicates 
were used for each concentration. a) the average Ct was plotted as a bar graph for each 
concentration. b) the standard curve was plotted from 3 replicates of each concentration generating 
an R2 value of 0.998 (replicates are shown as red boxes). c) the melt curve of each replicate at each 
cDNA concentration. 
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4.6 Identification and optimisation class II primers for RT-qPCR 
With appropriate housekeeping genes identified and optimised next appropriate primers 
were tested for each of the class II genes of interest; BLB1, BLB2, DMA, DMB1 and DMB2. 
BLB1 proved to be difficult to design primers that would amplify with a high efficiency (R2 
above 0.8). The best primer combination had an R2 value of 0.883 and a melt curve that 
showed the presence of one major peak indicating largely specific amplification (figure 
4.6.1). 
Figure 4.5.3 optimisation of housekeeping 18S showing the average Ct, standard curve 
and melt curve. 
RNA was extracted from IS19 WT cells, followed by cDNA synthesis. 2, 10 or 100 ng of cDNA was 
then used for qRT-PCR analysis to amplify the housekeeping gene 18S, 3 technical replicates were 
used for each concentration. a) the average Ct was plotted as a bar graph for each concentration. b) 
the standard curve was plotted from 3 replicates of each concentration generating an R2 value of 
0.919 (replicates are shown as red boxes). c) the melt curve of each replicate at each cDNA 
concentration. 
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Figure 4.6.1 optimisation of qRT-PCR primers for BLB1 showing the standard curve and 
melt curve. 
RNA was extracted from IS19 WT cells, followed by cDNA synthesis. 2, 10 or 100 ng of cDNA was 
then used for qRT-PCR analysis to amplify the BLB1; 3 technical replicates were used for each 
concentration. a) the standard curve was plotted from 3 replicates of each concentration generating 
an R2 value of 0.883 (replicates are shown as blue boxes). b) the melt curve of each replicate at each 
cDNA concentration. 
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The best set of primers for BLB2 gave an R2 value of 0.995 and a melt curve with one peak 
shown in figure 4.6.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.2 optimisation of qRT-PCR primers for BLB2 showing the standard curve and 
melt curve. 
RNA was extracted from IS19 WT cells, followed by cDNA synthesis. 2, 10 or 100 ng of cDNA was 
then used for qRT-PCR analysis to amplify the BLB2, 3 technical replicates were used for each 
concentration. a) the standard curve was plotted from 3 replicates of each concentration generating 
an R2 value of 0.995 (replicates are shown as red boxes). b) the melt curve of each replicate at each 
cDNA concentration. 
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The best set of primers for DMA gave an R2 value of 0.986 and a melt curve with one peak 
shown in figure 4.6.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.3 optimisation of qRT-PCR primers for DMA showing the standard curve and 
melt curve. 
RNA was extracted from IS19 WT cells, followed by cDNA synthesis. 2, 10 or 100 ng of cDNA was 
then used for qRT-PCR analysis to amplify the DMA; 3 technical replicates were used for each 
concentration. a) the standard curve was plotted from 3 replicates of each concentration generating 
an R2 value of 0.986 (replicates are shown as red boxes). b) the melt curve of each replicate at each 
cDNA concentration. 
103 
 
Primers designed to DMB1  gave an R2 value of 0.837 and a melt curve with one peak, shown 
in figure 4.6.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.4 optimisation of qRT-PCR primers for DMB1 showing the standard curve and 
melt curve. 
RNA was extracted from IS19 WT cells, followed by cDNA synthesis. 2, 10 or 100 ng of cDNA was 
then used for qRT-PCR analysis to amplify the DMB1, 3 technical replicates were used for each 
concentration. a) the standard curve was plotted from 3 replicates of each concentration generating 
an R2 value of 0.837 (replicates are shown as blue boxes). b) the melt curve of each replicate at each 
cDNA concentration. 
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The best set of primers for DMB2 gave an R2 value of 0.994 and a melt curve with one peak 
shown in figure 4.6.5. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.5 optimisation of qRT-PCR primers for DMB2 showing the standard curve and 
melt curve. 
RNA was extracted from IS19 WT cells, followed by cDNA synthesis. 2, 10 or 100 ng of cDNA was 
then used for qRT-PCR analysis to amplify the DMB2; 3 technical replicates were used for each 
concentration. a) the standard curve was plotted from 3 replicates of each concentration generating 
an R2 value of 0.994 (replicates are shown as blue boxes). b) the melt curve of each replicate at each 
cDNA concentration. 
105 
 
4.7 Discussion 
Successful indel events were generated in the IS19 cell type for BLB1, BLB2, DMA, DMB1 and 
DMB2. The screening of the class II KO cell lines showed a clear predictability for the position 
of the indel generated in relation to the guide RNA used, with indels occurring four 
nucleotides downstream of the PAM site. Analysis of these clonally generated KO lines 
showed that the indel event of each chosen line resulted in a frameshift event that disrupted 
the coding of the gene and in each case led to the generation of a premature stop codon. 
Targeting of BLB1 and BLB2 was initially a concern as there is high sequence homology 
between the two genes. To try and circumvent off-target effects guides were designed with 
a minimum of 3 bp mismatches between the targeted BLB and its counterpart, based on 
previous publications on mismatch tolerance in CRISPR-Cas9 mediated gene editing (Hsu et 
al 2013). This approach appeared to yield no detectable off-target effects when both BLB loci 
were screened for edits in each BLB KO line. 
One aspect of editing which was unexpected was that in multiple cases (DMA fig 4.3.3, 
DMB1 fig 4.3.4 and DMB2 4.3.5) the same indel was detected on both alleles, which seemed 
counter intuitive as the indel generation is assumed to be random. Upon further reading and 
through personal communication I found that this does not seem to be uncommon and a 
current hypothesis to explain this is that during the cutting and editing process one allele is 
edited first, subsequently a second allele is cut and instead of the second cut being repaired 
by NHEJ, it is repaired by HDR using the first allele as a template. After the HDR event has 
taken place this will then lead to the same indel on both alleles. 
 
To confirm that the indel events have disrupted the protein expression and that in fact both 
alleles have been edited (in the case where the indels are the same on both alleles) western 
blotting was performed to check that no protein was present for the targeted gene.  This 
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proved to be successful with the clonal lines having no protein for the targeted gene, (except 
for DMB1, where protein expression could not be measure) although we discovered some 
interesting effects on other class II protein expression in our clonal KO lines. 
Firstly, we found that in the BLB1 KO line there is no effect on BLB2 expression as expected, 
but in the BLB2 KO line BLB1 expression is reduced (fig 4.4.1). It was also seen in the DMB2 
KO line that DMA expression is reduced (fig 4.4.2). This was not unexpected, as we assume 
DMA and DMB2 to function as an α-β pair and in the absence of one of the two chains, one 
could anticipate that the remaining chain is targeted for degradation as it is lacking function 
in the absence of its cognate chain, similar results have been seen for DM KOs in human and 
mice cell lines. Interestingly, in the DMA KO line DMB2 expression disappears entirely (fig 
4.4.3), which is previously unseen in publications investigating class II antigen presentation in 
other model species. It could be assumed that because DMA is the common alpha chain for 
both DMB1 and DMB2, if DMA is removed then DMB2 is completely degraded without its 
functional partner, where as if DMB2 is removed DMA expression is reduced as there is 
surplus DMA to requirement, but some DMA remains present to pair with DMB1. It also 
needs to be considered that the chicken MHC class II differs in genes present and 
organisation when compared to other model systems. It appears to have two functional DM 
chaperones, comprised of DMA paired with either beta chain, DMB1 or DMB2 (Parker 2012) 
suggesting that the system may function differently from other models studied. 
 
A more unexpected result was seen in figure 4.4.3 where the BLB2 KO line appears to show a 
reduction in DMB2 expression. Current models we have put forward (previously discussed 
chapter 1, 1.7.5) suggest a handful of ways in which the two DMs could act on the two 
classical class IIs, one of which proposes that each DM could have a partial or full preference 
for one of the class II molecules. If this were to be the case and DMB2 functions primarily 
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with BLB2, then if BLB2 is removed DMB2 expression would reduce. We also saw that when 
DMA is deleted both BLB1 and BLB2 expression is reduced (fig 4.4.4) and when DMB1 is 
deleted both BLB1 and BLB2 expression is decreased but with a more pronounced effect on 
BLB1. Previous studies in humans have shown that deletion of DMA or DMB can result in a 
reduction on total class II protein expression but the effects are not as pronounced as the 
initial results seen in the chicken.  The findings that DMA deletion shows a large reduction of 
both BLB1 and BLB2, whereas DMB1 deletion has a more prominent effect on BLB1 
expression than BLB2 could also support the idea of preferential editing of a particular BLB 
for each DMB. 
Upon initial investigation of SDS-sensitivity, we found that like previous published data for 
human and mice class II alleles the B19 class II molecules are able to stay in complex when 
run by reducing PAGE if the samples are not boiled before loading (fig 4.4.4). B19 class II 
molecules did not show obvious DM-dependence (fig 4.4.4). When DMA, DMB1 or DMB2 
was deleted, the class II molecules were able to stay in complex if the samples were not 
boiled. Published works for humans and mice have shown that DM-dependence varies 
between alleles, with some alleles remaining in complex without DM in non-boiled 
conditions whilst others cannot. It is more than possible that the B19 haplotype is a DM-
independent class II allele and we may see DM-dependent alleles if we were to investigate 
different haplotypes. 
It is important to consider that, although all western blots shown in this chapter were 
completed three or more times with each showing the same result, the comparisons of class 
II protein expression are on X-ray film which has a very low dynamic range and is inaccurate 
for quantification and could conceivably be misleading. In chapter 5 the class II KO lines are 
fully characterised for effects on class II protein expression and to address the issue with X-
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ray film, all subsequent experiments for quantitative western blotting were carried out using 
an infrared antibody system or chemiluminescence directly from the membrane. 
 
Lastly, in preparation for analysis at the RNA level primers were tested for candidate 
housekeeping genes and for the class II genes of interest.  For housekeeping standards HPRT, 
GAPDH and 18S were screened, all of which gave high efficiency amplification and melt 
curves with a single peak (figures 4.5.1 - 3). GAPDH was selected for future experiments as it 
gave the largest range of Ct values from 21 – 17 (fig 4.5.2). Next primers were screened for 
all class II genes of interest BLB1, BLB2, DMA, DMB1 and DMB2. BLB2, DMA and DMB2 gave 
very high efficiency amplification and melt curves with a single peak (figures 4.6.2, 4.6.3 and 
4.6.5). BLB1 and DMB1 proved to be more difficult and required more primers to be 
designed and tested (detailed in materials and methods). Primers were found with 
acceptable amplification efficiencies, with R values of 0.883 and 0.837 for BLB1 and DMB1 
respectively and melt curves showing one major peak (figures 4.6.1 and 4.6.4).  With a 
housekeeping gene optimised and selected, and with primers that specifically amplify the 
targeted class II genes of interest, quantification of gene expression can begin in the class II 
single KO lines.  
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5. Characterisation of class II single KOs 
at the RNA and protein level 
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5. Characterisation of class II single KOs at the RNA and protein level  
5.1 Introduction 
Chapter four detailed the creation, screening, and validation of five IS19 class II KO cell lines; 
BLB1, BLB2, DMA, DMB1 and DMB2. The cell lines chosen for further experimentation were 
BLB1.1 cl-1, BLB2.1 cl-1, DMA.2. cl-1, DMB1.4 cl-10 and DMB2.1 cl-11; for simplicity from 
now on each cell line will be referred to as the relevant gene name plus KO e.g. BLB1 KO.  
Additionally in chapter four, RT-qPCR primers and conditions were optimised to allow 
characterisation of the KO cell lines at the mRNA level. In this chapter we analyse the 
expression of all class II genes in the IS19 class II KO cell lines at the RNA level and the 
protein level and look at the effect of DM KOs on the temperature stability of BLB. 
Furthermore, initial data on TG21 BLB temperature stability is assessed in DMA and DMB2 
KO lines and compared to that of IS19. 
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5.2 mRNA expression of class II genes, in IS19 single class II KO lines  
Initially we looked at RNA expression in all the single class II KOs, with RT-qPCR data being 
analysed by the delta delta Ct (2–∆∆Ct) method and plotted as either a fold change 
compared to wild type expression. Due to sensitivity of the RT-qPCR machine, it is assumed 
that changes less than one cycle (two-fold change) cannot be detected reliably. Therefore 
any change two-fold or above is considered as an appreciable change in mRNA expression. 
Furthermore, the fold changes between class II gene expression and the wildtype expression 
were analysed by unpaired t-test with significance denoted as follows; * P <0.05, ** P <0.01, 
*** P <0.001.  
Figure 5.2.1 shows BLA RNA expression fold changes. No significant upregulation is seen in 
any of the class II KO lines but it is observed that BLA undergoes a significant downregulation 
of ~15 fold in the DMB2 KO line.  
 
 
 
 
BLB1 RNA expression is measured in figure 5.2.2 and shows that there is no significant 
upregulation at the RNA level in any of the class II KOs, though the BLB2 KO line shows a 
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Figure 5.2.1 Fold change of BLA RNA of single class II KO cell lines by RT-qPCR  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were 
measured for RNA expression; expression was normalised to wild type IS19 GAPDH expression. 
mRNA was extracted for all cell lines, followed by cDNA synthesis, and BLA expression was 
measured by RT-qPCR using the UC29 (FP) and UC30 (RP) primers. Relative fold changes were 
generated using the 2–∆∆Ct method. a) BLA expression as relative fold increases compared to IS19 
wild type cells. b) BLA expression as relative fold decreases compared to IS19 wild type cells. 
 
 
 
** 
** 
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modest ~ 3-fold decrease in BLB1 expression. It is noted that BLB1 RNA expression is 
comparable to wild type in the BLB1 KO line, but due to the nature of CRISPR-Cas9 indel loss 
of function mutants it is common for the edited gene to still be transcribed into mRNA (if the  
RT-qPCR primer binding site is unaffected) even though the indel results in a loss of 
functional protein. 
 
 
 
 
Figure 5.2.3 shows changes in RNA expression of BLB2 in the class II KO lines. A small 
upregulation of BLB2 can be seen in the BLB1 KO but no significant upregulation can be seen 
0
0.5
1
1.5
2
2.5
IS-19 BLB1 KO BLB2 KO DMA KO DMB1 KO DMB2 KO
m
R
N
A
 f
o
ld
 in
cr
es
e
Figure 5.2.2 Fold change of BLB1 RNA of single class II KO cell lines by RT-qPCR  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were 
measured for RNA expression, expression was normalised to wild type IS19 GAPDH expression. mRNA 
was extracted for all cell lines, followed by cDNA synthesis, and BLB1 expression was measured by RT-
qPCR using the qPCR BLB1 FP1 and qPCR BLB1 RP1 primers. Relative fold changes were generated 
using the 2–∆∆Ct method. a) BLB1 expression as relative fold increases compared to IS19 wild type 
cells. b) BLB1 expression as relative fold decreases compared to IS19 wild type cells. 
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in any other line. A small but significant downregulation is seen in the DMB2 KO line.
 
 
 
 
Figure 5.2.4 shows the RNA expression of DMA, with no significant upregulation seen in any 
of the cell lines. Interestingly, DMA RNA is significantly down regulated in the DMB1 KO line, 
with a ~12 and ~4-fold reduction seen respectively. 
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Figure 5.2.3 Fold change of BLB2 RNA of single class II KO cell lines by RT-qPCR  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were 
measured for mRNA expression, expression was normalised to wild type IS19 GAPDH expression. 
RNA was extracted for all cell lines, followed by cDNA synthesis, and BLB2 expression was measured 
by RT-qPCR using the UC116 (FP) and UC118 (RP) primers. Relative fold changes were generated 
using the 2–∆∆Ct method. a) BLB2 expression as relative fold increases compared to IS19 wild type 
cells. b) BLB2 expression as relative fold decreases compared to IS19 wild type cells. 
 
 
 
Figure 5.2.4 Fold change of DMA RNA of single class II KO cell lines by RT-qPCR  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were 
measured for mRNA expression, expression was normalised to wild type IS19 GAPDH expression. 
RNA was extracted for all cell lines, followed by cDNA synthesis, and DMA expression was measured 
by RT-qPCR using the UC116 (FP) and UC118 (RP) primers. Relative fold changes were generated 
using the 2–∆∆Ct method. a) DMA expression as relative fold increases compared to IS19 wild type 
cells. b) DMA expression as relative fold decreases compared to IS19 wild type cells. 
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DMB1 RNA expression was analysed in figure 5.2.5 with no significant fold increase being 
seen in any of the KO lines but decreases in expression were seen in the BLB2, DMA and 
DMB2 KO lines with reductions of ~40, ~50 and ~25 fold respectively. 
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Figure 5.2.5 Fold change of DMB1 RNA of single class II KO cell lines by RT-qPCR  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were 
measured for mRNA expression, expression was normalised to wild type IS19 GAPDH expression. RNA 
was extracted for all cell lines, followed by cDNA synthesis, and DMB1 expression was measured by 
RT-qPCR using the qPCR DMB1 FP1.2 and qPCR DMB1 RP1.2 primers. Relative fold changes were 
generated using the 2–∆∆Ct method. a) DMB1 expression as relative fold increases compared to IS19 
wild type cells. b) DMB1 expression as relative fold decreases compared to IS19 wild type cells. 
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DMB2 RNA expression remains consistent in all KO lines with no significant increases or 
decreases seen in any of the KO cell lines (fig 5.2.6).  
 
 
5.3 Quantification of class II protein expression, in IS19 single class II KO lines 
Next the IS19 class II KO lines were characterised for protein expression, starting with flow 
cytometry analysis of BLB1 and BLB2 surface expression and total expression (intracellular 
staining of permeabilised cells). Figure 5.3.1a shows the cell surface levels of MHCII, with the 
BLB1 KO showing a ~55 % reduction in MHCII and the BLB2 KO showing a ~75 % reduction 
with the remaining expression presumably being BLB2 and BLB1, respectively. The DMA KO 
line shows a reduction of cell surface MHC II with a ~75 % reduction, whereas the DMB1 KO 
and the DMB2 KO lines have the same MHCII levels as the wildtype (WT). Analysis of total 
MHC II levels (permeabilised cells) (fig 5.3.1b) show a different pattern, with a ~25 % 
reduction of MHC II in the BLB1 KO and a ~90 % reduction in the BLB2 KO, indicating that 
proportionally more BLB2 compared to BLB1 remains trapped inside the cell than makes it to 
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Figure 5.2.6 Fold change of DMB2 RNA of single class II KO cell lines by RT-qPCR  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were 
measured for mRNA expression, expression was normalised to wild type IS19 GAPDH expression. 
RNA was extracted for all cell lines, followed by cDNA synthesis, and DMB2 expression was measured 
by RT-qPCR using the qPCR DMB1 FP1.2 and qPCR DMB1 RP1.2 primers. Relative fold changes were 
generated using the 2–∆∆Ct method. a) DMB2 expression as relative fold increases compared to IS19 
wild type cells. b) DMB2 expression as relative fold decreases compared to IS19 wild type cells. 
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the cell surface and vice versa for BLB1. For the DMA KO a ~50 % reduction is seen 
intracellularly compared to a 75 % reduction on the cell surface. In contrast, both the DMB1 
KO and DMB2 KO lines show a ~25 % reduction in total MHCII. 
        
 
BLB1 and BLB2 protein expression was also measured by quantative-Western blot (q-WB) 
using densitometry. Figure 5.3.2a shows a western blot that was used for quantification, 
where all class II KO cell lines were probed for BLB1 and BLB2 expression using the antibody 
BLBcyt10. The β-actin band can be seen at ~45 kDa, with BLB1 seen at ~35 kDa and BLB2 at 
32 kDa when compared to the molecular mass markers. Quantification of BLB1 and BLB2 
normalised to wild type level protein expression can be seen in figure 5.3.2.b and c, 
respectively. For BLB1 expression, BLB1 is completely absent in the BLB1 KO, a ~60 % 
reduction is seen in the BLB2 KO, a ~70 % reduction in the DMA KO, a ~90 % reduction in the 
DMB1 KO and a ~60 % reduction in the DMB2 KO. It is expected that DM KOs may result in 
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Figure 5.3.1 MHCII staining in IS19 KO cell lines by flow cytometry.  
MHCII KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were analysed for 
MHCII expression by flow cytometry and compared to the wild type. a) Non-permeabilised samples were 
assessed for cell surface expression of MHCII using the 2G11 antibody. b) Samples were fixed and 
permeabilised for staining of intracellular MHCII using the BLBcyt10 antibody. Fluorescence is plotted as the 
geometric mean fluorescence intensity and error bars represent standard error of the mean. 
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less BLB1, if BLB1 is dependent on either of the DM complexes for peptide editing. The 
absence of DM would be expected to result in a lower stability of BLB1 and therefore 
degradation. BLB1 protein expression is significantly reduced in the BLB2 KO cell line, 
suggesting that BLB1 protein expression or stability is linked to the presence of BLB2. 
For BLB2 quantification in the class II KO lines, a ~25 % reduction is seen in the BLB1 KO, 
BLB2 is completely absent in the BLB2 KO, an ~80 % reduction is seen in the DMA KO line, a 
~60 % reduction is seen in the DMB1 KO line and a ~75 % reduction in the DMB2 KO line. As 
mentioned above, it is expected that BLB2 expression is reduced in DM KO lines if BLB2 is 
dependent on DM editing. BLB2 expression is decreased in the BLB1 KO line, which again 
suggests that BLB2 expression or stability is linked to BLB1 expression. 
It is interesting to note that the DMB1 KO has a slightly more pronounced effect on BLB1 
compared to BLB2 and that the DMB2 KO has a slightly more pronounced effect on BLB2 
when compared to BLB1. 
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Next DMA protein expression was assessed; Figure 5.3.3a shows a western blot that was 
used for quantification. DMA is seen at ~31k Da when compared to the molecular mass 
marker. Quantification of DMA is normalised to wild type level protein expression in figure 
5.3.3.b. DMA expression is reduced by ~70 % in the BLB1 KO, a ~95 % reduction is seen in the 
BLB2 KO, DMA is completely absent in the DMA KO and a ~95 % reduction is seen in both the 
DMB1 and DMB2 KO lines. It is proposed that DMB1 and DMB2 are the β chains that 
associate with DMα to form two DM peptide editors, and so it is expected that a reduction in 
DMA would be seen in the DMB1 and DMB2 KO lines.  
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Figure 5.3.2 q-Western blots staining for BLB in IS19 single class II KO clonal lines. 
IS19 WT cells and the clonal derived cell lines BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and 
DMB2.1 cl-11 were lysed using digitonin after a membrane enriching protocol, lysates were boiled in 
DTT before loading. a) The lysates were probed for BLB protein expression by western blotting using 
the antibody BLBcyt10. Relative BLB1 (b) and BLB2 (c) expression was quantified by densitometry, 
results are plotted as a relative fold change compared to wild type expression, normalised to β-actin 
staining. Blots were performed in triplicate for quantification. 
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Lastly, DMB2 protein expression was analysed. Figure 5.3.4a shows a western blot that was 
used for quantification. DMB2 is seen at ~38k Da when compared to the molecular mass 
marker; quantification of DMB2 is normalised to wild type level protein expression in figure 
5.3.4.b. DMB2 expression is the same as the wild type in the BLB1 KO, DMB2 is absent in the 
DMA KO, and DMB2 is absent DMB2 KO line. It is expected that a reduction in DMB2 would 
be seen in the DMA KO line as DMA is the cognate chain of DMB2.  
0
0.2
0.4
0.6
0.8
1
1.2
Is19 BLB1 KO BLB2 KO DMA KO DMB1 KO DMB2 KOFo
ld
 c
h
an
ge
 in
 p
ro
te
in
 e
xp
re
ss
io
n
Figure 5.3.3 q-Western blots staining for DMA in IS19 single class II KO clonal lines. 
IS19 WT cells and the clonal derived cell lines BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and 
DMB2.1 cl-11 were lysed using digitonin after a membrane enriching protocol, lysates were boiled in 
DTT before loading. a) The lysates were probed for DMA protein expression by western blotting using 
the antibody DMA-8. b) Relative DMA expression was quantified by densitometry, results are plotted 
as a relative fold change compared to wild type expression, normalised to β-actin staining. Blots were 
performed in triplicate for quantification. 
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Figure 5.3.4 q-Western blots staining for DMB2 in IS19 single class II KO clonal lines. 
IS19 WT cells and the clonal derived cell lines BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1, DMB1.4 cl-10 and 
DMB2.1 cl-11 were lysed using digitonin after a membrane enriching protocol, lysates were boiled 
in DTT before loading. a) The lysates were probed for DMB2 protein expression by western blotting 
using the antibody DMB2-11. b) Relative DMA expression was quantified by densitometry, results 
are plotted as a relative fold change compared to wild type expression, normalised to β-actin 
staining. Blots were performed in triplicate for quantification. 
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A summary of the analysis at the mRNA and protein level in all class II KO cell lines is 
described in figure 5.3.5. This summary will be used for discussion in section 5.4. 
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Figure 5.3.5 Summary of mRNA and protein expression in IS19 class II KO lines. 
A summary of the findings of mRNA and protein expression is depicted for all IS19 class II KO lines. 
The data for each cell line is condensed into a flow diagram for BLB1 KO (a), BLB2 KO (b), DMA KO 
(c), DMB1 KO (d) and DMB2 KO (e). The KO cell line noted to the right of each diagram, with rows 
indicating the gene measured and columns describing how the data was measured. Effects on the 
gene are described as fold change or percentage. Red boxes indicate where class II could only be 
measured as total class II and BLB1 or BLB2 expression could not be individually discerned. 
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Figure 5.3.6 q-Western blots assessing temperature stability of BLB in IS19 WT and DM KO 
clonal lines. 
 
 IS19 WT cells and the clonal derived cell lines DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were lysed using digitonin after a 
membrane enriching protocol. Lysates were incubated on ice, room temperature (RT) 30oC, 40oC, 50oC, 60oC, 70oC, 80oC or 90oC before 
loading. All blots were probed for BLB protein expression by western blotting using the antibody BLBcyt10. The temperature stability 
was assessed in the wild type (A), DMA KO (B), DMB1 KO (C) and DMB2 KO (D). Blots were performed in triplicate for quantification. 
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Next temperature stability of BLB was assessed in the three DM KO lines. Figure 5.3.6 shows 
western blots of IS19 WT (a), DMA KO (b), DMB1 KO (c) and DMB2 KO (d), to assess the 
ability of the MHCII to stay in heterodimeric complex over a temperature gradient between 
the three different KO lines. The wildtype line shows that the complexed class II begins to 
predominately fall apart at ~ 50 oC. Comparing this observation to the DMA KO line where 
we see that the class II complex begins to fall apart at a much lower temperature ~30 oC, the 
DMB1 KO shows dissociation at ~50 oC (comparable to the WT) and the DMB2 KO shows 
major dissociation starting at ~40 oc.  
Western blots assessing temperature stability of the DM KOs were carried out in triplicate to 
allow for quantification, so the effect that the DM KOs have on stability could be quantified. 
Figure 5.3.7 shows the quantification of MHCII complex and MHCII single β chains plotted 
over the temperature gradient, for IS19 (a), DMA KO (b), DMB1 KO (c) and DMB2 KO (d). To 
determine the point at which the class II complex predominately falls apart we take the 
value at which the MHCII complex and the MHCII single chains intersect. For IS19 WT 
stability is ~55 oC, the DMA KO stability is ~30 oC, ~50 oC for the DMB1 KO and ~45 oC for the 
DMB2 KO. The DMA KO has the strongest effect on stability, presumably as DMA is required 
for the formation of both DM peptide editors it has the strongest effect on stability of BLB. 
In contrast, the DMB1 KO has the subtlest of effects dropping from ~55 oC in the wild type to 
~50 oC; again, this fits with the hypothesis that DMB1 is the poorly expressed DMB and 
comprises the minor DM editor. For the DMB2 KO we see a phenotype in between the DMA 
and DMB1 KO with temperature stability falling to 45 oc. This was expected as DMB2 is the β 
chain for the dominantly expressed DM peptide editor and is expected to be the prominent 
peptide editor, at least in haematopoietic cells. 
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Figure 5.3.7 q-Western blot quantification for temperature stability of 
BLB class II complex and single beat chains in IS19 WT and DM KO clonal lines. 
 
IS19 WT cells and the clonal derived cell lines DMA.2 cl-1, DMB1.4 cl-10 and DMB2.1 cl-11 were lysed 
using digitonin after a membrane enriching protocol. Lysates were incubated on ice, room 
temperature (RT) 30oC, 40oC, 50oC, 60oC, 70oC, 80oC or 90oC before loading. Al blots were probed for 
BLB protein expression by western blotting using the antibody BLBcyt10. The temperature stability 
was assessed in the wild type (A), DMA KO (B), DMB1 KO (C) and DMB2 KO (D). Blots were performed 
in triplicate for quantification from one lysate and reveal similar results of blots from an independent 
lysate. BLB complex and single chains were quantified by densitometry, results are plotted as a 
relative fold change normalised to either ice for class II complex or 90 oC for single chains. 
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The effect of DM KOs on IS19 were compared to another haplotype, starting with the B21 
haplotype using the B21 cell line, TG21. To compare the findings in TG21 with IS19 BLB1, 
BLB2, DMA, DMB1 and DMB2 KOs, replicate KO cell lines are under construction in TG21. All 
genes of interest have been knocked out at a polyclonal level with clonal lines derived for 
DMA and DMB2 KOs.  Figure 5.3.8 shows preliminary data for the effect of DMA and DMB2 
KOs on temperature stability (as done for IS19) compared to the wild type.  
Figure 5.3.8 q-Western blots assessing temperature stability of BLB in TG21 WT, DMA KO and 
DMB2 KO clonal lines. 
 TG21 WT cells and the clonal derived cell lines DMA.2 cl-2 and DMB2.1/2 cl-14 were lysed using digitonin after 
a membrane enriching protocol. Lysates were incubated on ice, room temperature (RT) 30oc, 40oc, 50oc, 60oc, 
70oc or 80oc before loading. Al blots were probed for BLB protein expression by western blotting using the 
antibody BLBcyt10. The temperature stability was assessed in the wild type (A), DMA KO (B) and DMB2 KO (C). 
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Figure 5.3.8a shows the temperature stability of wild type TG21, which begins to fall apart 
between 70-80 oC but is still not fully dissociated by 80 oC. This is in contrast to IS19 which 
begins to fall apart around 50 oC, showing that TG21 BLB has intrinsically higher 
thermostability. The TG21 DMA KO (fig 5.3.8b) shows full dependence on DM expression for 
a stable BLB complex to be expressed, with lysates incubated on ice not forming a stable 
heterodimeric complex. When this is compared to the DMB2 KO (fig 5.3.8c) we see an 
intermediate phenotype with the class II complex falling apart around 50-60 oC, suggesting 
that the absence of DMB2 results in less stable class II complex, presumably as the class II is 
unable to be edited by the DM2 peptide editor. The stable class II complex present 
compared to the DMA KO suggests that DM comprised of DMB1 can compensate to some 
degree.  It is important to note that this preliminary experiment has only been done once 
and will need to be repeated with at least two different lysate preparations and in triplicate 
for quantification. 
 
5.4 Discussion 
In this chapter we undertook a thorough analysis of the IS19 class II KO cell lines at the RNA 
and protein level, although we were unable to analyse BLA or DMB1 protein levels due to 
reagent limitations. Moreover, we looked at the effect that DM KOs have on the ability of 
IS19 to form thermostable class II complexes. Lastly, we show preliminary thermostability 
data in TG21 WT, DMA and DMB2 KO cell lines. 
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5.4.1 Characterisation of IS19 BLB1 KO at the RNA and protein level 
The RNA expression in the single class II KOs was compared to the protein expression to see 
how well the two results correlate (fig 5.3.5). Starting with the BLB1 KO, for BLA RNA 
expression we see no significant change (fig 5.2.1) and unfortunately due reagent limitations 
we are unable to assess what happens to BLA at the protein level. For BLB1 RNA expression 
no significant change was seen (fig 5.2.2) which as explained previously is not unexpected 
even though it is a BLB1 KO cell line, the indels generated in BLB1 do not necessarily disrupt 
the stability of the mRNA transcript and it is still able to be transcribed and remain stable. 
Though this is not always the case, and the mRNA can become unstable and be degraded to 
varying degrees. When this is compared to protein expression from q-Western blotting we 
see that no BLB1 protein is expressed (fig 5.3.2b). For BLB2 RNA expression we see a modest 
two-fold increase compared to the WT (fig 5.2.3), interestingly when this is compared to 
BLB2 protein expression the two results are in contention as q-western blotting reveals a ~25 
% reduction in BLB2 (fig 5.3.2c). There are multiple potential explanations for such a result. 
Firstly, reduction of BLB2 mRNA is at the edge of detection and it is possible that the mRNA 
expression could be a non-significant change. Secondly, the mRNA upregulation could be 
accurate but BLB2 is less stable when BLB1 is not present and is turned over at a level that 
still results in a net 25 % loss of BLB2. Although it is unclear why a lack of BLB1 expression 
would result in unstable BLB2 expression, as we do not expect the two class II molecules to 
interact or to be dependent on each other for expression. It is noted that BLB1 and BLB2 are 
in opposite transcriptional orientations and separated by the tapasin gene (Jacob et al 2000), 
so it is unexpected that the mRNA expression of one BLB would affect the other.  
Flow cytometry was also used to look at cell surface and total protein expression of BLB, but 
one limitation of this experiment is that the class II antibodies (2G11 and BLBcyt10) detect 
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both BLB1 and BLB2. In these experiments BLB1 and BLB2 expression can only be assumed 
by subtraction of class II expression between the BLB1 and BLB2 KO, though this method is 
flawed as the data suggests that BLB1 KO effects the regulation of BLB2 and vice versa. 
What is seen from the cytometry data is that the BLB1 KO loses ~55 % surface expression 
and ~25 % total expression (fig 5.3.1) suggesting that a large amount of BLB1 is present on 
the surface compared to the total amount of BLB1 found in the cell. This is interesting as it 
suggests that proportionally more BLB1 is trafficked to the cell surface than BLB2. 
For the DM proteins, starting with DMA, we see no significant change in DMA RNA (fig 5.2.4) 
but at the protein level we see a reduction of 70 % (fig 5.3.3b). This was unexpected, and it 
was expected that the expression of DMA would be independent of BLB1 expression. One 
explanation is that DM is expected to interact with BLB1 and in the absence of BLB1, less DM 
is required and therefore DMA is degraded to some extent. DMB1 shows no significant 
change at the RNA level (fig 5.2.5) and unfortunately due to limitations with DMB1 
antibodies we were unable to look at the effect of BLB1 deficiency on DMB1 protein. 
Lastly, we looked at DMB2, with no significant change being seen at the RNA level (fig 5.2.6) 
or at the protein level (fig 5.3.4b). This seemed inconsistent as DMA is reduced at the protein 
level, so it was expected that a reduction would be seen in DMB2 as well. Though it is noted 
that ~30 % of DMA is still expressed in the BLB1 KO and this could be enough substrate to 
interact with DMB2, and hence maintain DMB2 levels as wild type and not result in DMB2 
being degraded. 
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5.4.2 Characterisation of IS19 BLB2 KO at the RNA and protein level 
BLA mRNA expression shows no significant change (fig 5.2.1). BLB1 mRNA expression was 
down regulated three-fold (fig 5.2.2) and the protein expression is reduced ~60 % (fig 
5.3.2b), suggesting that the decrease in BLB1 expression comes from downregulation, rather 
than degradation.  BLB2 RNA expression has an 11-fold decrease (fig 5.2.3), suggesting that 
the indels generated in BLB2 effect the overall stability of BLB2 mRNA, at the protein level 
BLB2 is completely absent by q-western blot (fig 5.3.2c).  
Flow cytometry analysis of cell surface and total protein expression of BLB shows that the 
BLB2 KO loses ~75 % surface expression and ~90 % total expression (fig 5.3.1), suggesting 
that more BLB2 is present inside the cell compared to the cell, which is the opposite of what 
is seen with BLB1. These two results could indicate that the poorly expressed class II, BLB1, is 
preferentially transported to the cell surface when compared to BLB2 and may compensate 
for the lower expression of BLB1. 
DMA shows no significant change in mRNA expression (fig 5.2.4), but a 90 % reduction is 
seen at the protein level (5.3.3). As with the BLB1 KO, this reduction of DMA expression was 
unexpected, as it was thought that DMA expression would be independent of BLB 
expression. Again, this could be explained by the fact that DM is expected to interact with 
BLB and in the absence of BLB2 less DM is required, and excess DMA is degraded. It is 
interesting that deletion of BLB1 or BLB2 results in decreased DMA at the protein level and is 
consistent with the notion that DMA expression is dependent on BLB protein expression. It is 
also noted that knocking out BLB1 (the more poorly expressed BLB) has a reduction of 70 % 
DMA protein and knocking out the dominantly expressed BLB, BLB2, results in a greater 
reduction of DMA (90 %). This suggests that the proportion of DMA protein that is reduced 
depends on the amount of BLB (1 or 2) present in the cell. 
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  DMB1 shows a ~42-fold decrease at the RNA level in the BLB2 KO (fig 5.2.5) but cannot be 
compared to the protein level. Lastly, we looked at DMB2, with no significant change being 
seen at the mRNA level (fig 5.2.6) but a 25 % reduction is seen at the protein level (fig 5.3.4). 
It is curious that a reduction in DMB2 protein is only seen in the BLB2 KO and not the BLB1 
KO, it has been hypothesised that the two different DM peptide editors (comprised of either 
DMB1 and DMB2) might have a preference to the BLB they target. It was suggested that 
DMB1 may mainly work with BLB1 and DMB2 with BLB2. One interpretation of this result is 
that DMB2 protein levels are affected by the absence of BLB2 as this is the major substrate 
of DMB2. Another possibility is that the 90 % reduction of DMA results in degradation of 
DMB2 as there is not enough DMA for DMB2 to associate with. 
 
5.4.3 Characterisation of IS19 DMA KO at the RNA and protein level 
BLA RNA expression shows no significant change in the DMA KO (fig 5.2.1). BLB1 RNA 
expression shows no significant change (fig 5.2.2) and the protein expression is reduced ~70 
% (fig 5.3.2b). BLB2 mRNA expression shows no significant change (fig 5.2.3) and the protein 
expression is reduced ~80 % (fig 5.3.2c). It is thought that BLB reduction is the result of lower 
stability leading to degradation, as BLB1 and BLB2 cannot be loaded with high affinity 
peptide by the DM complexes.   
Flow cytometry analysis of cell surface and total protein expression of BLB shows that the 
DMA KO loses ~75 % surface expression and ~50 % total expression (fig 5.3.1). More class II 
is absent from the cell surface than in total. In the absence of DMA, BLB is unable to be 
edited by DM and is expected to result in class II being more frequently loaded with sub-
optimal peptides, which is would lower BLB stability. This could explain why less class II is 
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seen at the surface either because the class II is trafficked to the cell surface less efficiently 
or because unstable class II molecules on the surface are internalised more rapidly. 
DMA RNA expression is reduced by six-fold (fig 5.2.4), with no protein being expressed (fig 
5.3.3). DMB1 shows a ~50-fold decrease at the mRNA level (fig 5.2.5) and in future work will 
be validated in independent DMA KO clones as well as determining DMB1 protein expression 
when reagents become available. 
DMB2 shows no significant change at the mRNA level in the DMA KO (fig 5.2.6) but is 
completely absent at the protein level (fig 5.3.4). It was expected that DMB2 protein would 
be decreased without DMA to associate with, but it was unexpected that DMB2 would be 
undetectable. This is different from what is seen in mammals, where DMA deletion results in 
a small reduction in DMB protein or no change at all. 
 
5.4.4 Characterisation of IS19 DMB1 KO at the RNA and protein level 
BLA RNA expression shows no significant change in the DMB1 KO (fig 5.2.1). BLB1 RNA 
expression shows no significant change (fig 5.2.2) but the protein expression is reduced ~90 
% (fig 5.3.2b). BLB2 mRNA expression shows no significant change (fig 5.2.3) and the protein 
expression is reduced ~60 % (fig 5.3.2c). In concordance with the DMA KO It is thought that 
BLB reduction is the result of lower stability leading to degradation, as BLB1 and BLB2 cannot 
be loaded with high affinity peptide in the absence of DM complexes. In this case only DMB1 
is absent and it was unexpected that DMB1 deletion would have a pronounced effect on 
both BLB1 and BLB2. It is also noted that the DMB1 KO has a larger effect on BLB1 than BLB2 
again providing some evidence that DMB1 and DMB2 may have preferentially edit different 
BLB molecules.   
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Flow cytometry analysis of BLB shows that the DMB1 KO loses ~10 % surface expression and 
~25 % total expression (fig 5.3.1). More class II is absent from the cell surface than in total. 
This is the opposite pattern of what is seen in the DMA KO, where more total class II is 
reduced than at the cell surface.  
DMA RNA expression is reduced by 12-fold (fig 5.2.4), with a 95 % reduction in protein being 
expressed (fig 5.3.3). This suggests that DMB1 editing effects the RNA expression of DMA 
and in turn results in less protein. It is not conclusive that all or some of the DMA reduction 
is not due to degradation of DMA as it cannot associate with DMB1 and results in turnover 
of DMA. 
DMB1 shows no expression at the RNA level (fig 5.2.5), suggesting that the RNA is 
completely unstable due to the indels generated. DMB2 shows no significant change at the 
RNA level in the DMB1 KO (fig 5.2.6) but has a 40 % reduction at the protein level (fig 5.3.4). 
It was unexpected that a KO of DMB1 would affect the protein levels of DMB2, as DMB1 and 
DMB2 are not expected to interact. A possible explanation for this is that the DMB1 KO has 
greatly reduced DMA protein expression, and with such a large reduction in DMA it is 
possible that DMB2 is in excess compared to its cognate chain (DMA) and is therefore 
degraded. 
 
5.4.5 Characterisation of IS19 DMB2 KO at the RNA and protein level 
BLA RNA expression is reduced 15-fold in the DMB2 KO (fig 5.2.1). This is the only class II KO 
that effects BLA RNA. The reasons for this remain unclear and will need to be validated in 
independent DMB2 KO clones as well as assessing the protein level of BLA if and when 
reagents become available. BLB1 RNA expression shows no significant change (fig 5.2.2) but 
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the protein expression is reduced ~60 % (fig 5.3.2b). BLB2 mRNA expression shows no 
significant change (fig 5.2.3) and the protein expression is reduced ~75 % (fig 5.3.2c). As with 
the DMA KO, it thought that BLB reduction is the result of lower stability leading to 
degradation, as BLB1 and BLB2 cannot be loaded with high affinity peptide in the absence of 
DM complexes but in this case only DMB2 is absent. It is also noted that the DMB2 KO has a 
larger effect on BLB2 than BLB1, again providing some evidence that DMB1 and DMB2 may 
have preferentially edit different BLB molecules.   
Flow cytometry analysis of cell surface and total protein expression of BLB shows that the 
DMB2 KO has no significant change in surface expression and a ~25 % decrease in total 
expression (fig 5.3.1). As with the DMB1 KO changes in MHCII expression is seen dominantly 
for total expression and in this case no change in MHCII protein expression is seen at the cell 
surface.  
DMA mRNA expression is reduced by 3.5-fold (fig 5.2.4), with a 95 % reduction in protein 
being expressed (fig 5.3.3). This suggests that DMB2 deletion effects the mRNA expression of 
DMA, though not as much as the DMB1 KO, but the protein is reduced to the same 
staggering degree of 5 % of the total. It is unlikely that the reduction of DMA is purely down 
to the down regulation at the mRNA level and that the DMB2 KO is affecting the stability of 
DMA protein either because DMA does not have DMB2 to associate with or through other 
means.  
DMB1 shows a large down regulation at the RNA level of 26-fold in the DMB2 KO (fig 5.2.5), 
which was not expected. DMB2 shows no significant change at the mRNA level (fig 5.2.6) but 
is completely absent at the protein level (fig5.3.4).  
 
136 
 
5.4.6 Summary of IS19 class II KO characterisation at the mRNA and protein level 
Many interesting and currently unexplained results were obtained during this work, the 
results of which are summarised in figure 5.3.5. The trends that were consistently noticed 
were that the BLB1 KO reduces BLB2 expression and vice versa. It is also seen that BLB KOs 
effect the levels of DMA protein expressed and this is more pronounced in BLB2 than BLB1 
KOs. It is also seen that the BLB2 KO effects DMB2 expression whereas the BLB1 KO does 
not. Equally, the DMB KOs effect both BLBs but DMB1 has a more pronounced effect on 
BLB1 and the DMB2 KO on BLB2, which suggests there is a preference between DMBs for 
which BLB they edit. It is also seen by flow cytometry that BLB1 appears to have a higher 
percentage of the total go to the cell surface when compared to percentage of total BLB2 
that goes to the surface. This is interesting and suggests a possible preferential transport of 
BLB1 to the cell surface which could be a mechanism to compensate for the low expression 
of BLB1. 
 DM expression also appears to be complex, with deletions in any DM gene effecting the 
expression of the other DMs. It was expected that deletions in DMA would affect DMB1 and 
DMB2 expression, and deletions in DMB1 and DMB2 not to affect the expression of each 
other. What we observed was that a deletion in DMA, DMB1 or DMB2 effects (where 
measurable) the protein expression of the other two DMs and editing of either DMA or 
DMB2 result in down regulation of DMB1 RNA. There is a strong dependence of expression 
between the three DMs and it is currently unknown to what level this is down to interactions 
at the protein or transcriptional level.   
These results need to be validated by repeating the experiments in independently made 
class II KO cell lines, which have already been made and need to be tested. We also intend to 
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transfect in the knocked-out class II gene into the appropriate KO cell line to see if wild type 
expression is restored and the effects seen are rescued. 
 
5.4.7 Characterisation of temperature stability of IS19 DM KO cell lines 
After seeing such pronounced changes in class II expression in the DM KO cell lines, we 
looked at the effect each DM KO has on class II stability. As previously mentioned (general 
introduction) MHCII has been shown to run as a complex by western blot if lysates are run in 
a reducing gel but are not boiled before loading. To build upon this we treated the lysates at 
different temperatures ranging from 30 oC – 90 oC to assess at what temperature the MHCII 
complex begins to fall apart. This was completed in WT IS19 cells and the three DM KOs 
(DMA, DMB1 and DMB2); the results were quantified and compared (fig 5.3.6 and 5.3.7). It 
was observed that the WT IS19 MHCII complex predominately dissociated at 55 oC, the DMA 
KO at 30 oC , the DMB1 KO at 50 oC and the DMB2 KO at 40 oC (fig 5.3.7). This result was as 
expected, as IS19 appeared to be dependent on DM, the DMA KO would have the biggest 
effect on temperature stability, the DMB2 KO would have the second largest effect being the 
predominantly expressed DMB and DMB1 would have the smallest effect as it is poorly 
expressed. Part of the future work would be to devise an experiment where we can quantify 
the effect the DM KOs have on the temperature stability of each BLB. As the changes of the 
class II temperature stability are expected to be a result of the peptide that the class II is 
loaded with, we expect a change in the peptide repertoire of the three DM KO cell lines. In 
the future we hope to determine the changes in the DM KO cell line peptide repertoires by 
immunopeptidomics.  
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5.3.7 Initial characterisation of temperature stability of TG21 DMA and DMB2 KO cell lines 
We set out to make class II KOs in the TG21 cell line to allow comparison with the results 
shown in IS19. Preliminary results are shown of TG21 WT, DMA KO and DMB2 KOs 
temperature stability. Initial observations show that BLB in TG21 wildtype cells have a higher 
native temperature stability when compared to IS19. IS19 majorly dissociates at 55 oC, 
whereas BLB can still be seen in complex at 80 oC in TG21 and starts to dissociate between 
70-80 oc. In the DMA KO BLB is completely dissociated at all temperatures, showing that 
TG21 is fully dependent on DMA for SDS-stable class II dimers, which is not seen in IS19. The 
DMB2 KO has reduced temperature stability compared to the wild type with complexed 
class II falling apart between 50-60 oC and no complex being seen at 70 oc. This again 
indicates an important role for DMB1 in peptide editing of class II, as seen in IS19. Future 
work will consist of repeating this experiment in triplicate for quantification alongside the 
DMB1 KO, as well as assessing the peptide repertoire in TG21 DMA, DMB1 and DMB2 KO cell 
lines.  
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6. Characterisation of IS19 WT, BLB1, BLB2 and DMA 
KO cell lines at the peptide level 
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6. Characterisation of IS19 WT, BLB1, BLB2 and DMA KO cell lines at the peptide level 
6.1 Introduction 
In chapter 5 the MHCII KO cell lines (BLB1, BLB2, DMA, DMB1 and DMB2) were analysed at 
the RNA and protein level revealing complex and interesting results, with temperature 
stability data inferring changes in the peptide repertoire of DM KO lines. Previously, no work 
has been published detailing the peptide motifs of chicken class II molecules. 
In this chapter we use immunopeptidomics to assess the peptide repertoire of IS19 WT, 
BLB1 KO, BLB2 KO and DMA KO cell lines and use Gibbs clustering to elucidate the peptide 
motif. In addition, we look at the length distribution of peptides in each line and compare 
the numbers of shared and unique peptides between these lines. 
Firstly, one important consideration when analysing immunopeptidomics data needs to be 
discussed. The list of de novo sequenced peptides that are collected are not quantative and 
each unique peptide is only recorded once and does not reflect abundance of a particular 
peptide that is seen. Depending on the frequency of a peptide in the sample, this peptide 
may not be seen every time that sample is analysed by immunopeptidomics.  For example, if 
there are dominant peptides in the sample, that peptide will be seen in each run, whereas 
peptides that are low abundance may only be seen over multiple runs. This sampling issue 
generally results in groups of peptides that not seen in the same sample over the course of 
multiple immunopeptidomics runs and needs to be considered when characterising what 
peptides are unique to different samples. 
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6.2 Assessing length distribution of peptides eluted from class II KO lines 
Firstly, the number of peptides and the number of peptides at a particular length obtained 
from each cell line were assessed. Figure 6.2.1 shows the length distribution and total 
peptide numbers for IS19 WT, BLB1 KO, BLB2 KO and DMA KO, for all peptides (fig 6.2.1a), 
just peptides with post-translational modifications (PTM) (fig 6.2.1b) and peptides without 
PTM (fig 6.2.1c). For all three plots the wild type has the most peptides, followed by the 
BLB1 and the BLB2 KOs with roughly equal number of peptides, whilst the DMA KO has the 
fewest peptides overall (fig 6.2.1). The majority of peptides are 15-19 amino acids in length 
for all four lines (fig 6.2.1). Interestingly we notice that for total peptides and peptides 
without PTM an increased number of peptides are seen between 8-9 amino acids in length 
(fig6.2.1a and c).  
 
Figure 6.1.1 Illustration of sampling discrepancies found during immunopeptidomics analysis  
One sample is shown to contain four different peptides, shown as blue, purple, green and red. Three 
situations are shown representing example results that can be seen after immunopeptidomics analysis, 
with the three situations representing three immunopeptidomics runs of the sample. Different peptide 
subsets are only seen in some runs but not in all.  
 
 
142 
 
 
 
 
 
 
 
 
 
Figure 6.2.1 Length distribution of eluted peptides from WT and MHCII KO lines  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1 and WT IS19 were lysed and class II 
molecules were isolated by immunoprecipitation, using the antibody 2G11.  Samples were then 
prepared and analysed by LC-MS/MS, generating a list of de novo sequenced unique peptides. 
Peptides were plotted by length against peptide number. a) total peptide numbers, b) peptides 
with post-translational modifications and c) peptides without post-translational modifications. 
WT is shown in blue, BLB1 KO (orange), BLB2 KO (grey) and DMA KO (yellow).   
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6.3 Determining peptide motifs of class II KO lines 
Peptides between 15-19 amino acids long were analysed for a potential nine amino acid 
motif for all four cell lines by Gibbs clustering. Figure 6.3.1 shows that the wild type has a 
motif of mainly large hydrophobic amino acids, leucine, isoleucine phenylalanine and valine 
at position one, small hydrophobic and polar amino acids at position four, serine, alanine 
and threonine, with mainly hydrophobic amino acids at positions six, seven and nine (fig 
6.3.1a). When comparing the WT motif to the BLB1 KO (peptides from BLB2 alone), we see a 
similar motif, with the nearly the same amino acids at every position. The main differences 
are seen at position one where phenylalanine and tyrosine are missing in the BLB1 KO and at 
position four where valine is missing (fig 6.3.1a and b). Equally, when comparing the WT 
motif to that of the BLB2 KO (peptides from BLB1 alone), the motif is largely the same at 
positions six, seven and eight, with most differences being seen at positions one and four. 
The BLB2 KO has a dominant phenylalanine and tyrosine at position, whereas these residues 
are much less pronounced in the WT, similarly alanine and valine and isoleucine are 
dominant at position four for the BLB2 KO and the WT has a larger proportion of serine and 
threonine (fig 6.3.1 a and c). Interestingly, the DMA KO has a motif that is virtually identical 
to the BLB1 KO and is missing the phenylalanine and tyrosine seen in the WT and the BLB2 
KO at position one. It has the aspartic acid seen at position four in the WT and BLB1 KO but is 
absent in the BLB2 KO (fig 6.3.1). 
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Figure 6.3.1 shows clearly different motifs between the BLB1 and BLB2 KO. Moreover the 
motif for both BLBs appears to be present in the WT. To confirm that both BLB motifs are 
seen in the WT, the WT was subject to further Gibbs clustering to see if the motif of both 
BLBs is present. Figure 6.3.2 shows additional clustering of the WT which reveals two distinct 
motifs, IS19 WT cluster 1 shows a motif that is almost identical to the BLB1 KO, with the 
same residues seen at position one, four, six, seven and nine in the WT and BLB1 KO but with 
some variations in frequency at position four. Importantly, phenylalanine and tyrosine are 
missing at position one, showing that the BLB2 KO motif is not present (fig 6.3.2a and b).  
Conversely, the second WT cluster has a motif that is virtually identical to the BLB2 KO, with 
the same amino acids shared between the WT and the BLB2 KO at position one, four, six, 
seven and nine but again with some variations in amino acid frequency (fig 6.3.2c and d). 
Notably, at position one phenylalanine and tyrosine are seen and at position four aspartic 
acid is absent and valine is dominant (fig 6.3.2c and d). The two distinct motifs seen in the 
two WT clusters confirm that the motifs seen for the BLB1 and BLB2 KO lines are 
representative of motifs seen in the WT. 
a) b) c) d) 
IS19 WT IS19 BLB1 KO IS19 BLB2 KO IS19 DMA KO 
Figure 6.3.1 Peptide motif of eluted peptides from WT and MHCII KO lines  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1 and WT IS19 were lysed and class II 
molecules were isolated by immunoprecipitation, using the antibody 2G11.  Samples were then 
prepared and analysed by LC-MS/MS, generating a list of de novo sequenced unique peptides. 
Peptides of 15-19 amino acids in length from a) WT, b) BLB1 KO, c) BLB2 KO and d) DMA KO were 
analysed by Gibbs clustering to determine a motif.   
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6.4 Analysis of unique peptides shared between class II KO lines  
To further confirm that the motif seen in the BLB1 KO is shared with the WT, the eluted 
peptide repertoire from the WT and the BLB1 KO were compared for shared and uniquely 
presented peptides by Venn diagram (fig 6.4.1a). This comparison revealed 42.5 % of 
peptides between the two lines were shared, the motif of these shared peptides was then 
obtained by Gibbs clustering (fig 6.4.1b), as expected this motif revealed the BLB1 KO motif 
as seen in figure 6.3.1b, which is the same as the motif seen in WT motif cluster 1 (fig 
6.3.2a). A proportion of peptides (43.8 %) are seen to be presented in the WT only (fig 
6.4.1.a), which is not unexpected as the WT expresses BLB1 too and therefore will have 
peptides that are not seen in the BLB1 KO. Interestingly, 13.8 % of peptides from the BLB1 
a) 
b) 
c) d) 
IS19 BLB1 KO 
IS19 BLB2 KO 
IS19 WT cluster 1 
IS19 WT cluster 2 
Figure 6.3.2 Two peptide motifs found in WT by further Gibbs clustering  
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1 and WT IS19 were lysed and class II 
molecules were isolated by immunoprecipitation, using the antibody 2G11.  Samples were then 
prepared and analysed by LC-MS/MS, generating a list of de novo sequenced unique peptides. 
Peptides of 15-19 amino acids in length from WT were analysed by Gibbs clustering to reveal two 
different motifs a) & c) and compared to the motifs found in b) BLB1 KO and the d) BLB2 KO. 
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KO are not found in the WT, whereas we would expect that all peptides found in the BLB1 
KO to be present in the WT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To understand if the proportion of peptides that are unique to the BLB1 KO have a unique 
motif, these peptides were analysed by Gibbs clustering (fig 6.4.1c). The motif of peptides 
unique to the BLB1 KO revealed a motif that is almost identical to that of peptides shared 
with the WT. The same dominant residues are seen at position one, four, six, seven and nine; 
showing that these unique peptides still adhere to the same motif found for the BLB1 KO 
and is not an exclusive motif seen only in the BLB1 KO. Likely, these unique peptides have 
Figure 6.4.1 Comparison of Peptides derived from WT and BLB1 KO 
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1 and WT IS19 were lysed and class II 
molecules were isolated by immunoprecipitation, using the antibody 2G11.  Samples were then 
prepared and analysed by LC-MS/MS, generating a list of de novo sequenced unique peptides. 
Peptides of 15-19 amino acids in length from WT and BLB1 KO were compared for shared peptide 
and unique peptide using a Venn diagram a). Peptides that are shared by the WT and the b) BLB1 
KO and c) unique to the BLB1 KO were analysed by Gibbs clustering. 
 
a) 
b) c) 
Shared peptides Nonshared peptides 
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differences in the more variable positions (two, three, five and eight) and are present at low 
numbers and may not have been identified in the WT sample. 
The same analysis was carried out to examine whether the BLB2 KO motif is shared with the 
WT. This comparison revealed 21.5 % of peptides between the two lines were shared (fig 
6.4.2a). The motif of these shared peptides was then obtained by Gibbs clustering (fig 
6.4.2b). As expected this motif revealed the BLB1 KO motif as seen in figure 6.3.1c, which is 
the same as the motif seen in WT motif cluster 2 (fig 6.3.2c). As seen before, a large 
proportion of peptides (48.2 %) are seen to be presented in the WT only (fig 6.4.2.a), which 
is not unexpected as the WT expresses BLB2 and therefore will have peptides that are not 
seen in the BLB2 KO. Again, a subset of peptides (30.3 %) from the BLB2 KO are not found in 
the WT, against expectations.  
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The proportion of peptides that are unique to the BLB2 KO were analysed by Gibbs 
clustering (fig 6.4.2c). The motif of peptides unique to the BLB2 KO revealed a motif that is 
almost identical to that of peptides shared with the WT, with largely the same dominant 
residues are seen at position one, four, six, seven and nine. Showing that these unique 
peptides still adhere to the same motif found for the BLB2 KO and is not an exclusive motif 
seen only in the BLB2 KO, mimicking the results we saw for the BLB1 KO (fig 6.4.1). It is 
expected that these unique peptides have differences in the more variable positions (two, 
three, five and eight) that are present at low numbers and may not have been identified in 
the WT sample.  
a) 
b) c) 
Shared peptides Nonshared peptides 
Figure 6.4.2 Comparison of Peptides derived from WT and BLB2 KO 
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1 and WT IS19 were lysed and class II 
molecules were isolated by immunoprecipitation, using the antibody 2G11.  Samples were then 
prepared and analysed by LC-MS/MS, generating a list of de novo sequenced unique peptides. 
Peptides of 15-19 amino acids in length from WT and BLB2 KO were compared for shared peptide 
and unique peptide using a Venn diagram a). Peptides that are shared by the WT and the b) BLB2 
KO and c) unique to the BLB2 KO were analysed by Gibbs clustering. 
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The same analysis was carried out to examine the DMA KO motif is shared with the WT. This 
comparison revealed only 16 % of peptides between the two lines were shared (fig 6.4.3a). 
The motif of these shared peptides was then obtained by Gibbs clustering  
(fig 6.4.3b). As expected this motif revealed the DMA KO motif as seen in figure 6.3.1d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparable to both BLB KOs, a large proportion of peptides (69.9 %) are seen to be 
presented in the WT only (fig 6.4.3.a), although the DMA KO expresses both BLB1 and BLB2. 
This is likely due to reduced levels of BLB protein expression in the DMA KO (as shown in 
chapter five), which would mean that fewer peptides are being sampled. This notion is 
confirmed in figure 6.2.1 where it is seen that the DMA KO yielded significantly fewer 
a) 
b) c) 
Shared peptides Nonshared peptides 
Figure 6.4.3 Comparison of Peptides derived from WT and DMA KO 
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1 and WT IS19 were lysed and class II 
molecules were isolated by immunoprecipitation, using the antibody 2G11.  Samples were then 
prepared and analysed by LC-MS/MS, generating a list of de novo sequenced unique peptides. 
Peptides of 15-19 amino acids in length from WT and BLB2 KO were compared for shared peptide 
and unique peptide using a Venn diagram a). Peptides that are shared by the WT and the b) DMA 
KO and c) unique to the DMA KO were analysed by Gibbs clustering. 
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peptides than the WT, BLB1 and BLB2 KO lines. Again, unexpectedly a subset of peptides (14 
%) from the DMA KO are not found in the WT. 
This proportion of peptides that are unique to the DMA KO were analysed by Gibbs 
clustering (fig 6.4.3c). Unfortunately, these peptides failed to show a clear motif which could 
suggest that the peptides found to be unique to the DMA KO are diverse in sequence or that 
the number of unique peptides is too few for a clear motif to be discerned. It is interesting to 
note that the BLB1 KO has 252 peptides that are exclusive from the WT and this number of 
peptides is enough to see a clear motif (fig 6.4.1c). Similarly, the DMA KO has 257 peptides 
that are not shared with the WT but a clear motif cannot be identified (fig 6.4.3c), this 
suggests that the absence of DMA results in a greater diversity of peptide sequence. 
 
Lastly, the BLB1 and BLB2 KO lines were compared for shared and unique peptides. Figure 
6.4.4a shows a small number of peptides in common (7.6 %), with the majority of peptides 
being unique to the BLB1 KO (42.7 %) and the BLB2 KO (49.7 %), suggesting that a specific 
peptide repertoire is present by BLB1 and BLB2 as supported in figures 6.3.1 and 6.3.2. Gibbs 
clustering analysis of the BLB1 and BLB2 KO unique peptides (fig 6.4.4 c and d) shows two 
distinct motifs, these motifs are identical to what is seen in figures 6.3.1 and 6.3.2.  The 
motif of the shared peptides was also assessed by Gibbs clustering and unfortunately, these 
peptides failed to show a clear motif (fig 6.4.4b). This suggests that the shared peptides 
between the BLB1 and BLB2 KO are diverse in their sequence or that the number of unique 
peptides is too small for a clear motif to be discerned. 
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6.5 Discussion 
Initial immunopeptidomic analysis of IS19 WT, BLB1 KO, BLB2 KO and DMA KO revealed 
many interesting differences between the peptide diversity and total number of peptides 
found for each line. The first observation was that peptides of 15-19 amino acids in length 
were the most frequent for all four cell lines (fig 6.2.1). It was also noted that there is an 
increase in peptides seen in all lines between 8-9 amino acids in length, the motif of these 
peptides is the same in all lines and has the motif expected for MHCI (data not shown). It is 
shared peptides 
a) 
c) 
BLB2 KO unique peptides 
b) 
d) 
BLB1 KO unique peptides 
Figure 6.4.4 Comparison of Peptides derived from BLB1 and BLB2 KO 
Class II KO cell lines; BLB1.2 cl-1, BLB2.2 cl-1, DMA.2 cl-1 and WT IS19 were lysed and class II 
molecules were isolated by immunoprecipitation, using the antibody 2G11.  Samples were then 
prepared and analysed by LC-MS/MS, generating a list of de novo sequenced unique peptides. 
Peptides of 15-19 amino acids in length from BLB1 and BLB2 KO were compared for shared peptide 
and unique peptide using a Venn diagram a). Peptides that are shared between the b) BLB1 and the 
BLB2 KO , c) unique to the BLB1 KO and d) unique to the BLB2 KO were analysed by Gibbs clustering. 
 
152 
 
suggested that during the immunoprecipitation of MHCII during the sample preparation 
some MHCI molecules are also isolated from the cell membrane. 
The BLB1 and BLB2 KO lines have fewer peptide sequences than the WT, which is not 
unexpected as the WT expresses both BLB1 and BLB2. Interestingly, the DMA KO has 
significantly fewer peptide sequences than all other lines, although it expresses both BLB1 
and BLB2. This is expected to be because the DMA KO has a severe reduction in BLB1 and 
BLB2 protein expression as discussed in chapter 5. Reduced expression of BLB would 
drastically change the amount of peptide sequences that are seen by immunopeptidomics. 
This experiment will be repeated to validate the results shown in this chapter. One 
adjustment is to increase the cell numbers used for the DMA KO to attempt to normalise the 
amount of BLB expression in each LC-MS/MS run. This adjustment may result in more 
peptide sequences for the DMA KO. 
The peptide motif was assessed for peptides of 15-19 amino acids in length for each cell line. 
The clearest observations were that BLB1 and BLB2 have two distinct motifs, with clear 
differences being seen at positions one, four and six. The BLB1 KO line lacks phenylalanine 
and tyrosine at position one when compared to the BLB2 KO, at position four isoleucine is 
not seen in the BLB1 KO whereas aspartic acid is not seen the BLB2 KO, and at position six 
the BLB1 KO lacks glutamic acid and proline whereas the BLB2 KO lacks isoleucine, valine and 
tyrosine (fig 6.3.1 b and c). When the BLB1 and BLB2 KO motifs are compared to that of the 
WT, it is seen that the dominant motif of the WT is largely the same as the BLB1 KO, 
indicating that the BLB2 motif is the major component of the WT motif (fig 6.3.1a). This was 
expected as previous data shows that BLB2 is expressed 100X more than BLB1 at the RNA 
level in spleen and blood (Jacob et al 2000). Chapter 5 details protein expression of ~5X 
more BLB2 than BLB1. However, the BLB2 KO (BLB1) motif can still be seen in the WT motif, 
with the presence of phenylalanine and tyrosine at position one and valine at position four 
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(fig 6.3.1a). The presence of both the BLB1 and BLB2 KO motifs in the WT was supported by 
further clustering of the WT, revealing two motifs that are very similar to that of the BLB1 
and BLB2 KOs (fig 6.3.2). 
To further assess the similarities of the BLB1 and BLB2 KO peptides with the WT, Venn 
diagrams were used to illustrate how many shared and unique peptides were found in the 
BLB KOs compared to the WT. For both BLB KOs (fig 6.4.1 and 6.4.2); the peptides shared 
with the WT have the same motif as seen in figure 6.3.1 and 6.3.2. The most interesting 
result was that both BLB KOs had a proportion of peptides that are not seen in the WT, 
which could suggest a motif that is unique to the KO lines. Gibbs clustering of the peptides 
that are unique to the BLB KOs showed both BLB1 and BLB2 KO lines had a motif that is 
largely the same motif each BLB KO had for the peptides shared with the WT (fig 6.4.1 and 
6.4.2). This shows there isn’t a second motif that is expressed only in the BLB KO lines and 
the changes seen are in more variable positions of the peptide sequence and it is likely that 
these peptides are not seen in the WT because they are at low abundance and were not 
detected during the experiment. This hypothesis can be tested my repeating the experiment 
multiple times and looking to see if the unique peptides in the BLB KO lines are found in the 
WT of replicate experiments. 
It was observed that the DMA KO line had a motif that was almost identical to that of the 
BLB1 KO line (fig 6.3.1b and d) and the amino acids associated with the BLB2 KO (BLB1 motif) 
were not present. It noted that the DMA KO had much more variation in all positions. This 
result could suggest that BLB1 has a higher dependence on DMA for peptide loading than 
that of BLB2, and in the absence of DMA BLB1 fails to bind the peptides that fit the BLB1 
motif. This result could also be explained by the fact that the DMA KO has much less BLB1 
and BLB2 protein expressed and BLB1 is expressed at relatively low levels when compared to 
BLB2 generally. This reduction in BLB1 could lead to BLB1 associated peptides not being 
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seen. Increasing cell numbers of the DMA KO to compensate for this reduced MHCII 
expression would elucidate which explanation is likely to be true. 
 The second observation is that the peptides unique to the DMA KO when compared to the 
WT have no discernible motif with lots of variation at every position (fig 6.4.3c). The first 
explanation of why no clear motif was found by Gibbs clustering is that the number of 
peptides unique to the DMA KO is relatively low (257) (fig 6.4.3a) and therefore cannot 
resolve a motif. Interestingly, the BLB1 KO has only 252 peptides that are not found in the 
WT but this number was still enough to clearly resolve a sequence motif by Gibbs clustering, 
suggesting that in the absence of DMA there is a subset of MHCII peptides that have much 
more sequence variation. This is consistent with the notion in mammals that DM functions 
to provide high affinity peptide to MHCII and without DM a broader peptide sequence 
diversity is seen. Further analysis needs to be carried out on our immunopeptidomics data, 
beginning with a comparison of the number of shared and unique peptides of the BLB1 and 
BLB2 KOs with the DMA KO and what motifs, if any, are seen. In the future these results 
need to be confirmed by replicating the experiment. In addition, the DMB1 and DMB2 KO 
line peptide repertoire will also be assessed to understand how individual DM KOs effect the 
peptide repertoire of BLB1 and BLB2 and if the two DMs have differing effects on BLB. 
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7. Understanding TAP transporter-mediated peptide 
transport in the chicken 
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7. Understanding TAP transporter-mediated peptide transport in the chicken 
7.1 Introduction 
The TAP transporter is comprised of a heterodimer of TAP1 and TAP2 and is known to be the 
key player in the transport of cytosolic peptides into the lumen of the ER. This peptide 
transport provides most peptides that are subsequently loaded onto the MHC class I for CD-
8 t-cell recognition (as discussed in detail in the general introduction). Despite the 
importance of the TAP complex in immunity and its critical role in class I presentation, much 
is still unknown about the function and mechanisms of peptide mediated TAP transport. 
Many studies have proposed mechanisms of how the TAP transporter physically transports 
peptides from the cytosol to the ER and what changes in confirmation are required, but the 
question of which residues within the TAP membrane spanning domain (MSD) are require 
for specific peptide transport is still largely unknown. 
TAP1 and TAP2 are functionally monomorphic in humans and mice (Trowsdale et al 2011), 
which has been a major issue when trying to understand which residues are important for 
peptide binding to the TAP complex as there aren’t obvious residues under selection that 
could be proposed as candidates. Besides taking the approach of randomly mutating a 
selection of residues in the MSD or cross-linking peptides, a means of identifying potential 
residues of interest would need to be devised. The chicken however, has the unique 
property (compared to mammals) that the TAPs are polymorphic and as previously discussed 
are thought to have co-evolved with a specific MHCI gene, with the TAPs tailoring the 
peptides pumped for a specific MHC I allele (Walker et al 2011). This TAP polymorphism is 
assumed to have occurred by the selection of residues that determine the specificity of 
peptides pumped by the TAP transporter and potentially highlights candidate residues for 
peptide transport. To further narrow down candidate residues, the polymorphic amino acids 
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were overlaid on to a model of human TAPs, based on the structure of a bacterial ABC 
transporter. Polymorphic residues that fit with peptide translocation specificity were 
selected for mutagenesis. They can then be tested for their effect on the transport of 
peptides known to transport that fit the binding motif of chicken class I for a given haplotype 
(Jim Kaufman, unpublished data). It was further hypothesised that the polymorphic residues 
found in the chicken when mapped onto the bacterial ABC transporter could also be used to 
infer which residues may be important for peptide transport in the human and mouse when 
compared. 
Our lab previously attempted to look at the chicken residues of interest by using insect cells 
to express both chicken TAP1 and TAP2, isolate microsomes and use the microsomal fraction 
for radiolabelled peptide transport assays. This method yielded mixed results and was 
deemed to be unsuitable for the study. This chapter details the initial work to develop a 
system capable of answering the question of which TAP residues determine the specificity of 
peptide transport. With current advances in genome editing we decided to utilise CRISPR-
Cas9 to make TAP1 KO, TAP2 KO and TAP1 and TAP2 double KO (referred to as TAPD KO) 
lines, in the characterised IS19 cell line and to assess whether transport is abolished in single 
TAP and double TAP KO lines. 
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7.2 Generation and screening of TAP1, TAP2 and TAPD KO lines 
Two sgRNAs were designed to target largely conserved regions of TAP1 and TAP2, so the 
guides could be used in other REV cell lines of different MHC haplotypes. Details of the 
guides can be found in the material and methods section.  Two guides targeting TAP1 and 
two targeting TAP2 were separately transfected into IS19 cells giving four transfected lines, 
TAP1.1, TAP1.2, TAP2.1 and TAP2.2. The four lines were cell sorted for high GFP expression, 
GFP positive polyclonal populations were expanded and class I levels of these polyclonal 
populations were analysed by flow cytometry 
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Figure 7.2.1 shows flow cytometry staining of TAP1.1 and TAP2.1 polyclonal KO populations 
for β2m, class I heavy chain and class II β chains. In the TAP1.1 KO polyclonal population 
stained for β2m and class I (fig 7.2.1 a & b, orange) we see two distinct populations one that 
has largely normal β2m and class I expression when compared to wild type expression (blue) 
and one that has over a log decrease in cell surface expression. A similar result was seen for 
the TAP2.1 KO polyclonal population. These results were in accordance with previous 
Figure 7.2.1 Flow cytometry cell surface staining of B2m and class I heavy chain in IS19 
TAP1 and TAP2 polyclonal populations. 
 IS19 cells were separately transfected with a sgRNA:cas9 plasmid targeted to a genomic DNA 
sequence of TAP1 and TAP2. Cell pools were analysed via flow cytometry using the antibody F21-21 
and F21-2, to β2m and class I heavy chain respectively. IS19 cells transfected with PX458 TAP1 
sgRNA1 (a, b & c) and PX458 TAP2 sgRNA1 (d, e & f). Transfected cells were stained for β2m (a & d), 
class I heavy chain (b & e) and class II β-chain (c & f) in orange and compared to wild type cell 
expression (blue). All histograms include transfected cells stained with secondary only (red). 
 
 
 
β2m staining 
Class I staining 
Class II staining 
IS19 TAP1.1 KO 
polyclonal population 
IS19 TAP2.1 KO 
polyclonal population 
a) 
b) 
c) 
d) 
e) 
f) 
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findings in human and murine studies that also show that class I expression is decreased 
when one or both TAP molecules loss function due to mutation (Van Kaer et al 1992, de la 
Salle et al 1993). Additionally, both TAP KO polyclonal lines were stained for class II 
expression to check that this reduction was restricted to MHC class I, rather than being a 
result of greater loss in the MHC by a large deletion. Figure 7.2.1c and f show class II 
expression in the TAP KOs (orange) remains largely unchanged compared to wild type 
expression (blue). These initial findings gave confidence that our targeting of TAP was 
successful and give a phenotype that could be used for cell sorting to hasten the process of 
making clonal derived TAP KO lines whilst also showing that the lack TAP presentation 
effects MHC class I cell surface expression in the chicken.  
The next task was to isolate TAP1 KO and TAP2 KO clonal lines for further experimentation. It 
is noted in figure 7.2.1 that the TAP1 KO population is smaller than in TAP2. This difference is 
likely to be due to differences in transfection efficiency and/or the efficiency of editing after 
transfection. We decided to use the low class I phenotype in the TAP1 KO population as a 
target for cell sorting to enrich for class I KO cells.  
TAP1 KO cells with low class I were sorted as single cells into a 96 well plate, whilst TAP2 KO 
cells were cloned into 96 well plates by limiting dilution. Cell lines were then screened by 
PCR, cloning and sequencing for mutations in the relevant TAP. In addition, wild type IS19 
cells were simultaneously transfected with sgRNAs directed to TAP1 (TAP1.1) and TAP2 
(TAP2.1) in order to create a double TAP KO line.  
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                               360        370        380        390        400         
                       ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP1 WT          GGTGACGCGG GATGCGGAGG ACGTGC~GCG AGGCTCTGGG TGAGGCGCTG   
IS-19 TAP1.1 cl-1 (1)  GGTGACGCGG GATGCGGAGG ACGTGCCGCG AGGCTCTGGG TGAGGCGCTG   
IS-19 TAP1.1 cl-1 (2)  GGTGACGCGG GATGCGGAGG AC~~~~~~~~ ~~~~TCTGGG TGAGGCGCTG   
 
                               110        120        130        140        150         
                       ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP1 WT          QSITELRADG AGDVAMRVTR DAEDVREALG EALSLLLWYL ARGLCLFATM   
IS-19 TAP1.1 cl-1 (1)  QSITELRADG AGDVAMRVTR DAEDVPRGSG *GAEPPAVVS GTWPLPLRHH   
IS-19 TAP1.1 cl-1 (2)  QSITELRADG AGDVAMRVTR DAEDSG*GAE PPAVVSGTWP LPLRHHGLAV   
 
 
 
The selected TAP1 KO clonal line TAP1.1 cl-1, has two successful editing events that can be 
seen slightly downstream of the PAM site at position 381-383, the edits consist of a one base 
pair insertion on one allele and an eleven base pair deletion on the second allele (fig 7.2.2a). 
The effect of the editing on the coding sequence when compared to the original sequence 
showed disruptions to the gene begin at amino acid positions 126 and 125 for the two 
different edits. These changes in codon frame result in an early stop codon at positions 131 
and 127 terminating the protein (fig 7.2.2b).  
 
 
 
 
 
Figure 7.2.2 DNA and amino acid sequence alignment of clonal line TAP1.1 cl-1 
shows editing events and the generation of a premature stop codon. 
a) The editing events revealed by sequencing exon 3 of TAP1 were mapped onto a partial TAP1 cDNA 
sequence and compared to the wild type. Editing events can be seen in both alleles immediately before 
the PAM site (red line) at position 381-383. b)  The effect of these editing events on the whole amino 
acid sequence are shown for each of the two edited alleles. Changes in the coding sequence begin at 
position 125 and 126, premature stop codons can be seen downstream of these positions. 
The three sequences are labelled on the left-hand margin; wild type sequence (IS19 TAP1 WT), the first 
edited allele of clonal line TAP1.1 cl-1 (IS19 TAP1.1 cl-1 [(1)] and the second allele (IS19 TAP1.1 cl-1 [(2)]. 
a) 
b) 
162 
 
 
                               260        270        280        290        300         
                       ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP2 WT          TAGGTCTGCC TGGAGCTGCC CCGGTGCTGC TGGCCATGGC AACGCCGTCC   
IS-19 TAP2.1 cl-1 (1)  TAGGTCTGCC TGGAGCTGCC CCGG~~CTGC TGGCCATGGC AACGCCGTCC   
IS-19 TAP2.1 cl-1 (2)  TAGGTCTGCC TGGAGCTGCC CC~~~~CTGC TG~CCATGGC AACGCCGTCC   
 
 
                                60         70         80         90        100             
                       ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP2 WT          LGGAGQLLAP RGPRGAAVLL SLGPAIFLTL RGYVGLPGAA PVLLAMATPS   
IS-19 TAP2.1 cl-1 (1)  LGGAGQLLAP RGPRGAAVLL SLGPAIFLTL RGYVGLPGAA PAAGHGNAVL   
IS-19 TAP2.1 cl-1 (2)  LGGAGQLLAP RGPRGAAVLL SLGPAIFLTL RGYVGLPGAA PCCHGNAVLA   
 
                               110        120        130        140        150         
                       ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP2 WT          WLVLTHGTAV VALLTWSLLV PTVATGAKEA EAWVPLRRLL ALAWPEWPFL   
IS-19 TAP2.1 cl-1 (1)  AGADPRDSCG GIAHLEPPGP HCGHWGKGGR GLGAPEAAAG PRLARVALPW   
IS-19 TAP2.1 cl-1 (2)  GADPRDSCGG IAHLEPPGPH CGHWGKGGRG LGAPEAAAGP RLARVALPWL   
 
                               160        170        180        190        200         
                       ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP2 WT          GCAFLFLALA ALGETSVPYC TGRALDVLRQ GDGLAAFTAA VGLMCLASAS   
IS-19 TAP2.1 cl-1 (1)  LCLPLPRIGC TG*DLSALLH REGSGCPPPG GRPRRLHRCC RPHVPGLCQQ   
IS-19 TAP2.1 cl-1 (2)  CLPLPRIGCT G*DLSALLHR EGSGCPPPGG RPRRLHRCCR PHVPGLCQQL   
 
The selected TAP2 KO clonal line TAP2.1 cl-1 has two successful editing events which can be 
seen immediately downstream of the PAM site at position 269-271, the edits consist of a 
two base pair deletion on one allele and a five base pair deletion on the second allele (fig 
7.2.3a). 
The effect of the editing on the coding sequence when compared to the wild type sequence 
show disruptions to the gene begin at amino acid position 92 for the two different edits. 
These changes in codon frame result in an early stop codon at positions 163 and 162 
terminating the protein (fig 7.2.3b). 
 
Figure 7.2.3 DNA and amino acid sequence alignment of clonal line TAP2.1 cl-1 
shows editing events and the generation of a premature stop codon. 
a) The editing events revealed by sequencing exon 1 of TAP2 were mapped onto partial TAP2 cDNA 
sequence and compared to the wild type. Editing events can be seen in both alleles immediately before the 
PAM site at position 269-271. b)  The effect of these editing events on the whole amino acid sequence 
were then shown for each of the two edited alleles. Changes in the coding sequence begin at position 92, 
premature stop codons can be seen downstream of these positions. 
The three sequences are labelled on the left-hand margin; wild type sequence (IS19 TAP2 WT), the first 
edited allele of clonal line TAP2.1 cl-1 (IS19 TAP2.1 cl-1 [(1)]) and the second allele (IS19 TAP2.1 cl-1 [(2)]). 
a) 
b) 
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                                360        370        380        390        400         
                        ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP1 WT           GGTGACGCGG GATGCGGAGG ACGTGCGCGA GGCTCTGGGT GAGGCGCTGA   
IS-19 TAPD cl-2 (TAP1)  GGTGACGCGG GATGCGGAGG ACGT~CGCGA GGCTCTGGGT GAGGCGCTGA   
 
                                 260        270        280        290        300         
                         ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP2 WT            TAGGTCTGCC TGGAGCTGCC CCGGTGCTGC TGGCCATGGC AACGCCGTCC   
IS-19 TAPD cl-2 (TAP2)   TAGGTCTGCC TGGAGCTGCC CC~~~~CTGC TG~CCATGGC AACGCCGTCC   
 
The TAP double KO clonal line TAPD cl-2 shows successful editing in TAP1 which consists of a 
one base pair deletion immediately downstream of the PAM site at position 381-383 (fig 
7.2.4a). 
Editing can also be seen in TAP2 downstream of the PAM site a position 269-271; the edits 
consist of a five base pair deletion (fig 7.2.4b). Both edits appear to be same on both alleles 
for TAP1 and TAP2, these edits were confirmed by cloning and sequencing of two 
independent PCRs and direct sequencing of the PCR product.  
The effect of the TAP1 editing on the coding sequence when compared to the original 
sequence show disruptions to the gene begin at amino acid position 126 and results in a 
premature stop codon at position 133 (fig 7.2.5). The TAP2 editing shows disruptions to the 
amino acid sequence at position 92 and a premature stop codon is seen a position 162. 
 
Figure 7.2.4 DNA sequence alignment of clonal line TAPD cl-2 shows editing events and in 
TAP1 and TAP2. 
The editing events revealed by sequencing exon 3 of TAP1 and exon 1 of TAP2 were mapped onto 
partial TAP1 and TAP2 cDNA sequence respectively and compared to the wildtype. a) editing events 
can be seen in TAP1 immediately before the PAM site at position 381-383. b)  editing events can be 
seen in TAP1 immediately before the PAM site at position 269-271. 
Sequences are labelled on the left-hand margin; wild type sequences (IS19 TAP1 WT or IS19 TAP2 WT), 
the edited alleles of TAPD cl-2 are labelled IS19 TAPD cl-2 (TAP1) for TAP1 or TAD cl-2 (TAP2) for TAP2. 
a) 
b) 
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                                110        120        130        140        150         
                        ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP1 WT           QSITELRADG AGDVAMRVTR DAEDVREALG EALSLLLWYL ARGLCLFATM   
IS-19 TAPD cl-2 (TAP1)  QSITELRADG AGDVAMRVTR DAEDVARLWV RR*ASCCGIW HVASASSPPW   
 
                                 60         70         80         90        100             
                        ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP2 WT           LGGAGQLLAP RGPRGAAVLL SLGPAIFLTL RGYVGLPGAA PVLLAMATPS   
IS-19 TAPD cl-2 (TAP2)  LGGAGQLLAP RGPRGAAVLL SLGPAIFLTL RGYVGLPGAA PCCHGNAVLA   
 
                                110        120        130        140        150         
                        ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP2 WT           WLVLTHGTAV VALLTWSLLV PTVATGAKEA EAWVPLRRLL ALAWPEWPFL   
IS-19 TAPD cl-2 (TAP2)  GADPRDSCGG IAHLEPPGPH CGHWGKGGRG LGAPEAAAGP RLARVALPWL   
 
                                160        170        180        190        200         
                        ....|....| ....|....| ....|....| ....|....| ....|....|  
IS-19 TAP2 WT           GCAFLFLALA ALGETSVPYC TGRALDVLRQ GDGLAAFTAA VGLMCLASAS   
IS-19 TAPD cl-2 (TAP2)  CLPLPRIGCT G*DLSALLHR EGSGCPPPGG RPRRLHRCCR PHVPGLCQQL   
 
 
 
 
 
The selected KO clones for TAP1, TAP2 and TAPD were analysed for β2m expression by flow 
cytometry. Clear reductions of β2m can be seen in all KO lines, with reductions being of the 
same magnitude, just over a one log reduction. All KO cell lines appear to have one peak for 
Figure 7.2.5 Amino acid sequence alignment of clonal line TAPD cl-2 shows effects of editing 
on TAP1 and TAP2 coding sequence. 
The effect of the DNA editing of TAP1 and TAP2 were shown on the entire amino acid sequence. a) TAP1 
edits show changes in the coding sequence begin at position 126, premature stop codons can be seen 
down stream of these positions. b) TAP2 edits show changes in the coding sequence begin at position 92, 
premature stop codons can be seen down stream of these positions. 
Sequences are labelled on the left-hand margin; wild type sequences ( IS19 TAP1 WT or IS19 TAP2 WT), 
the edited alleles of TAPD cl-2 are labelled IS19 TAPD cl-2 (TAP1) for TAP1 or TAD cl-2 (TAP2) for TAP2. 
IS19 TAP1.1 cl-1 IS19 TAP2.1 cl-1 
a) b) c) 
β2m 
staining 
IS19 TAPD cl-2 
Figure 7.2.6 Flow cytometry cell surface staining of β2m in IS19 TAP1, TAP2 and TAPD KO 
clonal lines. 
Clonal KO lines were derived and screened by sequencing for TAP1, TAP2 and TAPD. These cell lines 
were analysed via flow cytometry using the antibody F21-21, to β2m. B2m expression is seen in 
orange for TAP1 KO (a), TAP2 KO (b) and TAPD KO (c), compared to wild type expression (blue). All 
histograms include transfected cells stained with secondary only (red). 
 
 
 
a) 
b) 
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β2m expression indicating that all cells have impaired class I presentation, something which 
we would not expect to see if the cell line had unedited alleles or a secondary population of 
cells that had not been edited. The flow cytometry results are as expected based on the 
results obtained from the cloning and sequencing of these lines. 
Lastly, Western blotting of the TAPs was attempted to confirm that no TAP protein was 
being produced in the KO lines. This proved difficult, especially when blotting for TAP1 as the 
western blots were often too messy to decipher. Blots of TAP2 were slightly better but again 
often too messy for interpretation. Figure 7.2.7 shows screening of TAP2 KO and TAPD KO 
clone lysates by western blotting for TAP2. TAP2 has a theoretical molecular weight of ~75 
kDa and can be seen in the wild type IS19 cell line in both blots (figure 7.2.7). The absence of 
the TAP2 band is seen in the TAP2 KO (figure 7.2.7a) and the TAPD KO (figure 7.2.7b), as 
expected from the flow cytometry and sequencing results.  
 
 
Figure 7.2.7 Western blots staining for TAP2 in IS19 TAP2 and TAPD KO clonal lines. 
IS19 WT cells and clonal derived cell lines TAP1.1 cl-1 and TAPD cl-2 were lysed using digitonin after 
a membrane enriching protocol. The clone lysates were probed for TAP2 protein expression by 
western blotting using the antibody F1-3.  
 
 
 
 
a) b) 
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7.3 Assessing peptide transport in TAP KO lines by radiolabelled peptide transport assays 
Before all clonal lines were derived and fully confirmed for all required TAP KO lines, 
transport assays were undertaken to assess the characterised clonal lines but also as part of 
the screening process for TAPD KO lines.  
The first transport assay (fig 7.3.1) shows transport and inhibition with the peptide 
KRYNASAY (P198), a peptide that has previously been shown in the lab to transport 
effectively in IS19 cells (Walker et al 2011). IS19 WT shows a high level of radioactivity as 
shown by the counts per minute (Y axis). This transportation is greatly inhibited in the 
addition of excess unlabelled P198 abolishing the transport. The TAP KO clones used at the 
time of this experiment were TAP1.1 cl-1 (the characterised and selected TAP1 KO line), 
TAP2.1 cl-4 and TAPD cl-1, neither of which are the selected cell lines for TAP2 KO and TAPD 
KO detailed and characterised above. 
TAP1.1 cl-1 showed a ~75% reduction in peptide transport with a further ~25% that could be 
inhibited with cold peptide. TAP2.1 cl-4 showed a ~50% reduction in transport, again that 
could be fully inhibited. TAPD cl-1 showed a ~75% reduction in peptide transport with the 
remaining transport being fully inhibited. These results had two unexpected outcomes; 
firstly, that transport is seen in all KO lines between 25 and 50%, as human and mouse data 
suggests that when one of the two TAP proteins are removed, transport is abolished. 
Secondly, that the TAP2 KO line shows 50% transport compared to 25% in the TAP1 KO line. 
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The differences in transport between TAP1 and TAP2 KO lines was quickly understood, as 
upon further screening it was seen that one allele of the TAP2.1 cl-4 KO line had an indel 
that was a multiple of three nucleotides which did not result in a frame shift mutation and 
presumably did not result in loss of function. Also, the TAPD cl-1 line was found to be a TAP2 
only KO and was renamed TAP2.1 cl-1 in section 7.2, but for the remainder of section 7.3 will 
continue to be called TAPD cl-2. Further screening was required to identify a TAPD KO, as 
well as continued transport assay analysis of the identified TAP KO lines TAP1.1 cl-1 (TAP1) 
and TAPD cl-1 (TAP2). 
Due to the unexpected result of seeing some transport in TAP KO lines we wanted to 
determine if this transport could be specifically inhibited. To test this, we used radiolabelled 
P198, which was either inhibited with unlabelled P198 or the B4 peptide ADYNDSAE (P167). 
Simultaneously, an aliquot of the TAP cell lines were stained for class I heavy chain 
expression (fig 7.3.2). 
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Figure 7.3.1 Radiolabelled transport and inhibition assay of P198 peptide initial IS19 TAP1, 
TAP2 and TAPD KO clonal lines.  
IS19 WT cells and clonal derived cell lines TAP1.1 cl-1, TAP2.1 cl-4 and TAPD cl-2 were assayed for the 
transport of 125I radiolabelled P198 peptide (KRYNASAY) and inhibited with excess unlabelled P198. 
Radioactive material present is represented as mean counts per minute (CPM) as assessed by γ-
counter.  Each condition is performed in triplicate with error bars representing standard error of the 
mean. X-axis shows labelling of cell line used and the peptide number used for inhibition in brackets. 
 
 
The clone lysates were probed for TAP2 protein expression by western blotting using the antibody F1-3.  
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In figure 7.3.2a, we observed that IS19 wild type showed expected transport with P198. This 
transport was fully inhibited with cold P198 but was barely inhibited by the B4 peptide 
(P167) suggesting specific transport through the TAPs. The exact same pattern was observed 
with the TAP1 and TAP2 KO lines (TAP1.1 cl-1 and TAPD cl-1), with transport of radiolabelled 
P198 being ~25% of the WT that is fully inhibited with unlabelled P198 but not inhibited by 
P167. Three additional potential TAP KO lines were also tested (TAPD cl-2, cl-4 and cl-5).  
After screening by sequencing, these new TAP KO clones were seen to be a TAPD KO (TAPD 
cl-2), a TAP1 KO (TAPD cl-4) and wild type (TAPD cl-5). The newly isolated TAPD KO clone 
behaved as expected and similarly to the TAP1 and TAP2 single KO lines, with ~25% of WT 
transport which is inhibited by P198 but not P167. The additional TAP1 KO (TAPD cl-4) 
behaved as TAP1.1 cl-1, and the clonal line that was found to be WT (TAPD cl-5) showed the 
same phenotype as WT IS19 cells (fig 7.3.2a).  
The transport assay data was then compared with the class I heavy chain staining of the TAP 
KO clones (fig 7.3.2). IS19 wild type staining was the same when compared with TAPD cl-5 
which had no edits in the TAPs. The two TAP1 KOs (TAP1.1 cl-1 and TAPD cl-4) showed the 
same ~90% reduction of class I. The TAP2 KO showed a ~85% reduction in class I expression 
and the TAPD a ~95% reduction in class I (fig 7.3.2.b).  
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Figure 7.3.2 Transport of radiolabelled P198 peptide in initial IS19 TAP1, TAP2 and TAPD KO 
clonal lines with P198 and P167 inhibition and flow cytometry staining of class I heavy chain.  
a) IS19 WT cells and clonal derived cell lines TAP1.1 cl-1, TAPD cl-1, 2, 4 and 5 were assayed for the 
transport of 125I radiolabelled P198 peptide (KRYNASAY). Inhibition was performed with excess unlabelled 
peptide, either P198 or P167 (ADYNDSAE). Radioactive material present is represented as mean counts per 
minute (CPM) measured by γ-counter.  Each condition was performed in triplicate with error bars 
representing standard error of the mean. b) aliquots of the above cell lines were taken before preparation 
for transport assays and stained for class I heavy chain expression using the antibody F21-2 for flow 
cytometry analysis. Fluorescence is plotted as the geometric mean fluorescence intensity (MFI). a) X-axis 
shows labelling of cell line used and the peptide number used for inhibition in brackets. b) X-axis shows 
labelling of cell line used and how the sample was stained in brackets, secondary antibody only (Ab2) and 
F21-2 (class I). 
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To begin to understand the ~25% of the WT transport that is in the TAP KO lines, the initial 
tests examined the possibility that peptides are being transported by an additional 
transporter or that the transport seen is due to peptides binding MHCI molecules. To test if 
the peptides capacity to bind MHCI effected inhibition of transport the transport assay in 
figure 7.3.2 was repeated using just the characterised and selected TAP1, TAP2 and TAPD 
clones (detailed in section 7.2), but additionally inhibited with the peptide RRRREQTVY 
(P149), that was shown to bind to IS19 MHCI by refolding but is not transported as assessed 
by transport assay (Tregaskes et al, 2016). 
Figure 7.3.3 shows transport of radiolabelled P198 that is fully inhibited by unlabelled P198, 
a small amount of inhibition is seen with P167 and P149 acts similarly to P167. All TAP KO 
lines show the same pattern in phenotype, with TAP KO having ~12.5 - 25% reduction in 
peptide transport of radiolabelled P198 that is fully inhibited by unlabelled P198 but not 
inhibited at all by P167 or P149.  
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Figure 7.3.3 Transport of the radiolabelled P198 peptide in selected IS19 TAP1 KO, TAP2 
KO and TAPD KO clonal lines, with P198, P167 and P149 inhibition.   
IS19 WT cells and selected clonal derived cell lines TAP1.1 cl-1, TAPD cl-1 and 2 were assayed for 
the transport of 125I radiolabelled P198 peptide (KRYNASAY). Inhibition is performed with excess 
unlabelled peptide, either P198, P167 (ADYNDSAE) or P149 (RRRREQTVY). Radioactive material 
present is represented as mean counts per minute (CPM) measured by γ-counter.  Each condition is 
performed in triplicate with error bars representing standard error of the mean. X-axis shows 
labelling of cell line used and the peptide number used for inhibition in brackets. 
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7.4 Creation of B2m and TAP KO cell lines for transport assay analysis.   
To understand the residual ~25% transport of the WT in the TAP KO cell lines, β2m was 
knocked out in the TAP KO lines to see whether the transport still remained. The selected 
TAP KO cell lines, TAP1 KO (TAP1.1 cl-1) TAP2 KO (TAPD cl-1, renamed to TAP2.1 cl-1) and 
TAPD KO (TAPD cl-2), were transfected with the β2m targeting sgRNA B2m.1 (detailed in 
chapter 3). Clonal lines were derived and initially screened by flow cytometry of β2m and 
class I heavy chain expression. Figure 7.4.1a shows the MFI of two TAP1+β2m KO clones (cl-1 
& 3). IS19 WT expression of β2m and class I heavy chain can be seen compared to the two 
TAP1+β2m KO clones. Both KO lines show β2m and class I expression at the level of the 
secondary antibody control, providing strong evidence that these clones are β2m KOs. These 
clones were confirmed to be β2m KOs by cloning and sequencing (data not shown). Figure 
7.4.1b, shows three TAP2+β2m KO clones (cl-1, 2 & 3). Again, all KO clones showed β2m and 
class I expression at the same level of the secondary antibody control, providing strong 
evidence that the clones are β2m KOs. These clones were also confirmed to be β2m KOs by 
cloning and sequencing (data not shown).  The same process was used make TAPD+β2m KO 
clonal lines.  
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Figure 7.4.1 Screening of TAP1+B2m and TAP2+B2m KO clonal lines by flow cytometry.  
a) Clonal derived cell line TAP1.1 cl-1 was transfected with the β2m targeting sgRNA B2m.1 and clonal lines 
were derived. Clones TAP1+β2m cl-1 and 3 were stained for B2m (F21-21) and class I heavy chain (F21-2) 
expression.  
b) Clonal derived cell line TAP2.1 cl-1 was transfected with the β2m targeting sgRNA B2m.1 and clonal lines 
were derived. Clones TAP2+B2m cl-1, 2 and 3 were stained for β2m (F21-21) and class I heavy chain (F21-2) 
expression.  
Fluorescence is plotted as the geometric mean fluorescence intensity. X-axis shows labelling of cell line used 
and how the sample was stained in brackets, secondary antibody only (Ab2), F21-21 (β2m) and F21-2 (class I) 
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Once the three new clonal lines (TAP1+β2m, TAP2+β2m and TAPD+β2m) were created, all 
the clonal cell lines were analysed together to check if the transport is dependent on MHCI 
expression and in conjunction an aliquot of each cell line was taken and stained for β2m 
expression by flow cytometry.  
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Figure 7.4.2 Transport of radiolabelled P198 peptide in IS19 TAP1 KO, TAP2 KO and TAPD KO 
with and without β2m KO clonal lines with P198 and P167 inhibition and flow cytometry 
staining of class I heavy chain.  
a) IS19 WT cells and clonal derived cell lines TAP1, TAP2, TAPD KOs and TAP1+β2m, TAP2+β2m and 
TAPD+β2m KOs were assayed for the transport of 125I radiolabelled P198 peptide (KRYNASAY). Inhibition is 
performed with excess unlabelled P198 peptide. Radioactive material present is represented as mean 
counts per minute (CPM) measured by γ-counter.  Each condition is performed in triplicate with error bars 
representing standard error of the mean. X-axis shows labelling of cell line used and the peptide number 
used for inhibition in brackets.  b) Aliquots of the above cell lines were taken before preparation for 
transport assays and stained for β2m expression using the antibody F21-21 for flow cytometry analysis. 
Fluorescence is plotted as the geometric mean fluorescence intensity. X-axis shows labelling of cell line 
used and how the sample was stained in brackets, secondary antibody only (Ab2) and F21-21 (β2m). 
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Figure 7.4.2a shows the transport assays for the TAP KO lines compared to the TAP+β2m KO 
lines. All cell lines are able to transport P198 and inhibited with P198. The wild type cell line 
shows decreased counts compared to the previous transport assays, but this was expected 
as the radiolabelled iodine had been through multiple half life cycles, but the transport is 
fully inhibited by unlabelled P198. Results for the TAP1 KO, TAP2 KO and double TAP KO lines 
show a similar pattern to previous results (fig 7.3.2, 7.3.3) with residual transport being seen 
in all three lines that can be inhibited by unlabelled peptide. Although, it is noted that the 
residual transport seen is at ~10% of the wild type compared to ~25% previously. When we 
compare this result to that of the three TAP+β2m KO lines, we see that the residual 
transport is completely abolished in the absence of MHCI. 
 
7.5 Discussion 
TAP sequences were analysed for guide sites that were largely conserved in TAP sequences 
for the B2, B4, B12, B15, B19 and B21 haplotypes. Initially, two guides were selected for 
TAP1 and TAP2. These guides were then cloned in PX458 for testing in the cell line IS19. The 
scientific literature describing human and mouse TAP KO lines shows that cell surface class I 
levels are reduced, when either or both TAPs are knocked out (Van Kaer et al 1992, de la 
Salle et al 1993).  We decided to see if this was true for the chicken, so that we could use cell 
surface MHCI to identify successful TAP KOs.  
Figure 7.2.1 shows the identification of two TAP-targeted sgRNAs (TAP1.1 & TAP2.1) that 
result in populations of reduced class I when transfected into IS19 cells. The IS19 cells were 
transfected with either TAP1.1 or TAP2.1, then sorted for GFP expression, and the polyclonal 
GFP positive population was expanded before being stained for MHCI expression. Both 
samples showed a distinct population of cells that have reduced β2m and class I heavy chain. 
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To check that this down regulation of MHC is restricted to MHCI molecules; transfected cells 
were also stained for MHCII, which had one clear population that was comparable to the 
WT. As the TAP targeting appeared to be a success, clonal cell lines were then derived from 
the transfected cells and analysed for edits in the appropriate TAP by PCR, cloning and 
sequencing.  
Multiple clonal derived lines for TAP1, TAP2 and TAPD KO were screened, with one 
successful KO clonal being selected for TAP1, TAP2 and TAPD for further analysis. Figures 
7.2.2 -7.2.4 show sequence analysis of the selected TAP KO lines (TAP1, TAP2 and TAPD). To 
confirm the reduced expression of class I the three KO cell lines were stained for β2m 
protein expression at the cell surface. Figure 7.2.6 shows a large reduction of β2m as seen in 
the polyclonal KO populations. To fully validate that these lines were indeed TAP KOs the KO 
lines were probed for TAP1 or TAP2 protein expression by western blotting. Figure 7.2.7 
shows the TAP2 KO line and the TAPD KO line blotted for TAP2, with the TAP2 band being 
absent in both lines, whilst present in the wild type IS19 line. It can be seen that the TAP2 
blots have many bands present and it was challenging to obtain a clear western blot. 
Unfortunately, TAP1 was more challenging and after multiple attempts a reliable blot for 
TAP1 could not be produced. We relied on the sequencing of the TAP1 locus that shows the 
generation of indels and the presence of a frameshift, in conjunction with the reduction in 
MHC I to confirm that TAP1 had been knocked out. Since undertaking the TAP KO work, the 
western blotting procedure has been optimised and improved, and in the future the TAP KO 
lines will be blotted for TAP1 and TAP2 using the optimised western blotting protocol. 
With the TAP KO lines made and characterised, we decided to investigate how these KO lines 
effect transport of designated peptides. We used the radiolabelled P198 peptide 
(KRYNASAY) for transport and initially tried to inhibit this transport with unlabelled P198, 
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shown in Figure 7.3.1. It is important to note that this experiment was carried out while the 
TAP KO lines were still being characterised and validated. The chosen TAP KO lines detailed 
in section 7.2 were not all used for the experiment in figure 7.3.1 as they had not been 
characterised yet. The samples used in were TAP1.1 cl-1, which is the chosen TAP1 KO. The 
TAP2 KO used was TAP2.1 cl-4, which after further analysis was found to have an indel that 
was in frame for one allele so was not used for further experimentation and a new TAP2 KO 
was used for final experiments. The creation of the TAPD line was created by transfecting 
wild type IS19 cells with two sgRNAs at once, one targeted to TAP1 and one to TAP2 and the 
TAPD line used in figure 7.3.1 was TAPD cl-1 which after complete analysis was shown to be 
a homozygote TAP2 KO. This clone (TAPD cl-1) was then selected to be used as the TAP2 KO 
clonal line and was renamed as TAP2.1 cl-1. In summary, the results in figure 7.3.1 show the 
transport of a TAP1 KO (TAP1.1 cl-1), a TAP2 mutant with a one allele KO and one allele with 
an in-frame mutation (TAP2.1 cl-4) and a TAP2 KO (TAPD cl-1). Figure 7.3.1 shows that wild 
type IS19 cells efficiently transport the P198 peptide, giving ~1300 CPM that can be inhibited 
to ~30 CPM with the addition of cold P198. TAP1.1 cl-1 loses ~75 % of P198 transport 
compared to wild type and interestingly the remaining ~25 % transport can be inhibited with 
cold P198.  The pseudo TAP2 KO (TAP2.1 cl-4) shows a ~50 % reduction in P198 transport, 
again this transport can be fully inhibited. The TAP2 KO (TAPD cl-1) shows a similar result to 
the TAP1 KO, with ~25 % residual transport that can be fully inhibited. At the time of 
experimentation the TAP2.1 cl-4 result was confusing as to why the TAP2 KO had ~50 % 
transport remaining when compared to the TAP1 KO, and suggested that perhaps TAP1 
could operate as a homodimer complex. This result was particularly interesting as previous 
data in human models showed that TAP1 could form a homodimer, be it non-functional. This 
idea is likely to be false as the TAP2.1 cl-4 line was only fully disabled on one allele. 
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Regardless, the question remained as to why both the TAP1 KO and the TAP2 KO lines both 
show ~25 % transport and could this be transport from TAP homodimer complexes? 
To address this question we took two approaches, firstly to carry on screening for a TAPD KO 
to test whether transport remains, secondly to test whether the transport that was seen was 
specifically inhibited by the P198 peptide or could a peptide that has been shown not to 
transport also inhibit the 25% transport seen. 
Figure 7.3.2a shows transport assays of P198 either inhibited with P198 or P167 (ADYNDSAE) 
a B4 peptide that is not has been shown to not transport in IS19. The lines used were the 
TAP1 KO, TAP2 KO (TAPD cl-1) and three new potential double KOs, TAPD cl-2, 4 and 5. IS19 
showed complete inhibition with P198 and was only marginally affected by inhibition with 
the B4 peptide, which was as expected and seen previously (Walker et al 2011). The TAP1 KO 
and the TAP2 KO clones both showed the same result as seen in 7.3.1, with ~ 25% transport 
of the P198 peptide that was fully inhibited with cold P198. Interestingly, the B4 peptide was 
unable to inhibit the transport which suggests that the transport seen is specific transport 
through a transporting system. Two of the new TAPD clones screened (2 & 4) both showed 
the same results as the TAP1 KO and TAP2 KO, whilst TAPD cl-5 showed results the same as 
the wild type. When the three new TAPD clones were fully analysed it was seen that TAPD cl-
2 was in fact a TAP1 and TAP2 KO (TAPD), TAPD cl-4 was a homozygous TAP1 KO and TAPD 
cl-5 was unedited for TAP1 and TAP2 (WT). The most surprising aspect of this result is that 
the TAP double KO, TAPD cl-2 still has residual transport of ~25% that is specifically inhibited 
by P198, showing that the residual transport is not due to homodimeric TAPs or is in fact due 
to TAP transport which suggests that the transport could be from separate peptide 
transporter, such as TAPL. 
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In conjunction to the transport assay, each cell line was stained for class I heavy chain cell 
surface expression (fig 7.3.2b). As expected and previously shown, TAP1, TAP2 and TAPD KOs 
show a ~90 % decrease in class I expression and TAPD cl-5 which was identified as wild type 
by cloning and sequencing had class I levels comparable with wild type. To try to understand 
why ~25 % transport is still seen in all TAP KO clones transport assays of P198 were repeated 
but with an additional inhibition condition, using a peptide that is known to bind class I 
(Walker et al 2011) but not to transport, RRRREQTVY (P149). Figure 7.3.3 shows that P147 
was unable to inhibit transport in the TAP KO lines. 
It was unclear whether this residual transport was dependent on the expression of MHCI, so 
to test whether MHCI was necessary for peptide exchange, B2m was knocked out in the TAP 
KO lines. Flow cytometry analysis of B2m and class I heavy chain expression is shown in 
figure 7.4.1, with all identified TAP1+β2m and TAP2+β2m KO clones showing a complete loss 
of β2m and heavy chain. All lines were used for transport assays of P198 and inhibited with 
unlabelled P198, shown in figure 7.4.2a. Transport of the wild type and TAP KO lines showed 
the same results as previously seen and described, but all TAP KO lines that had β2m 
additionally knocked out lose the residual ~25 % remaining transport. An important control 
that is missing from this experiment is the β2m KO line which was left out due to technical 
limitations, though transport of the β2m KO line has been assessed previously and shows no 
difference to the wild type (Tregaskes, unpublished data). With these considerations in 
mind, the current data suggests that there is ~25 % transportation of the P198 peptide that 
is not dependent on the TAPs but is dependent on class I expression. To fully understand this 
further experimentation is required, such as immunopeptidomic analysis of the TAP KO cell 
lines. 
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To summarise, the aim of this project was to create a system in which we could assess which 
polymorphisms in the TAPs are important for specific peptide transport, with the first stage 
being to create and characterise TAP KO lines, then assess the effect this has on the ability of 
the cell line to transport a B19 peptide. We have provided strong evidence that TAPs in 
chicken do not function as a homodimer in the B19 haplotype and found that even when 
both TAPs are absent we see ~25% remaining transport that is dependent on MHCI 
expression. The next stage of the project is to optimise transfection of TAPs (of varying 
haplotypes) into TAP KO lines (that still contain β2m) to see if MHCI protein levels can be 
restored on the cell surface, if these cells have restored peptide transport and if so for which 
peptides. 
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8. General discussion 
 
The aim of this project was to gain a deeper understanding of the antigen processing system 
of the chicken, utilising recent advances in genome editing, in particular the CRISPR-Cas9 
system. The aim was broken down into two main sections, peptide loading of MHCI and 
MHCII. 
 
8.1 Investigating TAP transport specificity in the chicken  
The MHCI antigen processing has multiple components such as the TAP transporters, tapasin 
and the relatively newly identified peptide editor TAPBPR. As mentioned in the general 
introduction, there are many differences between the chicken and human MHC loci. Key 
differences include that there is one dominantly expressed MHCI in the chicken and that the 
MHCI peptide loading genes (TAP1, TAP2 and tapasin) contained in the chicken MHC are 
polymorphic. The polymorphic MHCI genes are in strong linkage disequilibrium with the 
polymorphic peptide loading genes (tapasin and TAP), resulting in co-evolution. This co-
evolution of the class I system results in specific alleles of the TAP genes that specify peptide 
translocation of peptides with a motif that correlates with that of one particular MHCI, 
specifically the dominantly expressed BF2 but not BF1 (Walker et al 2011). As previously 
discussed it still unknown as to which polymorphic residues of the TAP complex MSD are 
responsible for the transport of peptides with a specific motif.  
 
The aim of this project was to understand which of these polymorphic residues of the TAP 
complex MSD are required for specific peptide transport. The initial experimental design was 
to use CRISPR-Cas9 to make IS19 TAP1 KO, TAP2 KO, TAPD KO lines, assess peptide transport 
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using a radiolabelled peptide and then proceed to transfect the TAP KO lines with the 
respective TAP(s) that have mutated polymorphic MSD residues of interest. It was expected 
that no transport of radiolabelled peptide would be seen in any of the TAP KO lines. 
Surprisingly, ~25% residual transport of the WT was observed for the P198 peptide, in the 
TAP1 KO, TAP2 KO and TAPD KO, which was inhibited with unlabelled peptide (fig 7.3.1). 
Further experimentation was required to understand the remaining transport. It was 
possible that the transport seen was due to non-specific peptide entry into the ER, for 
instance if the ER had become permeabilised during sample preparation. If peptide was able 
to enter the ER in a non-specific manner, then the residual transport could be inhibited by 
excess unlabelled peptide that is not transported by the TAP transporters. Additional 
experiments showed that the transport could not be inhibited by peptides known to not be 
transported by the TAP transporters of IS19, including a peptide that is able to bind to IS19 
MHCI by MHC refolding but cannot be transported (fig 7.3.3).  
 
The next step was to examine whether MHCI expression was required for the remaining 
transport seen. MHCI KOs were made in the TAP KO lines by editing β2m, producing three 
more KO lines (TAP1+ β2m KO, TAP2+ β2m KO and TAPD+ β2m KO) and were analysed by 
radiolabelled transport assay. Surprisingly, the ~25% residual transport of the WT seen in the 
TAP KOs disappeared when β2m was additionally edited (fig 7.4.2). One explanation for this 
result is that the remaining MHCI molecules are escaping the ER and migrating to the cell 
surface in the TAP KOs (fig 7.4.2), and then bind the radiolabelled P198 peptide. These MHCI 
molecules binding the radiolabelled peptide are then pulled down with concanavalin A and 
are therefore seen during analysis by γ-counter. If this is the case, then the radioactivity 
measured is not from transport and instead by peptide exchange. In the future we plan to 
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test this by immunoprecipitating MHCI from the samples before concanavalin A treatment, 
followed with assessment by γ -counter. Alternatively, the 25% residual transport of the WT 
could be from a second peptide transportation system, such as TAPL. 
 
8.1.2 Future work 
The second stage of this project will be to transfect constructs expressing WT TAPs and TAPs 
with point mutations, and assess MHCI surface expression and peptide transport to see if 
they are restored. This work has begun in conjunction with a visiting PhD student Magdalena 
Migalska, with preliminary data suggesting that MHCI protein expression can be restored 
when WT TAP constructs are transfected into IS19. Interestingly, MHCI protein expression is 
restored after transfection of WT TAPs from a different haplotype B15 that has similar 
peptide transport specificity but is not restored when TAPs from a haplotype (B4) with very 
different peptide transport specificity (9. Appendix). 
 
8.2 Understanding MHCII antigen processing 
The second aim focused on MHCII antigen processing and presentation in the chicken, which 
is much less understood than that of MHCI. What is known is that the chicken has two MHCII 
B genes (BLB1 and BLB2) and two DMB genes (DMB1 and DMB2), with BLB2 and DMB2 being 
dominantly expressed in hematopoietic cells, whilst BLB1 and DMB1 are dominantly 
expressed in intestinal epithelial cells (Jacob et al 2000, Parker and Kaufman 2017). The 
dominant expression of BLB and DMB pairings suggested that BLB and DMB may have co-
evolved for specific antigen processing functions, as seen for the MHCI system.  
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The main aim was to understand how each DMB interacts and effects each BLB molecule. To 
do this single KOs were made of most antigen processing and presentation genes in the 
chicken (BLB1 KO, BLB2 KO, DMA KO, DMB1 KO and DMB2 KO). Double KOs were made for 
each combination of BLB and DM (BLB1+DMA KO, BLB1+DMB1 KO, BLB1+DMB2 KO, 
BLB2+DMA KO, BLB2+DMB1 KO and BLB2+DMB2 KO). The experimental design was to use 
the double KO lines to assess the effect of each DM molecule (or no DM molecules) on each 
BLB molecule. The first step was to assess the protein expression of BLB1 and BLB2 in the 
single BLB1 KO, BLB2, DMA KO, DMB1 KO and DMB2 KO lines. It was expected that BLB1 and 
BLB2 expression would be independent of each other but surprisingly, the first observations 
showed that the BLB1 KO affected the protein expression of BLB2 and vice versa (fig 5.3.2). It 
was also seen that each DM KO affected protein expression of both BLB molecules, whereas 
we expected DMB1 to only affect BLB1 and DMB2 to only affect BLB2 (fig 5.3.2). It was also 
observed that DMA protein expression was reduced in both the DMB1 KO and the DMB2 KO 
(fig 5.3.3); and that DMB2 protein expression was reduced in the DMA KO and the DMB1 KO 
(fig 5.3.4). It was unexpected that DM protein expression would be strongly affected by the 
editing of any DM gene, particularly that DMB2 protein expression could be affected in the 
DMB1 KO, as the two DMB molecules are not expected to interact in any way. The nature of 
MHCII protein expression appears to be heavily influenced by all MHCII proteins involved in 
peptide processing and presentation. Much further work is required to understand the 
effects of MHCII protein regulation and stability in the MHCII system. 
 
Secondly, temperature stability of MHCII was assessed in the IS19 DMA KO, DMB1 KO and 
DMB2 KO lines. All DM KO lines were shown to reduce MHCII thermostability (fig 5.3.6, 
5.3.7). The DMA KO was found to decrease the thermostability of MHCII, with a lesser effect 
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found for the DMB1 KO and DMB2 KO lines. Interestingly, the DMB2 KO had a greater effect 
on thermostability than the DMB1 KO, suggesting that DMB2 plays a more prominent role in 
editing both BLB molecules (fig 5.3.7). It was noted that the DMB1 KO affects the 
thermostability of both BLBs. These initial findings suggest that both DMB molecules are 
important for peptide loading of both BLB molecules, which is in opposition to the 
hypothesis that DMB editing is restricted to just one BLB molecule. Similarly, in the B21 
haplotype the DMB2 KO was able to form thermostable MHCII complexes for BLB1 and 
BLB2, whereas the DMA KO was unable to form a stable complex at any temperature (fig 
5.3.8). This supports the notion that both DMBs have editing functions of both BLB 
molecules and is likely to be consistent between haplotypes. Interestingly, DM activity varies 
between haplotypes with B19 able to form stable MHCII complexes in the absence of DM at 
low temperatures, whereas B21 is not, suggesting a spectrum of DM-dependence. 
 
Lastly, the peptide repertoire of BLB1 and BLB2 was elucidated by immunopeptidomics. 
BLB1 and BLB2 were shown to have two distinct repertoires expressed, with very peptides 
shared between the two molecules (fig 6.3.1, 6.4.4). DM was also shown to influence the 
repertoire of MHCII molecules. DM deficient cells were shown to have a more diverse motif, 
that overall was very similar to that of BLB2 (fig 6.3.1). 
 
8.2.1 Future work 
Current and future work includes reconstitution of the edited MHCII protein to assess 
whether WT phenotypes are restored. Independent MHCII KO clones have all been created 
for the IS19 MHCII KO lines, for which protein and RNA levels will be assessed and compared 
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to the data presented in this thesis. BLB1 KO, BLB2 KO and DMB1 KO clonal lines need to be 
derived for the B21 haplotype. The analysis of DM-dependent thermostability of BLB1 and 
BLB2 in B21 needs to be continued, including characterization of the DMB1 KO and 
replication of all DM KO lines. Ultimately, characterization at the RNA and protein level 
needs to be carried out for all B21 MHCII KO lines for comparison with the B19 study. 
Furthermore, MHCII KO lines could be generated in a variety of common MHC haplotype cell 
lines, such as B2, B4 and B15. Comparisons at the RNA and protein level, and thermostability 
assays could then be compared between all haplotypes. This would allow unifying themes of 
the chicken MHCII processing and presentation system to be identified, as well as 
highlighting the variability of MHCII processing between haplotypes. Immunopeptidomics 
affords the opportunity to assess the diversity of peptides presented by BLB1 and BLB2 
between haplotypes and how these repertoires are affected by the absence of each or both 
DM molecules, starting with a comparison of B19 and B21. 
 
8.3 Future of genome editing in chickens 
Recent advances have enabled the culture of chicken primordial germ cells (PGCs). It has 
been demonstrated that cultured PGCs can be genetically edited and successfully 
transplanted back into the chicken embryo to generate transgenic chickens. This 
breakthrough drastically changes the landscape of chicken immunology, allowing the 
targeted KO of immune genes, and for the effects to be assessed in vivo. In collaboration 
with two groups at the forefront of this technology (Prof Benni Schusser and Dr Mike 
McGrew), our lab has commenced work to make MHCI and MHCII deficient birds. In the 
future, such birds could be studied in a variety of ways by the scientific community, including 
pathogen challenge experiments and vaccine responses. This work has the potential to make 
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groundbreaking progress, that will not only advance our understanding of immunology but 
also impact vaccination, breeding strategies and food security. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
 
 
 
 
 
9. Appendices 
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9.1 Appendix i 
 
 
 
 
 
 
 
 
 
 
 
Appendix ia.  Flow cytometry cell surface staining of B2m n IS19 TAD KO transfected with 
IS19 TAP1 and TAP2 polyclonal populations. 
 IS19 TAPD cell line was co-transfected with pcDNA plasmids expressing IS19 TAP1 and TAP2. IS19 
WT, TAPD KO and TAPD KO+TAP1 and TAP2 cells were analysed via flow cytometry using the 
antibody F21-21, to β2m. IS19 cells are shown with secondary antibody only (brown dotted line) 
and F21-21 (brown). TAPD KO cells are shown with secondary antibody only (green dotted line) and 
F21-21 (green). TAPD KO+TAP1 and TAP2 cells are shown with secondary antibody only (blue 
dotted line) and F21-21 (blue). Experiment carried out by Magdalena Migalska. 
 
n orange and compared to wild type cell expression (blue). All histograms include transfected cells 
stained with secondary only (red). 
 
 
 
Appendix ib.  Flow cytometry cell surface staining of B2m n IS19 TAD KO transfected 
with TG15 TAP1 and TAP2 polyclonal populations. 
 IS19 TAPD cell line was co-transfected with pcDNA plasmids expressing TG15 TAP1 and TAP2. IS19 
WT, TAPD KO and TAPD KO+TAP1 and TAP2 cells were analysed via flow cytometry using the 
antibody F21-21, to β2m. IS19 cells are shown with secondary antibody only (brown dotted line) 
and F21-21 (brown). TAPD KO cells are shown with secondary antibody only (green dotted line) and 
F21-21 (green). TAPD KO+TAP1 and TAP2 cells are shown with secondary antibody only (blue 
dotted line) and F21-21 (blue). Experiment carried out by Magdalena Migalska. 
 
n orange and compared to wild type cell expression (blue). All histograms include transfected cells 
stained with secondary only (red). 
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9.2 Appendix ii 
 
 
 
 
 
 
 
 
 
 
Clone = B2m.(B) cl-1 (this is a possible homozygote) (10bp deletion) 
 
B2m_RG5            1 CAAGGTGCAGGTGTACTCCCGCTTCCCCGCCTCTGCGGGCACCAAGAACG     
50 
                     ||||||||||||||||||||||||||||          |||||||||||| 
CB_PGC_B2m.1_      1 CAAGGTGCAGGTGTACTCCCGCTTCCCC----------GCACCAAGAACG     
40 
 
B2m_RG5           51 TCCTCAACTGCTTCGCGGCCGGCTTCCACCCACCCAAGATCTCCATCACG    
100 
                     |||||||||||||||||||||||||||||||.|||||||||||||||||| 
CB_PGC_B2m.1_     41 TCCTCAACTGCTTCGCGGCCGGCTTCCACCCGCCCAAGATCTCCATCACG     
90 
 
B2m_RG5          101 CTGATGAAGGACGGCGTGCCCATGGAGGGTGCGCAGTACTCCGACATGTC    
150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
CB_PGC_B2m.1_     91 CTGATGAAGGACGGCGTGCCCATGGAGGGTGCGCAGTACTCCGACATGTC    
140 
 
B2m_RG5          151 CTTCAACGACGACTGGACGTTCCAGCGCCTGGTGCACGCCGACTTCACGC    
200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
CB_PGC_B2m.1_    141 CTTCAACGACGACTGGACGTTCCAGCGCCTGGTGCACGCCGACTTCACGC    
190 
 
B2m_RG5          201 CCAGCAGCGGTTCCACCTACGCGTGCAAGGTGGAGCACGAGACCCTGAAG    
250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
CB_PGC_B2m.1_    191 CCAGCAGCGGTTCCACCTACGCGTGCAAGGTGGAGCACGAGACCCTGAAG    
240 
 
B2m_RG5          251 GAGCCGCAGGTCTACAAGT    269 
                     ||||||||||||||||||| 
Appendix iia DNA sequence alignment of B12 PGC clonal line B2m.1 cl-1 shows editing. 
 
The editing events revealed by sequencing exon 2 of B2m were mapped onto the exon 2 sequence of 
B2m and compared to the WT, the editing events can be seen in at position 29. The two sequences are 
labelled on the left-hand margin; WT sequence (B2m_RG5) and edited alleles of clonal line b2m.1 cl-1 
(CB_PGC_B2m.1). 
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B2m_RG5            1 CAAGGTGCAGGTGTACTCCCGCTTCCCCGCCTCTGCGGGCACCAAGAACG     
50 
                     ||||||||||||||||||           ||||||||||||||||||||| 
CB_PGC_B2m.7_      1 CAAGGTGCAGGTGTACTC-----------CCTCTGCGGGCACCAAGAACG     
39 
 
B2m_RG5           51 TCCTCAACTGCTTCGCGGCCGGCTTCCACCCACCCAAGATCTCCATCACG    
100 
                     |||||||||||||||||||||||||||||||.|||||||||||||||.|| 
CB_PGC_B2m.7_     40 TCCTCAACTGCTTCGCGGCCGGCTTCCACCCGCCCAAGATCTCCATCGCG     
89 
 
B2m_RG5          101 CTGATGAAGGACGGCGTGCCCATGGAGGGTGCGCAGTACTCCGACATGTC    
150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
CB_PGC_B2m.7_     90 CTGATGAAGGACGGCGTGCCCATGGAGGGTGCGCAGTACTCCGACATGTC    
139 
 
B2m_RG5          151 CTTCAACGACGACTGGACGTTCCAGCGCCTGGTGCACGCCGACTTCACGC    
200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
CB_PGC_B2m.7_    140 CTTCAACGACGACTGGACGTTCCAGCGCCTGGTGCACGCCGACTTCACGC    
189 
 
B2m_RG5          201 CCAGCAGCGGTTCCACCTACGCGTGCAAGGTGGAGCACGAGACCCTGAAG    
250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
CB_PGC_B2m.7_    190 CCAGCAGCGGTTCCACCTACGCGTGCAAGGTGGAGCACGAGACCCTGAAG    
239 
 
B2m_RG5          251 GAGCCGCAGGTCTACAAGT    269 
                     ||||||||||||||||||| 
CB_PGC_B2m.7_    240 GAGCCGCAGGTCTACAAGT    258 
 
Appendix iib DNA sequence alignment of B12 PGC clonal line B2m.1 cl-7 shows editing. 
 
The editing events revealed by sequencing exon 2 of B2m were mapped onto the exon 2 sequence of 
B2m and compared to the WT, the editing events can be seen in at position 19. The two sequences are 
labelled on the left-hand margin; WT sequence (B2m_RG5) and edited alleles of clonal line b2m.1 cl-1 
(CB_PGC_B2m.7). 
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Appendix iic DNA sequence alignment of B12 PGC polyclonal line BF2.1/2 shows a large 
deletion. 
 
Two BF2 targeting sgRNAs were co-transfected into B12 PGC cells and sorted for GFP expression, the 
GFP positive polyclonal population was expanded and genomic DNA was extracted. BF2 was amplified, 
cloned and sequenced.  Editing events revealed by sequencing exon 2 of BF2 were mapped onto the 
whole sequence of BF2 and compared to the WT.  The combination of both sgRNAs created a 120 bp 
deletion between the two targeted sites of the sgRNAs. sgRNA targeting sites (blue arrows) and the 
deletion generated (red arrow) are shown.  
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Appendix iid DNA sequence alignment of B12 PGC polyclonal line BF2.1/2 shows a large 
deletion. 
 
Two BF2 targeting sgRNAs were co-transfected into B12 PGC cells and sorted for GFP expression, the 
GFP positive polyclonal population was expanded and genomic DNA was extracted. BF2 was amplified, 
cloned and sequenced.  Editing events revealed by sequencing exon 2 of BF2 were mapped onto the 
whole sequence of BF2 and compared to the WT.  The combination of both sgRNAs created a 121 bp 
deletion between the two targeted sites of the sgRNAs. sgRNA targeting sites (blue arrows) and the 
deletion generated (red arrow) are shown.  
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